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Human milk oligosaccharides (HMO) are a family of structurally related glycans 
that are highly abundant in breast milk. Oligosaccharide fraction is the third largest solid 
component in human milk after lactose and lipids. There is an accumulating evidence that 
HMO can provide significant benefits to the breast-fed infants. However, understanding of 
the exact HMO functions is still incomplete due to the lack of individual compounds in 
sufficient quantities. Therefore, development of expeditious strategies for the chemical 
synthesis of HMO has been increasingly important. 
Among all the methods available for oligosaccharide synthesis, armed-disarmed 
strategy introduced by Fraser-Reid is based on chemoselective activation of different 
building blocks. Later, the scope of this armed disarmed strategy was broadened by the 
introduction of other reactivity levels that included superarmed glycosyl donors. One of 
those was invented by Bols and co-workers wherein and the superarming property was 
achieved by the conformational change to the glycosyl donor. The other type of glycosyl 
donors was introduced by our lab wherein the superarming was achieved using conventions 
of the O2/O5 cooperative effect (electronic effect). 
Presented herein is the expansion of our previous work on the investigation of 
hybrid glycosyl donors that combine aforementioned conformational and electronic 
effects. The major emphasis of this study was to compare the reactivity of differently 
protected S-ethyl and S-phenyl donors by competition studies. The applicability of the 
developed glycosyl donors in one-pot oligosaccharide synthesis has been demonstrated. 
This ultimately led us to the development of versatile chemical strategies for the synthesis 
of HMO. Reported herein is the synthesis of common core HMO including lacto-N-tetraose 
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1.1. Introduction: chemical synthesis of glycosides and oligosaccharides 
From the building blocks of nature to disease-battling therapeutics and vaccines, 
carbohydrates have had a broad impact on evolution, society, economy, and human 
health. Numerous applications of these essential molecules in many areas of science and 
technology exist, foremost of which can be found in the areas of therapeutic-agent and 
diagnostic-platform development. Although carbohydrate oligomers, oligosaccharides or 
glycans, are desirable for biological and medical communities, these molecules remain 
very challenging targets for chemists. Amongst a number of hurdles including 
functionalization, elaborate protecting and leaving group manipulations, tedious 
purification and sophisticated structure analysis, it is glycosylation, a coupling reaction 
performed between two monosaccharide units, that has proven particularly challenging to 
chemists. Nature flawlessly performs this reaction to obtain complex glycans and 
glycoconjugates.1,2 Chemical glycosylation, however, remains challenging even with the 
aid of recent methodological breakthroughs3-8 and modern technologies.9-17  
Many methods for chemical glycosylation have been developed, but it is the 
inability to control the stereoselectivity that has proven to be the major hurdle. The 
glycosylation typically follows a unimolecular SN1 mechanism
18,19 via four distinct steps: 
activation, dissociation, nucleophilic attack, and proton transfer (Scheme 1.1).18 In the 
case of a non-participating ether-type substituent at C-2, glycosylation proceeds via an 
oxacarbenium ion.5 The intermediacy of the flattened oxacarbenium ion typically results 
in the formation of anomeric mixtures in which 1,2-cis glycosides20 (for D-gluco/galacto 
series) are slightly favored due to the anomeric effect.21,22 The goal of stereocontrolling 
glycosylation has been approached in many ways and much effort dedicated to 
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developing new leaving groups (LG in schemes) and refining the reaction conditions. We 
know that leaving groups, temperature, promoter/additives, and the reaction solvent may 
have a significant effect on the reactivity of the reactants and the stereoselectivity of 
glycosylation.23 However, since these factors still often fail to adequately control the 
outcome of many glycosylations that tend to proceed via the oxacarbenium ion, studies 
are refocusing on gaining a better understanding of the reaction mechanism.  
Protecting groups are extensively used in carbohydrate chemistry to mask 
additional sites of reactivity in polyfunctional compounds, including both donors and 
acceptors. Protecting groups, however, can affect the glycosylation in a variety of other 
ways. As stated by Fraser-Reid “protecting groups do more than protect.”24 Amongst the 
best known effects of protecting groups is the neighboring acyl group participation,25 
which remains one of the most powerful modes for controlling the stereoselectivity of 
glycosylation reaction (protecting groups do more than protect). A vast majority of 1,2-
trans glycosides is obtained from glycosyl donors equipped with a 2-acyl protecting 
group. These reactions proceed via the intermediacy of a cyclic acyloxonium ion, which 
 
Scheme 1.1.  Outline of the chemical glycosylation.  
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is then opened with the glycosyl acceptor from the opposite (trans) face (Scheme 1.1).   
In addition, protecting groups may have a profound effect on the conformation 
and stereoelectronics of the starting material, key reaction intermediates, and the 
products.26,27 In the recent years dedicated studies of these intermediates have led to the 
development of many stereocontrolled reactions, and the synthesis of β-mannosides via 
anomeric triflates by Crich and co-workers is arguably the best example of such a 
study.28-36 Nevertheless, some linkages and targets remain challenging due to the 
requirement to achieve complete stereocontrol in each and every step,37,38 and suppress 
side reactions.23,39 
Beyond that, the synthesis of oligosaccharides may require additional synthetic 
steps between glycosylations. In accordance with the traditional oligosaccharide 
synthesis, the disaccharide intermediate should be converted into either a glycosyl 
acceptor or donor of the second generation. As depicted in Scheme 1.2, this can be 
accomplished via deprotection (Method A) or introduction of a leaving group instead of a 
temporary anomeric substituent (Method B), respectively. The modified disaccharide 
building blocks can then be reacted with other glycosyl donors or acceptors, resulting in 
the formation of a tri- or larger saccharide if the convergent approach is incorporated.  
These synthetic steps can be then reiterated to obtain larger oligosaccharides.   
 
Scheme 1.2.  Outline of conventional approaches to oligosaccharide synthesis. 
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A large number of additional synthetic steps between each glycosylation step 
typically lead to reduced yields and overall efficiency of the oligosaccharide assembly.  
Consequently, the past quarter of the century has witnessed the development of new 
strategies for oligosaccharide synthesis, amongst which selective and chemoselective 
concepts prevail.40 Synthetic strategies based on selective activations make use of 
different leaving groups that are sequentially activated and traditional selective 
activation,41,42 two-step activation,41,43-45 active-latent concept,46-49 and orthogonal 
strategy50 are just a few examples of such approaches.51 Another general direction in 
expeditious oligosaccharide synthesis involves chemoselective activations. This strategy 
is based on the so-called armed-disarmed strategy introduced by Fraser-Reid et al.52 
Building blocks used in chemoselective activations utilize only one type of a leaving 
group, and the building block reactivity is adjusted by the choice of protecting groups 
(protecting groups do more than protect). The next subchapter introduces this general 
strategy and subsequent sections elaborate on the recent progress that has been made in 
the area of tuning the reactivity of building blocks and their application in stereoselective 
glycosylation and chemoselective oligosaccharide synthesis.  
 
1.2. Fraser-Reid’s armed-disarmed strategy for oligosaccharide synthesis.  
Although the effect of protecting groups on reactivity has been known for many 
decades,53 Fraser-Reid was the first to describe a new mode by which the differential 
properties of protecting groups could be exploited.54  It was noticed that ester protecting 
groups reduce the reactivity (disarm) of the n-pentenyl leaving group, in comparison to 
that of its alkylated (armed) counterpart.  One explanation for this phenomenon is that the 
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increased electron-withdrawal of ester groups decrease the electron density 
(nucleophilicity) of the anomeric heteroatom. This translates into a reduced leaving group 
ability, and works with the leaving groups capable of either direct (thioglycosides) or 
remote activation (n-pentenyl).55 To differentiate the reactivity, mild reaction conditions 
are required and iodonium(di-γ-collidine)perchlorate (IDCP) was found to be a suitable 
mild activator for the armed O-pentenyl glycosyl donors allowing for direct 
chemoselective coupling between an activated (armed) glycosyl donor and a deactivated 
(disarmed) glycosyl acceptor. The disaccharide is then used directly in subsequent 
glycosidation, but the activation of its disarmed leaving group may require a stronger 
activator (NIS/TfOH in case of pentenyl leaving group).  In a more general sense, the 
differentiation can be achieved by modulating the reaction conditions that in addition of 
the choice of promoter, reaction temperature or solvent could be exploited.56 Discovered 
with n-pentenyl glycosides, this armed-disarmed strategy ultimately proved to be of a 
general nature, and has been applied to many other classes of glycosyl donor (see 
subsequent sections).57 
 
Scheme 1.3.  Fraser-Reid’s armed-disarmed strategy 
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A different rationalization of the arming and disarming effects has emerged with 
the discovery of the “O-2/O-5 cooperative effect.”58 In case of the armed donors, it is 
believed that the oxacarbenium ion intermediate is stabilized by integrated assistance 
from the lone pair of electrons on the adjacent ring oxygen (O-5, Figure 1.1). In case of 
the disarmed donors, it is believed that the oxacarbenium ion intermediate is stabilized by 
charge distribution via acyloxonium ion intermediate formed through the acyl type 
protecting group at O-2. The realization of the O-2/O-5 cooperative effect in 
glycosylation led to the discovery of electronically superarmed and superdisarmed 
glycosyl donors and acceptors (vide infra). Reinforcing early work by Isbell,59 Crich et 
al. emphasized that the 1,2-trans orientation of the 2-O-acyl and S-benzoxazolyl (SBox) 
leaving group is required for the anchimeric assistance to occur.60 A similar conclusion 
was reached by Bols and Demchenko for S-phenyl glycosides (vide infra).61 Presumably, 
the stabilization takes place via the concerted displacement of the leaving group.  
 
 
Figure 1.1.  O-2/O-5 Cooperative effect in glycosylation.  
 
1.3. Many reactivity levels exist between the armed and disarmed building blocks 
From the early days, the researchers were devising different approaches to 
quantifying the relative reactivity of different building blocks. Following the pioneering 
study by Fraser-Reid dedicated to determining relative reactivities of variously protected 
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pairs of the n-pentenyl glycosides,53 Ley and co-workers introduced a technique wherein 
building block reactivity could be “tuned.”62  In a series of competitive experiments, 
wherein two glycosyl donors were set to compete for one glycosyl acceptor, a series of 
relative reactivity ratios were established (Scheme 1.4).  For instance, the greatest 
disarming effect was seen from the 2-benzoyl substituent in compound 1.2 in comparison 
to that of 3-benzoyl and 4-benzoyl substituents (1.3 and 1.4).  Di-benzoylated glycosyl 
donors 1.5 and 1.6 were less reactive than their mono-benzoylated counterparts and, the 
disarmed per-benzoylated donor 1.7 being the least reactive in this series.    
 
Scheme 1.4.  Intermediate reactivity of a series of partially benzoylated 
rhamnosides. 
 
Wong and co-workers devised a comprehensive approach wherein a broad library 
of glycosyl donors and acceptors was assigned relative reactivity values (RRVs).63  The 
determination of RRVs was made using tolyl thioglycoside donors in the presence of an 
NIS/TfOH promoter system.  More recently, Hung and Wong created a comprehensive 
database of RRVs for the series of D-glucose building blocks (Figure 1.2).64 According to 
their database, some tri-benzylated acceptors 1.9-1.12 showed similar or even higher 
RRVs in comparison to that of the armed donor 1.8. Not surprisingly, RRVs of mono-
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benzoylated donors 1.13-1.16 was lower, but still much higher than that of the disarmed 
acceptor 1.17 or disarmed donor 1.18. The application of this approach to chemoselective 
oligosaccharide synthesis and determination of the RRVs of silylated donors will be 
discussed below.  
 
Figure 1.2.  RRVs of differently protected STol glycosyl donors and acceptors.  
 
Toshima et al. studied the effect of remote protecting groups of glycosyl donors 
of the 2,3-dideoxy series on the reactivity in glycosylations.65 For this purpose, 
glycosylation reactions of glycosyl acetate donors 1.19 and 1.20 with acceptor 1.21 were 
performed in the presence of several Lewis and protic acid activators including TMSOTf, 
TBSOTf, BF3-OEt2, TfOH, and momorillonite K-10 (MK-10). It was found that 
glycosidation of donor 1.20 yielded disaccharide 1.23 with excellent yield while donor 
1.19 with 4,6-dibenzoyl protection gave disaccharide 1.22 in low yield under the same 
reaction conditions. A similar reactivity profile was determined for 4-benzoyl-6-benzyl 
donor.65  
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Scheme 1.5.  Disarming effects on 2,3-dideoxy donors. 
 
Although most reactivity levels in the studies surveyed in this section fall between 
the traditional armed and disarmed building blocks, Wong’s and Hung’s studies revealed 
a number of building blocks that extend beyond this boundary.  For example, 2-hydroxyl 
galactoside63 or 3-hydroxyl glucoside64 were found to be 3 and 1.5 times more reactive 
than their respective per-benzylated counterparts.  This important discovery led to a new 
direction in studying building blocks, and a variety of new reactivity levels ranging from 
more reactive than the armed ones (superarmed) to even less reactive than the disarmed 
ones (superdisarmed) has been discovered. The studies arising from these two new 
directions will be discussed in the subsequent two subsections, respectively.   
 
1.4. Modes for enhancing the reactivity: superarmed building blocks 
Uniformly protected per-benzylated glycosyl donors have become the benchmark 
for describing the armed glycosyl donors, or reactivity levels associated with it. Over the 
years, benzyl groups had been almost exclusively used as arming ether protecting groups 
until Demchenko and co-workers showed that 2-O-picolinyl group has similar electronic 
properties and can also be used in chemoselective armed-disarmed activations.66 
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Uniquely, the picolinyl group is capable of affecting the stereoselectivity, which makes it 
suitable as an “arming participating group.” More recently, o-cyano and o-nitrobenzyl 
have been introduced as arming participating groups.67,68 
Other recent improvements have revealed the reactivity levels that far exceed the 
reactivity of traditional uniformly benzylated armed building blocks.  These 
“superarmed” glycosyl donors have further expanded the versatility of the armed-
disarmed concept.  Introduced by Bols for describing the reactivity of conformationally 
armed building blocks, the term superarmed is now used to describe all building blocks 
that are more reactive than per-benzylated armed building blocks.  Building upon early 
studies of the effect of conformational changes on reactivity69 Bols and co-workers 
hypothesized that the conformational change required to obtain a flattened oxacabenium 
intermediate that exists in a half-chair conformation will be facilitated in the axial-rich 
donor. If this conformational change could be facilitated, the activation energy of the rate 
determining step (RDS) should decrease, and the donor reactivity would be enhanced. 
The conformational change of SPh glucoside 1.24 was induced via creating steric 
congestion with tert-butyldimethylsilyl (TBS) groups at the C-2, 3 and 4 positions, 
resulting in a skew-boat conformation of 1.25 (Scheme 1.6).69-73  
 
Scheme 1.6.  Conformational superarming: conformation change leads to increased 
reactivity. 
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As a result, glycosyl donor 1.25 showed an estimated 20-fold increase in 
reactivity in comparison to the per-benzylated donor. This was ultimately translated into 
the direct chemoselective coupling of donor 1.25 with the armed acceptor 1.26 in the 
presence of NIS/TfOH at -78 °C to give disaccharide 1.27 in a high yield.71,72   
The RRVs of partially silylated STol glycosyl donors reported by Hung and 
Wong clearly reinforce Bols’ findings that the reactivity may vary drastically depending 
on the number of silyl groups present and their location on the sugar ring.64 For example, 
mono-silylated donors 1.28-1.31 express much higher reactivity than the standard armed 
donor 8 (Figure 1.3). Both TBS and their tri-isopropylsilyl (TIPS) counterparts have been 
studied and the latter showed a marginally higher reactivity across the range of all mono-
silylated derivatives studied. Di-silylated thioglycosides 1.32-1.35, in which silyl groups 
were remotely positioned to each other, showed 2 to 6 times higher RRVs compared to  
 
Figure 1.3.  RRVs of partially silylated superarmed glycosyl donors. 
 
their mono-silylated counterparts. The greater reactivity enhancement was detected for 
di-silylated derivatives 1.36 and 1.37 in which the two silyl substituents were placed at 
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the neighboring trans-vicinal positions of the ring, 2,3 and 3,4 respectively. Interestingly, 
TBS substituents were more arming than TIPS in all di-silylated donors 1.32-1.37. 
The scope of conformational superarming was broadened by the investigation of a 
series of glycosyl donors in which the axial-rich conformation was achieved via strategic 
tethering. Building upon their earlier studies of 2,4-diol tethering with di-tert-butyl 
silylene72 and Yamada’s 3,6-O-(o-xylylene)-bridging,74 Bols and co-workers devised a 
series of novel glycosyl donors. Under this, 3,6-di-tert-butyl silylene tethering in gluco-, 
manno-, galacto-, and 2-azido-gluco pyranosides have been investigated.75 All of these 
donors were found to adopt axial-rich B1,4 boat or 
3S1 skew boat conformations. To 
determine the relative reactivity, direct activations of the new donors over the armed tri-
benzylated acceptor 1.26 have been conducted.  As depicted in Scheme 1.7, 
chemoselective glycosylations with donors 1.38-1.40 afforded disaccharides 1.41-1.43 in 
51-70% yields with preferential α-selectivity. 
  
Scheme 1.7.  Conformational superarming via 3,6-silylene tethering. 
 
Demchenko and co-workers took a different approach for superarming glycosyl 
donors. The superarming of S-benzoxazolyl (SBox) and SEt glycosyl donors was based 
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on the O-2/O-5 cooperative effect in glycosylation (vide infra).58 In this scenario, it is 
believed that the oxacarbenium ion intermediate is stabilized by the cooperative 
assistance from both the lone pair of electrons on the adjacent ring oxygen (O-5) and 
charge distribution via acyloxonium ion intermediate formed through the acyl type 
protecting group at O-2 (Scheme 1.8). The 2-O-benzoyl-3,4,6-tri-O-benzyl derivatives 
gain extra stabilization upon activation through this O-2/O-5 cooperative mechanism and 
becomes a superarmed donor. As a result of the competitive glycosylation upon 
activation with dimethyl(thiomethyl)sulfonium trifluoromethanesulfonate (DMTST), it 
was observed that donors equipped with 2-OBz-3,4,6-tri-OBn pattern are 10-20 times 
more reactive than their armed counterparts.76-78 Thus, a competitive reaction of donors 
1.44 and 1.45 with acceptor 1.21 gave disaccharide 1.46 derived from the superarmed 
donor 1.44 in 95%. Meanwhile, the disaccharide 47 derived from the armed donor 45 was 
found only in trace amounts. 
 
Scheme 1.8.  Superarmed (1.44) and armed (1.45) glycosyl donors in the competitive 
glycosylation. 
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These results clearly showed that the superarmed donor is much more reactive 
than the armed counterpart. Further studies by the Demchenko group showed that the 
same trend of reactivity appears upon changing the leaving group. While efficient 
differentiation of glycosyl donors of the S-ethyl series could be efficiently achieved in the 
presence of iodine as promoter, the reactivity difference was notably lower for glycosyl 
donors of the SPh, S-Tolyl, STaz (S-thiazolinyl), and O-pentenyl series.78 
Through a collaboration between the Bols and Demchenko groups, the two 
different approaches to superarm glycosyl donors were combined in one universal 
platform. Glycosylations with 2-OBz-3,4-di-OTBS donor 1.49 was swift, high yielding 
and β-stereoselective (Scheme 1.9).61 In order to determine the relative reactivity of the 
new hybrid donor 1.49 in comparison to the previously investigated superarmed donors, a 
series of competitive experiments have been performed.  
 
Scheme 1.9.  Superarming by combined neighboring and conformational effects. 
 
Thus, a competition experiment between the hybrid donor 1.49 and the electronically 
super-armed donor 1.51 showed a 88% conversion of donor 1.49 to glycoside 1.52 
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whereas unreacted donor 1.51 was recovered in 94%. When a similar competition 
experiment was performed between donors 1.49 and 1.25, a higher conversion of donor 
1.25 to 1.53 has been observed. A significance of the anomeric configuration brought up 
by Crich60 was further reinforced by this comparison study that showed higher reactivity 
of donor 1.49 than its β-linked counterpart 1.50. It is also believed that the flipped skew-
boat conformation of the donor may also diminish the anchimeric assistance due to the 
non-antiperiplanar nature of the 2-OBz group to the anomeric leaving group.  
On the other hand, α-configured glycosyl donors equipped with a non-
participating group at C-2 typically by far exceed the reactivity of their β-
counterparts.61,79 This controversy reinforces the power of the anchimeric assistance that 
is able to invert the reactivity of α- and β-thioglycosides. Over the course of this study the 
order of relative reactivity of various glycosyl donors was determined. It was also learned 
that the conformational arming is a very powerful tool to increase the reactivity and 
achieve excellent yields. The anchimeric superarming effects are weaker, but the 
participation ensures high 1,2-trans selectivity, which was unavailable with other 
conformationally superarmed donors. A recent relevant study revealed that SEt glycosyl 
donors follow a very similar relative reactivity trend, but all SEt glycosides are 
marginally more reactive than their SPh counterparts.80 
 
1.5. Modes for decreasing the reactivity: superdisarmed building blocks 
Standard disarmed building blocks are uniformly protected with benzoyl groups 
(per-benzoates). Madsen et al have revealed that building blocks can be deactivated by 
placing a single electron-withdrawing group at a remote position.81,82 Thus, they have 
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shown that 6-O-pentafluorobenzoyl (PFBz) group disarms the leaving group of 1.55. The 
disarming effect is sufficient to selectively activate per-benzylated armed donor 1.54 over 
acceptor 55 to obtain disaccharide 1.56 (Scheme 1.10A). This concept was further 
extended to disarming building blocks of the galacto, manno and manosamine series. 
Crich and co-worker have investigated the disarming effect that 6-fluoro-6-deoxy 
glycosyl donors in terms of reactivity, selectivity and stability of the intermediate 
glycosyl triflates. Thus, it was observed that di- and tri-fluorinated D- or L-mannosyl 
triflates were more stable than their mono-fluorinated counterpart. This was accessed by 
comparing the decomposition temperatures specific to each glycosyl triflate as depicted 
in Scheme 10B.83  
 
Scheme 1.10.  Deactivation by strong electron withdrawal from C-6.  
  
The effect of cyclic acetals and ketals has also been studied towards expanding 
the scopes of armed- disarmed strategy. Fraser-Reid et al.84 and Ley85 et al. have shown 
that the presence of such cyclic protecting groups can deactivate the sugar derivative by 
increasing the rigidity of the sugar ring and thereby locking the 4C1 chair conformation 
that may interfere with the formation of the flattened oxacarbenium ion.84,86 Extensive 
studies have led to the realization that reactivity of building blocks protected with cyclic 
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groups can even be lower than that of the corresponding per-benzoylated disarmed 
building blocks. Thus, Boons and co-workers have shown that presence of the cyclic 2,3-
carbonate group disarms the thioglycosidic donor more than per-acylation, making the 
former superdisarmed.87 As a result, disarmed per-benzoylated glycosyl donor 1.60 could 
be selectively activated over the superdisarmed acceptor 1.61 to yield disaccharide 1.62 
in a good yield (Scheme 1.11). Along similar lines, Demchenko et al. showed that even a 
conventional benzylidene acetal groups can superdisarm building blocks of the SBox 
series.58 
 
Scheme 1.11.  Chemoselective activation of disarmed donors over acceptors bearing 
fused rings. 
 
The Bols group brought up the fact that the disarming effect of cyclic acetals can 
be not only due to the ring rigidity, but also due to the electron withdrawing effect of C-6 
group which is further enriched by its orientation.88  From model studies, they have 
concluded that the torsional effect, which greatly depends on the substituent orientation, 
plays a role in disarming the sugar moieties. More recently, Crich and co-workers 
investigated the effect of a 4,6-O-alkylidene acetal or its 7-carba analog on the rates of 
hydrolysis of methyl and 2,4-dinitrophenyl galactopyranosides in which the methoxy 
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group adopts either an equatorial or an axial position according to the configuration.89 
This study reinforced previous findings, and it was determined that the alkylidene acetal 
leads to decreased rates of hydrolysis with respect to comparable systems lacking the 
cyclic protecting group. A combination of the two effects, torsional and electronic, may 
be one of the reasons the donors containing the fused ring systems tend to be less reactive 
than the pure-electronically disarmed, acylated building blocks. In contrast, 7-carba 
analogs had practically no effect on the rates of hydrolysis.  
Demchenko et al discovered that S-benzoxazolyl (SBox) glycosyl donor protected 
with arming benzyl at C-2 and disarming benzoyl groups at C-3, 4 and 6 shows greatly 
diminished reactivity compared to both the armed per-benzylated and disarmed per-
benzoylated glycosyl donors.58   
 
Scheme 1.12.  Electronically superdisarmed building blocks. 
 
While glycosylation of acceptor 1.66 with SBox donors 1.45 and 1.63 in the presence of 
copper(II) triflate gave the respective disaccharides 1.67 and 1.68 in good yields, donor 
1.69 remained totally unreactive.  Interestingly, this observation was contradictory to 
previously predicted higher reactivity for such 2-O-benzylated glycosides compared to 
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disarmed per-benzoylated donors.62,63 This discrepancy was rationalized by the “O-2/O-5 
cooperative effect”.58 In this application, the carbocation stabilization can neither be 
achieved from the endocyclic ring oxygen (O-5) as in the armed glycosyl donors, nor 
from O-2 as in disarmed donors.  As a result, this combination gave rise to the 
“superdisarming” protecting group pattern overall. 
Demchenko and co-workers discovered a conceptually new way of disarming the 
leaving groups. The conceptual difference of this approach from Fraser-Reid’s armed-
disarmed approach is that herein the disarming is achieved by acylation of the leaving 
group itself, not by introducing the neighboring acyl substituents in the sugar moiety. 
This was investigated in application to S-benzimidazolyl (SBiz) leaving group versus N-
anisoylated SBiz.90 First, SBiz donor 1.70 was activated with MeI over the disarmed 
acceptor 1.71 to afford disaccharide 1.72 (Scheme 1.13).  
 
Scheme 1.13.  Disarming by placing an acyl substituent on the leaving group. 
 
The disarmed N-anisoylated SBiz disaccharide was then glycosylated with the glycosyl 
acceptor 1.21 in the presence of AgOTf to give the trisaccharide 1.73 in 84% yield. It was 
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noted that benzylated and benzoylated SBiz imidates can also be activated in the 
conventional armed-disarmed fashion. 
 
1.6. Application of armed and disarmed building blocks in stereocontrolled 
glycosylation 
Armed and disarmed building blocks follow general stereoselectivity trends in 
glycosylations: armed per-benzylated derivatives provide some α-stereoselectivity, 
whereas disarmed benzoylated ones give complete β-selectivity due to the participation 
of 2-benzoyl. As aforementioned, picolinyl can be used as an arming group at C-2, but 
the chemoselective activation of the 2-O-picolinylated donors leads to 1,2-trans 
glycosides, inverse stereoselectivity in comparison to that achieved with traditional 
benzylated armed glycosyl donors. Thus, upon activation with Cu(OTf)2 the armed S-
thiazolinyl (STaz) glycosyl donor 1.74 gives the stable cyclic intermediate.  
 
Scheme 1.14.  Arming participating picolinyl group mediated 1,2-trans-
glycosylation. 
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The latter is subsequently glycosylated with the disarmed STaz acceptor 1.75 to 
give 1,2-trans-linked disaccharide 1.76 in 74% yield (Scheme 1.14).  The resulting 
disarmed disaccharide donor 1.76 has been further glycosylated with the acceptor 1.21 in 
the presence of stronger promoter AgOTf to obtain the trans-trans-linked trisaccharide 
1.77 in 91% yield.66   
Mlynarski and co-workers investigated ortho-nitrobenzyl (NBn) as an arming 
participating group.67 They theorized that 2-O-ortho-nitrobenzyl will participate in 
glycosylation by stabilizing the oxacarbenium ion intermediate and hence blocking the 
bottom face from the nucleophilic attack (Scheme 1.15A). The activation of glucosyl 
donor 1.78 with Ph2SO/Tf2O/TTBP (2,4,6-tri-tert-butylpyrimidine) afforded disaccharide 
1.79 in a high yield and preferential 1,2-trans selectivity.  Liu and co-workers 
investigated another arming participating group, o-cyanobenzyl (CBn) at C-2 position of 
a glycosyl donor.68 
The interesting feature of this glycosylation method is that a single glycosyl donor 
can yield either α- or β-linked products depending on the nature of the glycosyl acceptor. 
It is believed that the dual directing effect of o-nitrobenzyl group is due to the 
equilibrium in reaction intermediates A-C (Scheme 1.15B). Thus, the activation of donor 
1.80 will result in the formation of oxacarbenium ion B that is stabilized via cis-
nitronium ion A. The latter will direct the nucleophilic attack from the top face hence 
offering β-directing effect that is preferred with reactive electron-rich glycosyl acceptors. 
Another mode by which o-cyanobenzyl group can react is via H-bond-mediated aglycone 
delivery (HAD). Discovered with remote picolinyl and picoloyl groups, the HAD method 
has already yielded a number of highly selective syntheses and applications.91-100  A 
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similar HAD action can be envisaged for 2-O-ortho-cyanobenzyl group (see intermediate 
C in Scheme 1.15B). It was concluded that this mechanism of action leading to high α-
selectivity is preferred with electron-deficient acceptors.  
 
Scheme 1.15.  Use of  O-nitrobenzyl and O-cyanobenzyl arming participating 
groups. 
 
In the context of the stereoselective synthesis of α-glycosides, electronically 
superdisarmed glycosyl donors, which are also 2-O-benzylated, often provide higher 
stereoselectivity than their per-benzylated counterparts.20 A valuable application of 
superdisarmed SEt donors has emerged with the synthesis and glycosidation of glycosyl 
sulfonium salts as activated intermediates of thioglycoside glycosidation. The mode of 
activation of thioglycosides has been proposed multiple times although direct evidence 
could only be acquired with superdisarmed thioglycosides due to high stability of the 
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intermediate. Thus, direct alkylation of a superdisarmed ethylthio glycoside with MeOTf 
led to a sulfonium salt that could be isolated and characterized by NMR.79 A number of 
other anomeric sulfonium salts, most notably that derived from the reaction with 
dimethyl(methylthio)sulfonium triflate (DMTST) was obtained.79 Various experiments 
with simple alcohol acceptors showed high 1,2-cis stereoselectivity of glycosidation of 
sulfonium salt intermediates. 
Bromine-activated glycosylation of thioglycosides introduced by Demchenko et 
al. gave high stereoselectivity only with superdisarmed thioglycosides.101 Thus, it was 
demonstrated that the 1,2-trans glycosyl bromide is the only intermediate leading to 
products while the 1,2-cis bromide remains unreactive and the oxacarbenium 
intermediate does not form. Resultantly, the nucleophilic displacement of β-bromide 
takes place in a concerted bimolecular fashion leading to exclusive α-stereoselectivity. 
For instance, 3,4,6-tri-O-benzoyl-2-O-benzyl thioglycoside 1.86 was coupled with 
acceptor 1.21 in the presence of bromine to afford disaccharide 1.87 with exclusive 1,2-
cis selectivity in 67% yield (Scheme 1.16).  
 
Scheme 1.16.  Bromine-mediated activation of S-ethyl donors.101 
The use of α-thioglycoside starting material was found advantageous for generating β-
bromide intermediate. The average yield, which is due to the competing isomerization of 
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β- to α-bromide, could be further improved by using HgBr2 as the co-promoter, but this 
could also decrease the stereoselectivity. For comparison, armed donor 1.85 or 4-benzoyl 
donor 1.88, gave no stereoselectivity for the formation of the respective disaccharides 
1.47 and 1.89. 
Bennett and co-workers devised new promoter systems that gave high α-
selectivity for both armed and disarmed glycosyl donors of the 2-deoxy series 1.90 and 
1.93, respectively (Scheme 1.17).102 NMR monitoring showed that the armed hemiacetal 
donor 1.90 is first converted into to the respective glycosyl chloride intermediate by the 
action of 3,3-dichloro-1,2-diphenylcyclopropene promoter. The latter is then converted 
into a mixture of α- and β-glycosyl iodides with TBAI, but predominantly the more 
reactive β-iodide reacts with glycosyl acceptor 1.91. Presumably, this displacement 
proceeds in the SN2 fashion leading to glycosides in high α-selectivity. Interestingly, 3,3-
dichloro-1,2-diphenylcyclopropene promoter failed to activate the disarmed donor 1.93 
due to the high stability of the intermediate chloride. In this case, 3,3-dibromo-1,2-
diphenylcyclopropene was found to be an effective promoter that provided glycosides 
1.94 in excellent stereoselectivity. 
 
Scheme 1.17.  Highly stereoselective glycosylation with armed and disarmed 2-deoxy 
donors. 
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Superarmed glycosyl donors allow to achieve various selectivities depending on their 
structure and the mode of superarming. Conformationally superarmed donor 1.25 
introduced by Bols et al is capable of providing high stereoselectivity that was attributed 
to the steric hindrance from the bulky 2-O-silyl substituents.69-72 Depicted in Scheme 1.6 
is a β-stereoselective glycosylation of acceptor 1.26 that afforded disaccharide 1.27 in a 
high yield of 85% and complete selectivity. In application of the synthesis of 
rhamnosides, a drastic temperature effect on stereoselectivity was observed. The 
conformationally superarmed rhamnosyl donors produced modest β-selectivity at low 
temperatures, but increasing the temperature gave excellent α-selectivity.103 
Table 1.1.  Survey of stereoselectivity in glycosylation with different donors. 
Type of donors Stereoselectivity Ref 
Armed per-benzyl Cis/trans-mixtures, mainly 
1,2-cis  
52,54,104,105 
Disarmed per-benzoyl Complete 1,2-trans 52,54,104,105 
Armed with 2-O-arming participating 
group 
Complete 1,2-trans 66-68,106 
Electronically superdisarmed Moderate or high 1,2-cis 58,101 
Superdisarmed by fused ring systems High or complete 1,2-cis* 31,34,107-111 
Conformationally superarmed Cis/trans-mixtures 70,71 
Conformationally and anchimerically 
superarmed 
Complete 1,2-trans 61 
Anchimerically superarmed Complete 1,2-trans 76-78 
Conformational superarming by tethering High 1,2-cis 75 
* - high stereoselectivity can be achieved in 4,6-benzylidene or 2,3-
cyclocarbonyl/ oxazolidinone systems. However, little has been investigated 
in the context of the chemoselective oligosaccharide synthesis. 
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A relaxed stereoselectivity obtained with conformationally superarmed donors was 
addressed by the introduction of a hybrid donor 1.49 in which the superarming was 
achieved by the combined anchimeric and conformational factors (2-O-Bz-3,4-di-O-TBS 
protection). All glycosylations with donor 1.49 were completely β-selective61 as well as 
the electronically superarmed donors bearing 2-O-Bz-tri-O-Bn protection.76-78 Very 
differently, glycosyl donors in which the superarming is achieved by 3,6-silicon 
tethering, such as donor 1.38, provide predominant α-selectivity, which was attributed to 
the steric hindrance of the top face of the oxacarbenium intermediate.75 Table 1.1 surveys 
currently known modes for arming/ disarming and stereoselectivities that can be achieved 
by using these approaches. 
 
1.7. Application of armed/superarmed and disarmed building blocks in 
chemoselective oligosaccharide synthesis. 
The expeditious preparation of complex oligosaccharides remains a significant 
challenge to synthetic organic chemistry. The combined demands of regio- and 
stereoselectivity in glycosidic bond formation, has led to complex synthetic schemes and 
extensive protecting group manipulations. As aforementioned, the use of a 
chemoselective activation strategy avoids such extraneous manipulations, thus offering 
significant advantages for expeditious glycoside synthesis. Since the glycosidation of 2-
O-acylated glycosyl donors typically proceeds via the formation of the bicyclic 
acyloxonium intermediate, the overall two-step armed-disarmed activation sequence 
leads to a cis-trans-patterned trisaccharide. Starting with Fraser-Reid’s pentenyl-based 
synthesis,54 a number of relevant examples have emerged.57 For instance, Hashimoto et 
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al. activated the armed galactosyl donor 1.95 over the disarmed galactosyl acceptor 1.96 
with TMSOTf at –46 oC to obtain disaccharide 1.97 in 85% yield. The latter was then 
glycosidated with glycosyl acceptor 1.98 in the presence of TMSOTf at 0 oC to provide 
the requisite cis-trans-sequenced trisaccharide 1.99 in 85% yield.112 While this synthesis 
is highly stereoselective, a majority of glycosylation with armed donors suffers from low 
stereoselectivity. 
 
Scheme 1.18.  Armed-disarmed synthesis112 of glycosphingolipid 1.99. 
 
While the traditional armed-disarmed strategy provides a straightforward access 
to cis-trans sequenced trisaccharides, other sequences cannot be directly accessed. It was 
quickly realized that for this excellent concept to become universally applicable it should 
be expanded to a broader range of linkages, protecting group patterns, and 
oligosaccharide sequences. Major improvements in this direction that have emerged in 
the past decade are summarized in Table 1.2. With the discovery of other levels of 
reactivity, a more flexible synthesis of a variety of oligosaccharide sequences using the 
chemoselective activation has become possible. 
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Table 1.2.  A survey of oligosaccharide sequences that can be obtained by 
chemoselective activation. 
Sequence* Building blocks needed Ref 
Cis-trans Traditional armed → disarmed  54,112 
Cis-trans-cis Armed → disarmed → superdisarmed 58 
Cis-trans-trans Programmable strategy 63 
Cis-cis Armed → disarmed with the interim reprotection  
Armed → torsionally or anchimerically superdisarmed 




Trans-trans 2-Pico armed → traditional disarmed (Scheme 14)  
Anchimerically superarmed → armed 
66,106 
77 
Trans-cis 2-Pico armed → superdisarmed 
Anchimerically superarmed → disarmed 
106 
77 
Trans-cis-trans Conformationally superarmed → armed → disarmed  
Anchimerically superarmed → armed → disarmed 
70 
78 
* - practically any sequence can be achieved with the use of selective 
activations based on building blocks with different leaving groups. 
Preactivation concept pioneered by Huang and Ye is another way to 
achieve flexible sequencing. 
 
 For example, cis-trans oligosaccharide sequence obtained through the traditional 
armed and disarmed donor could be extended to cis-trans-cis sequence by adding a 
superdisarmed acceptor to this combination.58 However, if the extension to another trans-
linkage is desired, Wong’s programmable strategy is the only way to achieve the 
chemoselective synthesis of cis-trans-trans oligosaccharides.63 With many reactivity 
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levels, the programmable strategy can be applied to many other targets and sequences and 
some representative examples will be discussed below. 
A number of approaches have been developed for the synthesis of cis-cis 
sequenced oligosaccharides.82,84,106,113,114 Arming participating 2-O-picolinyl and other 
similar groups can simplify the syntheses wherein the trans-linkage needs to be 
introduced first.66-68,106 For instance, activation of 2-picolinyl donor over disarmed or 
superdisarmed acceptors can be used to obtain trans-trans or trans-cis oligosaccharide 
sequences, respectively.106 The trans-cis-trans sequence has been obtained by the 
combination of either conformationally superarmed or anchimerically superarmed donor 
with armed and disarmed acceptors. 70,78 Preactivation-based strategies, which tend to be 
classified as selective rather than chemoselective, also allow for obtaining many of these 
sequences. A few examples of such sequences are discussed below. 
 
Scheme 1.19.  Sequential activation of armed → disarmed → superdisarmed 
building blocks.58 
 
With the discovery of the anchimerically superdisarmed building blocks, it is now 
possible to produce the cis-trans-cis oligosaccharide sequence.58 Thus, it was 
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demonstrated that disarmed disaccharide 1.101, obtained by classic armed-disarmed 
approach from building blocks 1.45 and 1.100, could be chemoselectively activated over 
superdisarmed building block 1.102 (Scheme 1.19).  This was affected in the presence of 
Cu(OTf)2/TfOH to produce trisaccharide 1.103 (70% yield),
58 which can be used for 
further glycosylations directly. 
The programmable strategy revealed many reactivity levels, which allow to 
modulate building blocks to obtain various sequences. An example of a sequence wherein 
no other chemoselective approaches could be used is depicted in Scheme 1.20. This 
approach was conducted in one-pot with no isolation and characterization of intermediate 
oligosaccharides. Armed glycosyl donor 1.104 was chemoselectively activated over 
glycosyl acceptor 1.105 in the presence of NIS/TfOH.  The resulting disaccharide 
intermediate was then reacted with added disarmed glycosyl acceptor 1.106 to form the 
trisaccharide intermediate that was then glycosidated with added glycosyl acceptor 1.107 
to provide cis-trans-trans-linked tetrasaccharide 1.108 in 39% overall yield.63   
 
Scheme 1.20.  Sequential activation in one-pot for the synthesis of cis-trans-trans-
linked tetrasaccharide. 
Van Boom and co-workers invented a two-step method, glycosylation and 
protecting group manipulation, to obtain cis-cis-linked oligosaccharides.113 Here, after the 
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first armed-disarmed activation step the resulting disaccharide was reprotected (OBz → 
OBn) prior to the subsequent glycosidation.  A more recent example of this strategy 
wherein propargyl mannosyl donors have been used is shown in Scheme 1.21.114 
Glycosylation of the armed mannosyl donor 1.109 with disarmed acceptor 1.110 was 
performed in the presence of 5 mol % of AuCl3 and AgSbF6 in CH3CN/CH2Cl2 (1/1) at 
25 °C. As a result, the disarmed disaccharide 1.111 obtained in 85% yield was then 
reprotected with benzyls to obtain the armed disaccharide 1.112 in 84% yield. The 
glycosylation between disaccharide 1.112 and disarmed acceptor 1.113 was performed 
under the same conditions to obtain the desired trisaccharide 1.114 in 21% yield.  
 
Scheme 1.21.  Synthesis of cis-cis-patterned trisaccharide via the interim 
reprotection. 
 The utilization of the cooperative effect allows for the direct synthesis of cis-cis-
linked oligosaccharides, similar to that discussed previously. In this application, the 
sequential activation of armed per-benzylated glycosyl donor over superdisarmed 3,4-di-
O-benzoyl-2-O-benzyl protected STaz glycosyl acceptor led to the cis-cis-linked 
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oligosaccharide.106 The presence of the remote 6-O-pentafluorobenzoyl group disarms the 
glycosyl acceptor and also facilitates the synthesis of cis-cis-linked sequences.82 
 As aforementioned, the application of the 1,2-trans-directing picolinyl 
functionality of armed glycosyl donor in activation over the standard disarmed glycosyl 
acceptor will allow for the synthesis of trans-trans-patterned oligosaccharides (see 
Scheme 1.14). The programmable strategy was also applied to the synthesis of trans-
trans linked oligosaccharide as shown in Scheme 1.22.64 Coupling of thioglycoside 1.115 
and acceptor 1.116 in the presence of NIS/TMSOTf followed by quenching the activator 
with tripropargylamine and glycosylation with the lactosyl diol 1.117 in the presence of 
NIS/AgOTf afforded tetrasaccharide 1.118 in 40% yield in one pot. 
 
Scheme 1.22. Programmable strategy for the synthesis of trans-trans-linked 
oligosaccharide. 
The application of the trans-directing 2-O-picolinylated armed glycosyl donors in 
activation over the superdisarmed acceptors allows to obtain a trans-cis glycosylation 
pattern, which is opposite to the traditional armed-disarmed methodology.106 Thus, 
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glycosylation between S-thiazolinyl donor 1.74 and the disarmed acceptor 1.119 in the 
presence Cu(OTf)2/TfOH afforded trans-linked disaccharide 1.120 in 70% yield. 
Disaccharide 1.120 was then glycosylated with acceptor 1,21 in the presence of AgOTf to 
give the anticipated inverse-patterned trans-cis-linked trisaccharide 1.121 in 54% yield 
(Scheme 1.23). 
 
Scheme 1.23.  Sequential activation of picolinylated armed → superdisarmed 
building blocks: synthesis of trans-cis-linked trisaccharide 1.121. 
 
The conformational superarming concept has been successively proven by a one-
pot glycosylation reaction performed between three building blocks 1.25, 1.122, and 
1.123, which were placed in the same reaction vessel from the beginning (Scheme 
1.24).70 In this method, it is essential that all reaction components, not only glycosyl 
donors (1.25 and 1.122), but also glycosyl acceptors (1.122 and 1.123) have differential 
reactivity. The superarmed glycosyl donor 1.25 will be glycosylated with the more 
reactive primary glycosyl acceptor 1.122. The resulting disaccharide intermediate with 
then react with the remaining glycosyl acceptor 1.123 to yield the desired trisaccharide 
1.124 in 64% in the one-pot fashion. 
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Scheme 1.24.  Superarmed → armed → disarmed activation for the one-pot 
synthesis.   
 
A similar sequence was obtained with the electronically superarmed glycosyl 
donors, but in this approach a more conventional stepwise synthesis was performed. 
Thus, disaccharide 1.127 was obtained in 80% yield from the glycosylation between 
superarmed glycosyl donor 1.125 and armed acceptor 1.126 upon activation with iodine 
at -25 °C (Scheme 1.25).  The resulting disaccharide 1.127 was glycosylated with the 
disarmed acceptor 1.128 in the presence of iodine at room temperature to afford 
trisaccharide 1.129 in 55% yield. Finally, trisaccharide 1.129 was glycosylated with 
glycosyl acceptor 1.21 in the presence of NIS/ TfOH to obtain the desired tetrasaccharide 
1.130 composed of the trans-cis-trans sequence.  
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Scheme 1.25.  Synthesis of tetrasaccharide with alternating trans-cis linkages. 
 
Preactivation concept is independent of the building-block reactivity since the 
leaving group of the glycosyl donor is first converted into a highly reactive species 
(preactivation) and then the acceptor is added.115 Although this approach involves 
additional steps because the glycosylation herein is a two-step reaction, it offers more 
flexibility with the leaving and/or protecting groups. A relevant example illustrating this 
excellent concept in application to the synthesis of the tumor associated carbohydrate 
antigen Globo H hexasaccharide is shown in Scheme 1.26.116  The fucosyl donor 1.131 
was preactivated at -78 oC with p-TolSCl/AgOTf and then the first acceptor 1.132 was 
added along with a sterically hindered base TTBP. The temperature was then raised to -
20 oC to obtain the trisaccharide intermediate. Upon complete disappearance of acceptor 
1.132, the reaction mixture was cooled again to -78 oC followed by the sequential 
addition of AgOTf, p-TolSCl, galactose acceptor 1.133, TTBP and then warming up the 
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reaction to -20 oC. After complete disappearance of the acceptor 1.133, the temperature 
was lowered to -78 oC and the sequence was reiterated for glycosylation of lactoside 
1.134. The resulting Globo H hexasaccharide -1.135 was isolated in 47% overall yield 
based on the four-component one-pot reaction within 7 h. 
 
Scheme 1.26.  One-pot synthesis of Globo H hexasaccharide based on preactivation. 
 
Mong et al. investigated the possibility of using DMF-modulated glycosylation 
concept117 in so-called disarmed-armed glycosylation, which is also based on 
preactivation.118 In accordance with this approach, the glycosyl donor produces β-
glycosyl imidinium triflate in the presence of DMF. It has been shown that dioxalenium 
ion and β-imidinium triflate are in equilibrium and the acceptor can react with both of 
these species resulting in an α/β-mixture of glycosides. The β-selectivity is inversely 
W. M. Mithila D. Bandara | UMSL 2019 | Page  38 
 
correlated to the amount of DMF, and pure β-selectivity was achieved with 1.2 equiv of 
DMF.117 Since DMF modulated glycosylations induce a preactivation step, this method 
opens the glycosyl donor to iterative glycosylations.  
 
Scheme 1.27. DMF modulated disarmed–armed iterative glycosylation 
 
To demonstrate the applicability of this method in oligosaccharide synthesis several 
different trisaccharides, including the one-pot synthesis of the α-(1,2)-linked trisaccharide 
1.139 shown in Scheme 1.27, were obtained. Gildersleeve et al. have shown that the 
aglycone transfer side reaction may occur when the preactivation method is applied for 
the glycosylations of armed acceptors with the disarmed donors.119 A number of 
approaches including the use of sterically hindered leaving groups (aglycones)119-121 have 
been invented to overcome the aglycone transfer in such preactivation glycosylations.   
 
1.8. Conclusions and Outlook 
Since the first glycosylation reactions performed in the late 1800s, carbohydrate 
chemistry has evolved into a broad area of research that has persistently captured the 
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interest of the scientific community. With recent advances in the rapidly expanding fields 
of glycosciences, the demand for reliable and stereocontrolled glycosylation methods has 
increased. Nevertheless, the installation of the glycosidic linkages and the assembly of 
oligosaccharide sequences remain cumbersome due to the lack of understanding of the 
mechanistic detail of glycosylation or the inability to translate such knowledge into 
practical execution. A number of excellent strategies that offer a reasonably efficient 
route to oligosaccharide assembly have already emerged and the armed-disarmed 
approach for chemoselective oligosaccharide synthesis is undoubtedly amongst them.  
The search of new concepts continues, and the field of armed-disarmed glycosylations 
enjoyed an explosive expansion. New reactivity levels have been revealed and a few new 
concepts for glycosyl donor activation have been introduced and tested in armed-
disarmed strategies.122-124 Many new sequences can now be achieved directly, but in a 
majority of application, one needs to take care of protecting groups: protecting groups do 
more than protect. Although recent advancements discussed in this Chapter have already 
significantly expanded the scope of the armed-disarmed methodology it is clear that 
further development of efficient and general methods for the expeditious synthesis of 
complex carbohydrates will remain an important and active arena for scientific endeavors 
of the 21st century.   
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2.1. Introduction 
Mechanistic challenges of the chemical glycosylation reaction have been 
consistently capturing the attention of the synthetic community.1-5 Many classes of 
glycosyl donors have been developed6,7 and many strategies for oligosaccharide synthesis 
have emerged.8-10 Among the methods and strategies available, the development of the 
armed-disarmed strategy for chemoselective oligosaccharide synthesis occupies an 
important niche.11-13 Reactivity tuning of various series of thioglycosides has been 
reported and applied to the synthesis of a variety of oligosaccharide sequences.14-19 
Beyond the traditional scope of the armed-disarmed strategy, superarmed and 
superdisarmed building blocks have also been identified and studied.20 Bols and co-
workers developed an approach to superarm glycosyl donors by changing the equatorial-
rich 4C1 conformation to an axial-rich conformation.
21-25 These conformational changes 
were induced by creating steric congestion with tert-butyldimethylsilyl (TBS) or related 
bulky protecting groups at the C-2, 3 and 4 positions of S-phenyl (SPh) glucosides, 
resulting in a skew-boat conformation. These donors showed a 20-fold increase in 
reactivity as compared to the armed per-O-benzylated counterparts.23 The Demchenko 
group also reported superarmed S-benzoxazolyl (SBox) and S-ethyl (SEt) glycosyl 
donors, but the superarming was based on the O2/O5-cooperative effect in 
glycosylation.26 Thus, it was demonstrated that donors equipped with 2-O-benzoyl-3,4,6-
tri-O-benzyl protecting group pattern are 10 times more reactive than their armed 
counterparts.27-29  
With the two different approaches to superarm glycosyl donors, our groups 
jointly developed a 2-O-benzoyl donor 2.1 with 3,4-di-O-TBS protection (Scheme 2.1). 
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Over the course of that study we learned that conformational arming is a powerful tool to 
increase the reactivity and achieve excellent yields and the 2-O-benzoyl substituent 
ensures complete 1,2-trans stereoselectivity.30 The anchimeric superarming effects in the 
conformationally modified donor 2.1 are significantly weaker to the extent that 2-O-
benzoylated SPh donor 2.1 is 5.8 and 4.5 times less reactive than its 2-O-TBS and 2-O-
benzylated counterparts 2.2 and 2.3, respectively (Scheme 2.1).  Although glycosylations 
with the hybrid donor 2.1 were swift, high yielding and β-stereoselective,30 we feared that 
the reduced reactivity could translate into the decreased efficacy of these building blocks 
in application to sequential chemoselective glycosylations in one-pot.  This led us to a 
hypothesis that the use of a more reactive S-ethyl leaving group31,32 would help us to 
develop a complementary superarmed glycosyl donor with a superior reactivity profile 
while still maintaining β-stereoselectivity.  
 
Scheme 2.1.  The relative reactivity of the conformationally superarmed S-phenyl 
glycosyl donors.30  
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2.2. Results and discussion 
Right off the start, when donor 2.1 was subjected to the competition 
experiment with the equally protected SEt donor 2.5, a much higher reactivity of the 
latter has been detected. The competition experiments for this study were conducted 
following essentially the same experimental conditions and ratios as in our previous 
study.30 Two glycosyl donors, used in equimolar amounts (1.0 equiv. each), were set to 
compete for excess glycosyl acceptor 2.433 (2.0 equiv.) in the presence of NIS (1.0 equiv.) 
and TfOH (0.1 equiv.) at -78 oC. The use of low temperature, that was allowed to 
gradually increase over the course of the reaction, and the use of a very limited amount of 
the promoter helped to maintain workable reaction rates. All competition experiments 
were quenched after 1 h and the remaining glycosyl donors were isolated and quantified.  
 
Scheme 2.2.  The relative reactivity of S-phenyl versus S-ethyl glycosyl donors of the 
superarmed series. 
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Thus, as a result of the first competition experiment, SPh donor 2.1 remained 
as the major monosaccharide component of the mixture and was isolated in 87% yield, 
whereas only 13% of SEt donor 2.5 was remaining (Scheme 2.2). This translates into the 
1/6.7 reactivity ratio between the two donors, or in other words, the SEt donor 2.5 is 6.7 
times more reactive than its SPh counterpart 2.1.  
Subsequent competition experiments led to a realization that 2-O-benzoyl SEt 
donor 2.5 is nearly as reactive as 2-O-benzyl SPh donor 2.3 (1/1.1) and even only slightly 
less reactive than the most reactive superarmed 2-O-TBS protected SPh donor 2.2 known 
to date (1/1.6, Scheme 2). To explore the reactivity limits of superarmed glycosyl donors 
of the SEt series, we obtained donor 2.6 equipped with 2-O-benzyl protecting group. The 
competition experiment with equally protected SPh donor 2.3 led to a realization of the 
higher reactivity of donor 2.6 (2,3/2.6 = 1/3.8). Along similar lines, we determined that 
donor 6 is 3.7 times more reactive than the 2-O-TBS SPh donor 2.2.30 
Being encouraged by the first series of comparative experiments, we decided to 
investigate the new hybrid donor 2.5 in the context of other SEt donors. For this study we 
obtained anchimerically superarmed derivative 2.7 along with two conformationally 
superarmed donors equipped with 6-O-benzoyl and 2,6-di-O-benzoyl protections, 2.8 and 
2.9, respectively. The first competition experiment between donors 2.5 and 2.7 provided a 
very impressive reactivity difference: donor 2.5 was 95 times more reactive that donor 
2.7 (Scheme 2.3). This result is more indicative of the superior reactivity of 2.5 rather 
than poor reactivity of 2.7. The latter is still superarmed because it is much more reactive 
than its per-benzylated counterpart. In addition, donor 2.7 is 2.2 times more reactive than 
the previously developed hybrid SPh donor 2.1. Moreover, compound 2.7 is also 2.3 
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more reactive than the conformationally superarmed SEt donor 2.8 equipped with two 
benzoyl groups at O-2 and O-6.  
 
Scheme 2.3.  The effect of the conformational and electronic superarming in the 
series of S-ethyl glycosyl donors. 
 
A comparison of donors 2.5 and 2.8 showed a very significant deactivating effect 
of 6-O-benzoyl in comparison with 6-O-benzyl, the only structural difference between 
the two donors.34 Thus, 6-O-benzyl donor 2.5 was 97 times more reactive than its 6-O-
benzoylated counterpart 2.8. Donor 2.5 was also found to be 5.3 times more reactive than 
donor 2.9 with the reverse positioning of benzyl and benzoyl substituents: 2-O-benzyl, 6-
O-benzoyl.  
With this comprehensive set of competitive experiments, we began 
investigating the glycosyl donor properties of compounds 2.5-2.8 with the model 
acceptor 2.4.  After screening a number of promoters for the activation of thioglycosides, 
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we chose NIS/TfOH and DMTST. These reaction conditions offered a good balance of 
reactivity, selectivity and yields. Other promoters, including iodine that was successfully 
used in our previous study of the anchimerically superarmed SEt donors, let to decreased 
yieds resulting from high rates of major side reactions: TBS cleavage and/or SEt 
hydrolysis. Thus, NIS/TfOH-promoted coupling between donor 2.5 and acceptor 2.4 
swiftly (20 min) produced disaccharide 2.10 in 83% yield and complete β-
stereoselectivity (entry 1, Table 2.1). Practically the same outcome was achieved in the 
DMTST-promoted reaction listed in entry 2. NIS/TfOH-promoted activation of donor 2.6 
gave disaccharide 2.11 in 81% yield (entry 3). In this case, the reaction was non-
stereoselective due to the absence of neighboring group participation.  DMTST was less 
effective and TBS groups showed high propensity to cleavage. As a result, disaccharide 
2.11 was obtained in a poor yield of 21% (entry 4). The outcome of this reaction could be 
improved (44% yield) using only a slight excess DMTST (1.3 equiv.).  
Glycosidation of the anchimerically superarmed donor 2.7 was successful in 
case of either NIS/TfOH or DMTST-promoted activations. Disaccharide 2.12 was 
obtained with complete β-stereoselectivity in 82 or 85% yield, respectively (entries 5 and 
6). In case of donor 2.8, only NIS/TfOH gave a practical result, whereas DMTST showed 
a high level of competing processes. Thus, NIS/TfOH-promoted activation of 2.8 
produced disaccharide 2.13 in 85% yield and complete β-stereoselectivity (entry 7). The 
conformational properties of disaccharide 2.10 were studied by X-ray crystallography 
(Figure 2.1). The crystals of 2.10 were obtained by slow evaporation of aq. MeOH. The 
skew-boat conformation of disaccharide 2.10 was deduced from the X-ray data and was 
consistent with altered coupling constants obtained from its 1H NMR spectrum.  
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Table 2.1.  Glycosylation of acceptor 2.4 with different superarmed SEt donors. 
 
entry donor conditions,a time 
product 




A, 20 min 
 
2.10 (83, β-only) 




A, 15 min 
 
2.11 (81, 1.0/1) 




A, 30 min 
 
2.12 (82, β-only) 




A, 30 min 
 
2.13 (85, β-only) 
a – Conditions A: NIS/TfOH (1.3 equiv), 3 Å mol sieves; B: DMTST (2.0 equiv), 4 Å 
mol sieves;  b - the yield is impacted by fair stability of the TBS groups (see text)  













Figure 2.1.  The X-ray structure of disaccharide 2.10 (hydrogens and protecting 
groups have been omitted for clarity) 
 
With a series of glycosyl donors of differential reactivity, we began studying 
the applicability of this method to the one-pot oligosaccharide synthesis.35 With a number 
of different concepts for the one-pot synthesis, we chose one-pot/one-addition method, 
the pure fashioned approach wherein all building blocks are present from the beginning. 
Invented by Kahne,36 and further explored by Fraser-Reid37 and Bols21, this approach 
requires fine tuning of reactivity for differentiation of all reaction components. The 
general idea underpinning this approach is that the more reactive donor will react with the 
more reactive acceptor (hydroxyl). Subsequently, the second-step coupling will involve 
the coupling between the less reactive donor with the less reactive acceptor. 
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With these considerations, we chose highly reactive donor 2.5 to couple with 
the reactive 6-OH in benzylated building block 2.14 equipped with the anomeric SEt 
group. Fast first-step reaction will permit the sequential (rather than competitive) 
activation of the SEt leaving group of the intermediate disaccharide in reaction with the 
less reactive acceptor 2.15 (Scheme 2.4).  
 
Scheme 2.4.  One-pot one-addition synthesis of trisaccharides 2.16, 2.18 and 2.20. 
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Building block 2.14 is the key reaction component in the mixture because it is set 
to react both as the more reactive acceptor and then as the less reactive donor. The role of 
the highly reactive superarmed donor is also essential to ensure that the first coupling step 
is swift. The synthesis of trisaccharide 2.16 was conducted from building blocks 2.5, 2.14 
and 2.15 that were mixed together and NIS/TfOH were added. As a result, compound 
2.16 was obtained in one pot in 42% yield and high stereoselectivity (α/β = 14/1, Scheme 
2.4). A substantial quantity of the cross-coupled disaccharide resulting from the reaction 
between 2.5 and 2.15 indicated that the reactivity difference between primary hydroxyls 
in 2.15 and 2.16 is insufficient to ensure effective one-pot coupling. A simple competitive 
experiment set up between the two acceptors and donor 2.5 showed that 2.14 is only 2.1.6 
times reactive than 2.15 (Scheme 2.5).  
To improve the outcome of the one-pot synthesis we prepared secondary acceptor 
2.17 that was deactivated by surrounding benzoyl substituents.38,39 The competition 
experiment showed that primary acceptor 2.14 is 10.1 times more reactive than its 
secondary counterpart 2.17 (Scheme 2.5). Theorizing that this reactivity difference will 
be sufficient, we set up the synthesis of trisaccharide 2.18 from building blocks 2.5, 2.14 
and 2.17 that were mixed and NIS/TfOH were added. As a result, trisaccharide 2.18 was 
obtained in one pot in 37% yield and high stereoselectivity (α/β = 11/1, Scheme 2.4). No 
cross-coupled disaccharide was found in the reaction mixture, but attempts to push the 
reaction to completion promoted competitive TBS group hydrolysis. In a further search 
of suitable building blocks for the one-pot synthesis, we obtained acceptor 2.19 
benzylated at C-6. This acceptor is only 2.5 times less reactive than its primary 
counterpart 2.14 (Scheme 2.5). Nevertheless, this reactivity difference was sufficient for 
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the synthesis of trisaccharide 2.20 in a good yield of 65% and high stereoselectivity (α/β 
= 10/1, Scheme 2.4) showing the utility of this approach and also the necessity to fine-
tune all reaction components. 
 
Scheme 2.5.  The relative reactivity of glycosyl acceptors 2.14, 2.15, 2.17 and 2.19. 
 
2.3. Conclusions 
We have developed a series of superarmed SEt glycosyl donors that were 
applied to stereoselective glycosylations and multi-step oligosaccharide synthesis in one-
pot. Further application of these highly reactive compounds to glycosylation of various 




3.4.1 General methods  
The reactions were performed using commercial reagents and the ACS grade 
solvents were purified and dried according to standard procedures.  Column 
chromatography was performed on silica gel 60 (70-230 mesh), reactions were monitored 
by TLC on Kieselgel 60 F254. The compounds were detected by examination under UV 
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light and by charring with 10% sulfuric acid in methanol. Solvents were removed under 
reduced pressure at <40 oC. CH2Cl2 was distilled from CaH2 directly prior to application. 
Acetonitrile was dried by refluxing with CaH2 and then distilled and stored over 
molecular sieves (3 Å). Molecular sieves (3 or 4Å), used for reactions, were crushed and 
activated in vacuo at 390 °C during 8 h in the first instance and then for 2-3 h at 390 °C 
directly prior to application. Optical rotations were measured using a polarimeter. 1H 
NMR spectra were recorded at 300 or 600 MHz, 13C NMR spectra were recorded at 75 
MHz or 150 MHz. The 1H chemical shifts are referenced to the signal of the residual 
CHCl3 (δH = 7.24 ppm). The 
13C chemical shifts are referenced to the central signal of 
CDCl3 (δC = 77.23 ppm). HRMS determinations were made with the use of a mass 
spectrometer with FAB ionization and ion-trap detection.  
 
3.4.2 Preparation of glycosyl donors 2.1, 2.2, 2.3, 2.5, 2.6, 2.8, 2.9 
 
Scheme 2.6.  Preparation of glycosyl donors 2.5, 2.6, 2.8, 2.9. 
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Ethyl 2-O-benzoyl-6-O-benzyl-1-thio-β-D-glucopyranoside (2.22).  A mixture of ethyl 
2-O-benzoyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (2.21,40 2.56 g, 6.15 mmol) 
and molecular sieves (3 Å, 3.0 g) in dry THF (80 mL) was stirred under argon for 1 h at 
rt. NaCNBH3 (5.15 g, 81.8 mmol) and a 2 M solution of HCl in diethyl ether (40.9 mL, 
81.8 mmol) were added and the resulting mixture was stirred for 30 min at rt. After that, 
the volatiles were removed under reduced pressure and the residue was diluted with 
CH2Cl2 (~150 mL). The solid was filtered off through a pad of Celite and rinsed 
successively with CH2Cl2. The combined filtrate (~250 mL) was washed with water (50 
mL), sat. aq. NaHCO3 (50 mL), and water (3 x 50 mL). The organic phase was separated, 
dried over MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate – hexane gradient elution) to afford the title 
compound in 82% yield (2.11 g, 5.04 mmol) as a white amorphous solid. Analytical data 
for 2.22: Rf = 0.25 (ethyl acetate/hexane, 3/7, v/v); []D
27 -54.4 (c = 1, CHCl3); 
1H NMR 
(300 MHz, CDCl3): δ, 1.21 (t, 3H, J = 7.4 Hz, CH2CH3), 2.68 (m, 2H, CH2CH3), 3.48 (m, 
1H, H-5), 3.65-3.78 (m, 3H, H-3, 4, 6b), 3.90 (s, 1H, OH), 3.82 (s, 1H, OH), 4.51 (d, 1H, 
J1,2 = 9.5 Hz, H-1), 4.55 (br. s, 2H, CH2Ph), 5.06 (dd, 1H, J2,3 = 9.5 Hz, H-2), 7.29-8.04 
(10H, aromatic) ppm;  13C NMR (75 MHz, CDCl3): δ, 15.2, 24.1, 70.1, 71.8, 73.0, 73.7, 
76.7, 78.7, 83.3, 127.9 (×3), 128.5 (×4), 129.7, 130.1 (×2), 133.4, 137.7, 166.4 ppm; HR-
FAB MS [M+Na]+ calcd for C22H26NaO6S
+ 441.1348, found 441.1334. 
 
Ethyl 2,6-di-O-benzyl-1-thio-β-D-glucopyranoside (2.24).  A mixture of ethyl 2-O-
benzyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (2.23,41 1.58 g, 3.92 mmol) and 
molecular sieves 42 in dry THF (65 mL) was stirred under argon for 1 h at rt. NaCNBH3 
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(3.29 g, 52.0 mmol) and a 2 M solution of HCl in diethyl ether (26.1 mL, 52.0 mmol) 
were added and the resulting mixture was stirred for 30 min at rt. After that, the volatiles 
were removed under reduced pressure and the residue was diluted with CH2Cl2 (~50 mL). 
The solid was filtered off through a pad of Celite and rinsed successively with CH2Cl2. 
The combined filtrate (~100 mL) was washed with water (20 mL), sat. aq. NaHCO3 (20 
mL), and water (3 x 20 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate – hexane gradient elution) to afford the title compound in 98% yield (1.65 
g, 4.07 mmol) as a white amorphous solid. Analytical data for 2.24: Rf = 0.25 (ethyl 
acetate/hexane, 3/7, v/v); []D
26.6 -28.7 (c = 1, CHCl3);
 1H NMR (300 MHz, CDCl3): δ, 
1.32 (t, 3 H, J = 7.4 Hz, CH2CH3), 2.76 (m, 2H, CH2CH3), 3.05 (s, 1H, OH), 3.26 (dd, 
1H, J2,3 = 8.6 Hz, H-2), 3.41-3.62 (m, 3H, H-3, 4, 5), 3.67-3.79 (m, 2H, H-6a, 6b), 4.46 
(d, 1H, J1,2 = 9.6 Hz, H-1), 4.57 (dd, 2H, 
2J = 13.7 Hz, CH2Ph), 4.81 (dd, 2H, 
2J = 10.9 
Hz, CH2Ph), 7.19-7.50 (m, 10H, aromatic) ppm; 
13C NMR (75 MHz, CDCl3): δ, 15.3, 
25.3, 70.6, 72.0, 73.8, 75.3, 77.8,78.2, 80.9, 85.0, 127.9 (×2), 128.0, 128.3, 128.5 (×2), 
128.7 (×2), 128.8 (×2), 137.9, 138.1 ppm; HR-FAB MS [M+Na]+ calcd for 
C22H28NaO5S
+ 427.1554, found 427.1555. 
 
Ethyl 2-O-benzoyl-1-thio-β-D-glucopyranoside (2.25).  Compound 2.21 (0.71 g, 1.70 
mmol) was dissolved in a mixture of trifluoroacetic acid in wet CH2Cl2 (20 mL, 
2/0.2/17.8, v/v/v) and the resulting mixture was stirred for 30 min at rt. After that, the 
reaction mixture was neutralized with trimethylamine (~3 mL) and the volatiles were 
removed under reduced pressure. The residue was purified by column chromatography on 
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silica gel (methanol - dichloromethane gradient elution) to afford the title compound in 
86% yield (0.48 g, 1.46 mmol) as a white amorphous solid. Analytical data for 2.25: Rf = 
0.27 (methanol/dichloromethane, 1/9, v/v); []D
19.9 -8.1 (c = 1, MeOH); 1H NMR (300 
MHz, CD3OD): δ, 1.18 (t, 3H, J = 7.5 Hz, CH2CH3), 2.70 (m, 2H, CH2CH3), 3.38-3.47 
(m, 2H, H-5, 4), 3.64-3.73 (m, 2H, H-3, 6a), 3.89 (dd, 1H, J6a,6b = 12.1 Hz, J5,6b = 1.8 Hz, 
H-6b), 4.65 (d, 1H, J1,2 = 10.0 Hz, H-1), 4.97 (dd, 1H, J2,3 = 9.3 Hz, H-2), 7.45-8.00 (m, 
5H, aromatic) ppm; 13C NMR (75 MHz, CD3OD): δ, 15.2, 24.9, 62.8, 71.6, 74.5, 77.4, 
82.2, 84.6, 129.5 (×2), 130.7 (×2), 131.5, 134.3, 167.2 ppm; HR-FAB MS [M+Na]+ calcd 
for C15H20NaO6S
+ 351.0879, found 351.0875. 
 
Ethyl 2-O-benzyl-1-thio-β-D-glucopyranoside (2.27).  Compound 2.23 (0.55 g, 1.36 
mmol) was dissolved in a mixture of trifluoroacetic acid in wet CH2Cl2 (20 mL, 
1.5/0.2/14.8, v/v/v) and the resulting mixture was stirred for 30 min at rt. After that, the 
reaction mixture was neutralized with trimethylamine (~2.5 mL) and the volatiles were 
removed under reduced pressure. The residue was purified by column chromatography on 
silica gel (methanol - dichloromethane gradient elution) to afford the title compound in 
85% yield (0.36 g, 1.16 mmol) as a white amorphous solid. Analytical data for 2.27: Rf = 
0.35 (methanol/dichloromethane, 1/9, v/v); []D
21.5 -45.4 (c = 1, MeOH); 1H NMR (300 
MHz, CD3OD): δ, 1.17 (t, 3H, J = 7.4 Hz, CH2CH3), 2.65 (m, 2H, CH2CH3), 3.07 (dd, 
1H, J2,3 = 8.8 Hz, H-2), 3.11-3.26 (m, 2H, H-4, 5), 3.39 (dd, 1H, J3,4 = 8.8 Hz, H-3), 3.54 
(dd, 1H, J5,6a = 5.5 Hz, J6a,6b = 12.0 Hz, H-6a), 3.74 (dd, 1H, J5,6b = 2.1 Hz, H-6b), 4.36 (d, 
1H, J1,2 = 9.7 Hz, H-1), 4.70 (s, 2H, CH2Ph), 7.10-7.32 (m, 5H, aromatic) ppm; 
13C NMR 
(75 MHz, CD3OD): δ, 15.5, 25.5, 63.0, 71.8, 76.2, 79.8, 82.0, 82.9, 85.9, 128.8, 129.3 
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Ethyl 2,6-di-O-benzoyl-1-thio-β-D-glucopyranoside (2.26).  A solution of BzCN (0.08 
g, 0.81 mmol) in dry CH3CN (10.0 mL) was added dropwise to a solution of 2.25 (0.19 g, 
0.58 mmol) and triethyl amine (6.0 mL) in dry CH3CN (10.0 mL), and the resulting 
mixture was stirred under argon for 3 h at -30 oC.  MeOH (~1 mL) was added and the 
volatiles were removed under reduced pressure. The residue was purified by column 
chromatography on silica gel (ethyl acetate – hexane gradient elution) to afford the title 
compound in 70% yield (0.175 g, 0.41 mmol) as a white amorphous solid.  Analytical 
data for 2.26: Rf = 0.37 (ethyl acetate/hexane, 1/1, v/v); []D
26.6 -7.7 (c = 1, MeOH); 1H 
NMR (300 MHz, CDCl3): δ, 1.24 (t, 3H, J = 7.4 Hz, CH2CH3), 2.71 (m, 2H, CH2CH3), 
3.16 (d, 1H, J = 3.9 Hz, OH), 3.52 (d, 1H, J = 3.1 Hz, OH), 3.57-3.72 (m, 2H, J5,6b = 4.2 
Hz, H-4, 5), 3.84 (ddd, 1H, J3,4 = 9.3 Hz, H-3), 4.57 (dd, 1H, J6a,6b = 12.2 Hz, 6a), 4.63 (d, 
1H, J1,2 = 9.8 Hz, H-1), 4.74 (dd, 1H, H-6b), 5.11 (dd, 1H, J2,3 = 9.3 Hz, H-2), 7.51-8.04 
(m, 10H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, 15.2, 24.3, 63.9, 70.7, 73.0, 
76.7, 78.2, 83.6, 128.7 (×4), 129.6, 129.7, 130.1 (×2), 130.2 (×2), 133.6, 133.7, 166.5, 
167.5 ppm; HR-FAB MS [M+Na]+ calcd for C22H24NaO7S
+ 455.1141, found 455.1145. 
 
Ethyl 6-O-benzoyl-2-O-benzyl-1-thio-β-D-glucopyranoside (2.28). A solution of BzCN 
(0.138 g, 1.02 mmol) in dry CH3CN (15.0 mL) was added dropwise to a solution of 2.27 
(0.305 g, 0.970 mmol) and triethylamine (10.0 mL) in dry CH3CN (15.0 mL) at -30 
oC 
and the resulting mixture was stirred under argon for 3 h at that temperature.  After that, 
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MeOH (1.0 mL) was added to the reaction mixture and the volatiles were removed under 
reduced pressure. The residue was purified by column chromatography on silica gel 
(ethyl acetate – hexane gradient elution) to afford the title compound in 75% yield (0.30 
g, 0.727 mmol) as a white amorphous solid.  Analytical data for 2.28: Rf = 0.34 (ethyl 
acetate/hexane, 1/1, v/v); []D
21.5 -31.3 (c = 1, CHCl3);
 1H NMR (300 MHz, CDCl3): δ, 
1.30 (t, 3H, J = 7.4 Hz, CH2CH3), 2.75 (m, 2H, CH2CH3), 3.11 (br. s, 1H, OH), 3.26 (dd, 
1H, J2,3 = 9.7 Hz, H-2), 3.39-3.56 (m, 3H, H-4, 5, OH), 3.58-3.64 (m, 1H, H-3), 4.48 (d, 
1H, J1,2 = 9.7 Hz, H-1), 4.51-4.60 (m, 2H, H-6a, 6b), 4.80 (dd, 
2J = 10.9 Hz, CH2Ph), 
8.73-7.89 (m, 10H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, 15.3, 25.3, 64.3, 70.2, 
75.3, 77.8, 78.0, 80.9, 85.1, 128.3, 128.5 (×2), 128.6 (×2), 128.8 (×2), 129.8, 130.0 (×2), 





lucopyranoside (2.1).  The synthesis of the title compound was performed in accordance 




(2.2).  The synthesis of the title compound was performed in accordance with the 
reported procedure and its analytical data was in accordance with that previously 
described.22 
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Phenyl 2,6-di-O-benzyl-3,4-di-O-tert-butyldimethylsilyl-1-thio-β-D-glucopyranoside 
(2.3).  The synthesis of the title compound was performed in accordance with the 




glucopyranoside (2.5).  TBSOTf (2.7 mL, 12.0 mmol) was added to a solution of 2.22 
(1.67 g, 4.0 mmol) in 2,6-lutidine (12.0 mL) and the resulting mixture was heated at 130 
oC for 1 h. After that, the reaction mixture was allowed to cool to rt, diluted with ethyl 
acetate (~250 mL), and washed with 1 M aq. HCl (3 × 50 mL), water (50 mL), sat. aq. 
NaHCO3 (50 mL), and brine (2 x 50 mL). The organic phase was separated, dried with 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate – toluene gradient elution) to afford the title compound in 92% 
yield (2.35 g, 3.64 mmol) as a colorless syrup. Analytical data for 2.5: Rf = 0.71 (ethyl 
acetate/ toluene, 1/9, v/v); []D
26.9 -3.7 (c = 1, CHCl3); 
1H NMR (300 MHz, CDCl3): δ, 
0.05, 0.06, 0.07, 0.08 (4 s, 12H, 2 x SiMe2), 0.83, 0.85 (2 s, 18H, 2 x Si
tBu), 1.25 (t, 3H, 
J = 7.4 Hz, CH2CH3), 2.71 (m, 2H, CH2CH3), 3.65 (dd, 1H, J6a,6b = 9.7 Hz, H-6a), 3.74-
3.82 (m, 2H, H-4, 6b), 3.84-3.91 (m, 2H, J5,6a = 6.6 Hz, H-3, 5), 4.58 (dd, 2H, 
2J = 12.0 
Hz, CH2Ph), 4.85 (d, 1H, J1,2 = 8.8 Hz, H-1), 5.13 (dd, 1H, J2,3 = 4.1 Hz, H-2), 7.22-8.04 
(m, 10H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, -4.2, -4.0, -3.6, -3.4, 0.2, 15.2, 
18.2 (×2), 24.6 (×3), 26.1 (×3), 71.0, 71.5, 73.6, 74.5, 75.8, 81.6, 81.7, 127.8, 127.8 (×2), 
128.5 (×4), 130.2 (×2), 130.3, 133.3, 138.5, 165.7 ppm; HR-FAB MS [M+Na]+ calcd for 
C34H54NaO6SSi2
+ 669.3078, found 669.3064. 




(2.6). TBSOTf (1.05 mL, 4.60 mmol) was added to a solution of 2.24 (0.85 g, 1.53 
mmol) in 2,6-lutidine (5.0 mL) and the resulting mixture was heated at 130 oC for 1 h. 
After that, the reaction mixture was allowed to cool to rt, diluted with ethyl acetate (~100 
mL) and washed with 1 M aq. HCl (3 × 20 mL), water (20 mL), sat. aq. NaHCO3 (20 
mL) and brine (2 x 20 mL). The organic phase was separated, dried with MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate – toluene gradient elution) to afford the title compound in 90% yield 
(0.87g, 1.37 mmol) as a colorless syrup. Analytical data for 2.6: Rf = 0.75 (ethyl acetate/ 
toluene, 1/9, v/v); []D
26.8 -26.4 (c = 1, CHCl3);
 1H NMR (300 MHz, CDCl3): δ, -0.04, -
0.01, 0.01, 0.03 (4 s, 12H, 2 x SiMe2), 0.80, 0.84 (2 s, 18H, 2 x Si
tBu), 1.26 (t, 3H, J = 
7.4 Hz, CH2CH3), 2.69 (m, 2H, CH2CH3), 3.33 (dd, 1H, J2,3 = 3.6 Hz, H-2), 3.56 (dd, 1H, 
J5,6a= 6.6 Hz, J6a,6b = 9.6 Hz, H-6a), 3.62-3.84 (m, 4H, H-3, 4, 5, 6b), 4.51 (dd, 2H, 
2J = 
12.0 Hz, CH2Ph), 4.51 (dd, 2H, 
2J = 10.9 Hz, CH2Ph), 4.74 (d, 1H, J1,2 = 8.6 Hz, H-1), 
7.17-7.37 (m, 10H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, -4.2, -3.9, -3.5, -3.4, 
15.3, 18.2 (×2), 25.3, 26.1 (×3), 26.3 (×3), 71.3, 71.7, 73.4 (×2), 76.5, 81.3, 82.7, 82.8, 
127.6, 127.7, 127.8 (×4), 128.3 (×2), 128.5 (×2), 138.6, 138.6 ppm; HR-FAB MS 
[M+Na]+ calcd for C34H56NaO5SSi2
+ 655.3285, found 655.3291. 
 
Ethyl 2-O-benzoyl-3,4,6-tri-O-benzyl-1-thio-β-D-glucopyranoside (2.7). The synthesis 
of the title compound was performed in accordance with the reported procedure and its 
analytical data was in accordance with that previously described.43 




(2.8). TBSOTf (1.13 mL, 4.93 mmol) was added to a solution of 2.26 (0.71 g, 1.64 
mmol) in 2,6-lutidine (4.0 mL) and the resulting mixture was heated at 130 oC for 1 h. 
After that, the reaction mixture was allowed to cool to rt, diluted with ethyl acetate (~100 
mL) and washed with 1 M aq. HCl (3 × 15 mL), water (20 mL), sat. aq. NaHCO3 (20 
mL), and brine (2 x 20 mL). The organic phase was separated, dried with MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate – toluene gradient elution) to afford the title compound in 89% yield (0.96 
g, 1.46 mmol) as a colorless syrup. Analytical data for 2.8: Rf = 0.75 (ethyl acetate/ 
toluene, 1/9, v/v); []D
26.9 -0.3 (c = 1, CHCl3); 
1H NMR (300 MHz, CDCl3): δ, -0.02, -
0.01, -0.01, 0.00 (4 s, 12H, 2 x SiMe2), 0.75, 0.79 (2 s, 18H, 2 x Si
tBu), 1.12 (t, 3H, J = 
7.4 Hz, CH2CH3), 2.58 (m, 2H, CH2CH3), 3.75 (dd, 1H, J4,5 = 5.4 Hz, H-4), 3.84-3.91 (m, 
2H, J3,4 = 5.4 Hz, J5,6a = 7.0 Hz, J5,6b = 4.6 Hz, H-3, 5), 4.36 (dd, 1H, J6a,6b = 11.4 Hz, H-
6a), 4.60 (dd, 1H, H-6b), 4.78 (d, 1H, J1,2 = 8.6 Hz, H-1), 5.07 (dd, 1H, J2,3 = 4.9 Hz, H-
2), 7.40-8.05 (m, 10H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, -4.2, -3.9, -3.4, -
3.2, 15.2, 18.2 (×2), 24.8, 26.1 (×3), 26.2 (×3), 65.2, 71.5, 74.1, 75.6, 79.7, 81.9, 128.5 
(×2), 128.6 (×2), 129.8 (×4), 130.2 (×2), 130.3, 133.3, 165.7, 166.5 ppm. HR-FAB MS 
[M+Na]+ calcd for C34H52NaO7SSi2
+ 683.2870, found 683.2877. 
 
Ethyl 6-O-benzoyl-2-O-benzyl-3,4-di-O-tert-butyldimethylsilyl-1-thio-β-D-
glucopyranoside (2.9).  TBSOTf (0.30 mL, 1.28 mmol) was added to a solution of 2.28 
(0.18 g, 0.429 mmol) in 2,6-lutidine (3.0 mL) and the resulting mixture was heated at 130 
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°C for 1 h. After that, the reaction mixture was allowed to cool to rt, diluted with ethyl 
acetate (~60 mL) and washed with 1 M aq. HCl (3 × 5 mL), water (5 mL), sat. aq. 
NaHCO3 (5 mL) and brine (2 x 5 mL). The organic phase was separated, dried with 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate – toluene gradient elution) to afford the title compound in 86% 
yield (0.24g, 0.37 mmol) as a colorless syrup. Analytical data for 2.9: Rf = 0.75 (ethyl 
acetate/ toluene, 1/9, v/v); []D
21.6 -0.8 (c = 1, CHCl3);
 1H NMR (300 MHz, CDCl3): δ, -
0.05-0.02 (4 s, 12H, 2 x SiMe2), 0.80, 0.82 (2 s, 18H, 2 x Si
tBu), 1.18 (t, 3H, J = 7.4 Hz, 
CH2CH3), 2.62 (m, 2H, CH2CH3), 3.32 (dd, 1H, J2,3 = 4.0 Hz, H-2), 3.71 (dd, 1H, H-4), 
3.78-3.86 (m, 2H, J3,4 = 5.0 Hz, H-3, 5), 4.32 (dd, 1H, J5,6a = 7.4 Hz, J6a,6b = 11.3 Hz, H-
6a), 4.52 (dd, 1H, J5,6b = 4.8 Hz, H-6b), 4.65 (dd, 
2J = 11.1 Hz, CH2Ph), 4.74 (d, 1H, J1,2 
= 8.4 Hz, H-1), 7.10 – 8.01 (m, 10H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, -4.2, 
-3.8, -3.3, -3.2, 15.3, 18.2, 18.3, 25.4, 26.1 (×3), 26.4 (×3), 65.6, 71.7, 73.6, 76.5, 79.4, 
82.5, 82.9, 127.6, 127.8 (×2), 128.3 (×2), 128.5 (×2), 129.8 (×2), 130.2, 133.2, 138.5, 
166.4 ppm; HR-FAB MS [M+Na]+ calcd for C34H54NaO6SSi2
+ 669.3077, found 
669.3087.  
 
2.4.3 Synthesis of glycosyl acceptors 2.4, 2.14, 2.15, 2.17, 2.19 
Methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.4).  The synthesis of the title 
compound was performed in accordance with the reported procedure and its analytical 
data was in accordance with that previously described.33,44 
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Ethyl 2,3,4-tri-O-benzyl-1-thio-β-D-glucopyranoside (2.14).  The synthesis of the title 
compound was performed in accordance with the reported procedure and its analytical 
data was in accordance with that previously described.45 
 
Methyl 2,3,4-tri-O-benzoyl-α-D-glucopyranoside (2.15).  The synthesis of the title 
compound was performed in accordance with the reported procedure and its analytical 
data was in accordance with that previously described.46  
 
Methyl 2,3,6-tri-O-benzoyl-α-D-glucopyranoside (2.17).  The synthesis of the title 
compound was performed in accordance with the reported procedure and its analytical 
data was in accordance with that previously described.47 
 
Methyl 2,3-di-O-benzoyl-6-O-benzyl-α-D-glucopyranoside (2.19).  The synthesis of 
the title compound was performed in accordance with the reported procedure and its 
analytical data was in accordance with that previously described.48 
 
2.4.4. General procedures for competition experiments 
Donor competition experiments.  A mixture of two glycosyl donors (0.035 mmol each), 
glycosyl acceptor 2.4 (0.071 mmol), and freshly activated molecular sieves (3 Å, 150 mg) 
in CH2Cl2 (2.0 mL) was stirred under argon for 16 h at rt. The mixture was cooled to -78 
°C, NIS (0.035 mmol) and TfOH (0.0035 mmol) were added, and the resulting mixture 
was stirred under argon for 1 h. During this time, the temperature of the reaction mixture 
was allowed to gradually increase to 0 °C.  After that, triethylamine (~ 0.1 mL) was 
W. M. Mithila. D. Bandara | UMSL 2019 | Page  79 
 
added, the solid was filtered off, and rinsed successively with CH2Cl2. The combined 
filtrate (~60 mL) was washed with sat. aq. NaHCO3 (5 mL), 10% aq. Na2S2O3 (5 mL) and 
water (3 x 10 mL). The organic layer was separated, dried with MgSO4, and concentrated 
in vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate 
– toluene gradient elution) and the amount of unreacted donors quantified. 
 
Acceptor competition experiments.  A mixture of two glycosyl acceptors (0.042 mmol 
each), glycosyl donor 2.5 (0.038 mmol), and freshly activated molecular sieves (3 Å, 150 
mg) in CH2Cl2 (2.0 mL) was stirred under argon for 16 h at rt. The mixture was cooled to 
-78 °C, NIS (0.038 mmol) and TfOH (0.0038 mmol) were added, and the resulting 
mixture was stirred under argon for 1 h. During this time, the temperature of the reaction 
mixture was allowed to gradually increase to 0 °C.  After that, triethylamine (~0.1 mL) 
was added, the solid was filtered off and rinsed successively with CH2Cl2. The combined 
filtrate (~60 mL) was washed with sat. aq. NaHCO3 (5 mL), 10% aq. Na2S2O3 (5 mL) and 
water (3 x 10 mL). The organic layer was separated, dried with MgSO4, and concentrated 
in vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate 
– toluene gradient elution) and the amount of unreacted acceptors quantified. 
 
2.4.5. Synthesis of disaccharides 
Method A. General glycosylation procedure in the presence of NIS/TfOH.  A mixture 
of glycosyl donor (0.039 mmol), glycosyl acceptor (0.043 mmol), and freshly activated 
molecular sieves (3Å, 60 mg) in CH2Cl2 (2.0 mL) was stirred under argon for 16 h at rt. 
The mixture was cooled to -78 °C, NIS (0.051 mmol) and TfOH (0.0039 mmol) were 
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added, and the resulting mixture was stirred under argon for 15-30 min (see Table 1 of 
the article). During this time, the temperature of the reaction mixture was allowed to 
increase gradually.  After that, triethylamine (~0.1 mL) was added, the solid was filtered 
off and rinsed successively with CH2Cl2. The combined filtrate (~60 mL) was washed 
with sat. aq. NaHCO3 (5 mL), 10% aq. Na2S2O3 (5 mL) and water (3 x 10 mL). The 
organic layer was separated, dried with MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (ethyl acetate – toluene gradient 
elution) to afford the corresponding disaccharide derivative.  
 
Method B. General glycosylation procedure in the presence of DMTST.  A mixture 
of glycosyl donor (0.039 mmol), glycosyl acceptor (0.043 mmol), and freshly activated 
molecular sieves (4Å, 60 mg) in CH2Cl2 (2.0 mL) was stirred under argon for 16 h at rt. 
The mixture was cooled to -78 °C, DMTST (0.051-0.078 mmol, see Table 1 of the 
article) was added, and the resulting mixture was stirred under argon for 10-20 min (see 
Table 1 of the article). During this time, the temperature of the reaction mixture was 
allowed to increase gradually. After that, triethylamine (~0.1 mL) was added, the solid 
was filtered off and rinsed successively with CH2Cl2. The combined filtrate (~60 mL) 
was washed with sat. aq. NaHCO3 (5 mL), 10% aq. Na2S2O3 (5 mL) and water (3 x 10 
mL). The organic layer was separated, dried with MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (ethyl acetate – toluene 
gradient elution) to afford the corresponding disaccharide derivative. 
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Methyl 6-O-(2-O-benzoyl-6-O-benzyl-3,4-di-O-tert-butyldimethylsilyl-β-D-
glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.10).  The title compound 
was prepared from donor 2.5 and acceptor 2.4 by Method A or B in 83 or 85% yield, 
respectively, as a colorless crystalline solid.  Analytical data for 2.10: Rf = 0.43 (ethyl 
acetate/ toluene, 1/9, v/v); m.p. 111-112.5 oC (methanol/water); []D
26.9 +3.2 (c = 1, 
CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 0.01, 0.02, 0.04, 0.12 (4 s, 12H, 2 x SiMe2), 0.84 
(s, 18H, 2 x SitBu), 3.24 (s, 3H, OCH3), 3.44-3.49 (m, 2H, J2,3 = 9.3 Hz, H-2, 4), 3.67-
3.73 (m, 3H, H-5, 6a, 6aʹ), 3.77 (dd, 1H, J6aʹ,6bʹ = 9.7 Hz, H-6bʹ), 3.82 (dd, 1H, J4ʹ,5ʹ = 4.0 
Hz, H-4ʹ), 3.86 (dd, 1H, J3ʹ,4ʹ = 4.3 Hz, H-3ʹ), 3.91 (dd, 1H, J3,4 = 9.3 Hz, H-3), 3.95 (m, 
1H, J5ʹ,6aʹ = 3.6 Hz, J5ʹ,6bʹ = 6.4 Hz, H-5ʹ), 4.16 (br. d, 1H, J = 8.9 Hz, H-6b), 4.49 (dd, 2H, 
2J = 10.7 Hz, CH2Ph), 4.50 (d, 1H, J1,2 = 3.5 Hz, H-1), 4.53 (dd, 2H, 
2J = 10.8 Hz, 
CH2Ph), 4.67 (dd, 2H, 
2J = 12.1 Hz, CH2Ph), 4.82 (dd, 2H, 
2J = 11.0 Hz, CH2Ph), 4.94 
(d, 1H, J1ʹ,2ʹ = 6.3 Hz, H-1ʹ), 5.11 (dd, 1H, J2ʹ,3ʹ = 3.3 Hz, H-2ʹ), 7.07-7.99 (m, 25H, 
aromatic) ppm; 13C NMR (150 MHz, CDCl3): δ, -4.3, -4.1 (×2), -3.8, 18.1, 18.2, 26.0 
(×6), 55.2, 67.9, 69.8, 71.1, 71.2, 73.5, 73.6, 75.1 (×2), 75.7 (×2), 77.6, 79.5, 79.9, 82.2, 
98.2, 100.2, 127.6, 127.7 (×4), 127.8, 128.0 (×5), 128.3 (×2), 128.4 (×3), 128.5 (×4), 
128.6 (×2), 130.0 (×2), 130.1, 133.1, 138.4 (×2), 138.5, 139.1, 165.4 ppm; HR-FAB MS 
[M+Na]+ calcd for C60H80NaO12Si2
+ 1071.5085, found 1071.5066. 
 
Methyl 6-O-(2,6-di-O-benzyl-3,4-di-O-tert-butyldimethylsilyl-α/β-D-glucopyranosyl)-
2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.11).  The title compound was prepared from 
donor 6 and acceptor 2.4 by Method A or B in 81 or 21% yield, respectively, as a 
colorless syrup. Selected analytical data for α-11: Rf = 0.50 (ethyl acetate/ toluene, 1/9, 
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v/v); 1H NMR (600 MHz, CDCl3): δ, 3.28 (s, 3H, OCH3), 3.29 (dd, 1H, H-2ʹ) ppm; 
13C 
NMR (150 MHz, CDCl3): δ, 96.7 (C-1), 98.1 (C-1ʹ) ppm; Selected analytical data for β-
2.11: Rf = 0.50 (ethyl acetate/ toluene, 1/9, v/v);  
1H NMR (600 MHz, CDCl3): δ, 3.36 (s, 
3H, OCH3) ppm; 
13C NMR (150 MHz, CDCl3): δ, 98.2 (C-1), 102.6 (C-1ʹ) ppm; HR-
FAB MS [M+Na]+ calcd for C60H82NaO11Si2
+ 1057.5293, found 1057.5288. 
 
Methyl O-(2-O-Benzoyl-3,4,6-tri-O-benzyl-β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-




2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.13).  The title compound was prepared from 
donor 2.8 and acceptor 2.4 by Method A in 85% yield as a colorless syrup. Analytical 
data for 2.13: Rf = 0.60 (ethyl acetate/ toluene, 1/9, v/v); []D
26.9 +12.5 (c = 1, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 0.01, 0.05, 0.10, 0.14 (4 s, 12H, 2 x SiMe2), 0.84, 0.86 (2 
s, 18H, 2 x SitBu), 3.16 (s, 3H, OCH3), 3.44 (dd, 1H, J2,3 = 9.7 Hz, H-2), 3.46 (dd, 1H, 
J4,5 = 9.4 Hz, H-4), 3.64-3.67 (m, 2H, H-5, 6a), 3.85 (dd, 1H, J4’,5’ = 3.7 Hz, H-4’), 3.88 
(dd, 1H, J3,4 = 9.3 Hz, H-3), 3.93 (dd, 1H, J3’,4’ = 3.7 Hz, H-3ʹ), 4.08 (m, 1H, H-5), 4.14 
(d, 1H, J6a,6b = 9.3 Hz, H-6b), 4.49 (dd, 2H, 
2J = 10.9 Hz, CH2Ph), 4.50 (d, 1H, J1,2 = 3.2 
Hz, H-1), 4.57-4.59 (m, 2H, H-6aʹ, 6bʹ), 4.66 (dd, 2H, 2J = 11.8 Hz, CH2Ph), 4.82 (dd, 
2H, 2J = 10.9 Hz, CH2Ph), 4.91 (d, 1H, J1’,2’ = 4.4 Hz, H-1ʹ), 5.06 (dd, 1H, J2’,3’  = 4.4 Hz, 
H-2ʹ), 7.11-8.05 (m, 25H, aromatic) ppm; 13C NMR (150 MHz, CDCl3): δ, -4.4, -4.1 
(×2), -3.8, 18.2 (×2), 26.0 (×6), 29.9, 55.0, 65.6, 67.8, 69.7, 70.7, 73.5, 73.7, 74.6, 75.1, 
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75.7, 77.6, 79.9, 82.2, 98.0, 100.0, 127.6, 127.8, 128.0 (×5), 128.3 (×2), 128.4 (×2), 128.5 
(×4), 128.6 (×4), 129.8 (×2), 130.0, 130.1 (×2), 130.4, 133.2 (×2), 138.4 (×2), 139.2, 
165.5, 166.4 ppm; HR-FAB MS [M+Na]+ calcd for C60H78NaO13Si2
+ 1085.4878, found 
1085.4913. 
 
3.4.6. One-pot one-addition trisaccharide synthesis 
General procedure. A mixture of glycosyl donor 2.5 (0.038 mmol), glycosyl 
donor/acceptor 2.14 (0.038 mmol), glycosyl acceptor 2.15, 2.17 or 2.19 (0.042 mmol), 
and freshly activated molecular sieves (3 Å, 150 mg) in CH2Cl2 (2.0 mL) was stirred 
under for 16 h at rt. The mixture was cooled to -78 °C, NIS (0.116 mmol) and TfOH 
(0.0116 mmol) were added, and the resulting mixture was stirred under argon for 5 h. 
During this time, the temperature of the reaction mixture was allowed to gradually 
increase to rt.  After that, triethylamine (~0.1 mL) was added, the solid was filtered off 
and rinsed successively with CH2Cl2. The combined filtrate (~60 mL) was washed with 
sat. aq. NaHCO3 (5 mL), 10% aq. Na2S2O3 (5 mL) and water (3 x 10 mL). The organic 
layer was separated, dried with MgSO4, and concentrated  in  vacuo. The residue was 
purified by column chromatography on Sephadex LH-20 (methanol – dichlorometane, 




O-benzoyl-α-D-glucopyranoside (2.16). The title compound was prepared from building 
blocks 2.5, 2.14, and 2.15 in accordance with the general procedure in 42% yield as a 
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colorless syrup. Analytical data for α-2.16: Rf = 0.46 (ethyl acetate/ toluene, 1/9, v/v); 
1H 
NMR (600 MHz, CDCl3): δ, -0.01, 0.03, 0.05, 0.12 (4 s, 12H, 2 x SiMe2), 0.80, 0.83 (2 s, 
18H, 2 x SitBu), 3.35-3.39 (m, 4H), 3.40 (d, 1H), 3.48 (dd, 1H), 3.56 (t, 1H), 3.60-3.66 
(m, 2H), 3.72 (dd, 1H), 3.76-3.82 (m, 2H), 3.86-3.89 (m, 1H), 3.90-3.93 (m, 1H), 4.06 
(dd, 1H), 4.15 (d, 1H), 4.23-4.28 (m, 1H), 4.39-4.47 (m, 3H), 4.52-4.58 (m, 2H), 4.67 
(dd, 3H), 4.85 (d, 1H), 4.92 (d, 1H), 5.05 (dd, 2H), 5.20 (dd, 2H), 5.48 (t, 1H), 7.95-6.12 
(m, 40H, aromatic) ppm; 13C NMR (150 MHz, CDCl3): δ, -4.3, -4.1 (×2), -3.8, 18.2 (×2), 
26.1 (×6), 29.9, 55.9, 67.8, 68.7, 69.0, 70.1, 70.7, 70.9, 71.2, 72.4, 73.4, 74.5, 74.6, 75.0, 
75.1, 75.2, 75.6, 79.0, 82.4, 84.7, 96.9, 100.1, 104.2, 127.8 (×2), 127.9 (×2), 128.2 (×2), 
128.4 (×7), 128.5 (×6), 128.6 (×3), 129.2, 129.3, 129.5, 129.9 (×2), 130.1 (×2), 130.1 
(×2), 130.1 (×2), 133.1, 133.23, 133.5, 138.2, 138.6, 138.8, 139.0, 165.4, 165.6, 166.0 
(×2) ppm; HR-FAB MS [M+Na]+ calcd for C87H104NaO19Si2





O-benzoyl-α-D-glucopyranoside (2.18).  The title compound was prepared from 
building blocks 2.5, 2.14 and 2.17 in accordance with the general procedure in 37% yield 
as a colorless syrup. Analytical data for α-2.18: Rf = 0.55 (ethyl acetate/ toluene, 1/9, 
v/v); 1H NMR (600 MHz, CDCl3): δ, -0.03, 0.00, 0.03, 0.08 (4 s, 12H, 2 x SiMe2), 0.81 
(s, 18H, 2 x SitBu), 3.24 (dd, 1H), 3.40 (s, 3H), 3.45-3.50 (m, 1H), 3.64-3.56 (m, 2H), 
3.70-3.76 (m, 1H), 3.79-3.89 (m, 4H), 3.95 (d, 1H), 4.05 (d, 1H), 4.19 (dd, 3H), 4.31 (d, 
1H), 4.39 (d, 1H), 4.48-4.71 (m, 6H), 4.79 (d, 1H), 4.84 (d, 1H), 5.05 (m, 1H), 5.08 (d, 
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1H), 5.12 (d, 1H), 5.18 (dd, 1H), 6.18 (dd, 1H), 7.01-8.04 (m, 40H, aromatic) ppm; 13C 
NMR (150 MHz, CDCl3): δ, -4.4, -4.3, -4.2, -4.0, 18.1, 18.2, 26.0(×6), 29.9, 55.5, 63.5, 
67.6, 68.9, 70.8, 71.0, 71.4, 72.3, 72.4, 73.1, 73.5, 75.0, 75.3, 75.4, 75.5, 75.8, 79.1, 79.8, 
81.4, 96.9, 98.9, 99.9, 127.4, 127.6, 127.7 (×4), 127.9 (×4), 128.0 (×2), 128.3 (×4), 128.4 
(×4), 128.5 (×2), 128.6 (×4), 129.9 (×2), 130.00 (×2), 130.2 (×2), 133.0, 133.1, 133.3, 
133.4, 138.2, 138.4, 138.6, 139.1, 165.3, 165.6, 166.1, 166.2 ppm. HR-FAB MS 
[M+Na]+ calcd for C87H104NaO19Si2




benzoyl-6-O-benzyl-α-D-glucopyranoside (2.20).  The title compound was prepared 
from building blocks 2.5, 2.14 and 2.19 in in accordance with the general procedure in 
65% yield as a colorless syrup. Analytical data for α-18: Rf = 0.60 (ethyl acetate/ toluene, 
1/9, v/v); 1H NMR (600 MHz, CDCl3): δ, 0.01, 0.05, 0.05, 0.12 (4 s, 12H, 2 x SiMe2), 
0.83, 0.84 (2s, 18H, 2 x SitBu), 3.18 (dd, 1H), 3.41 (s, 3H), 3.51 (dd, 1H), 3.65-3.73 (m, 
2H), 3.76 (dd, 1H), 3.79-3.92 (m, 6H), 3.92-4.05 (m, 4H), 4.20-4.27 (m, 2H), 4.35 (d, 
1H), 4.46 (s, 2H), 4.50 (dd, 2H), 4.54-4.63 (m, 3H), 4.87 (d, 1H), 4.97 (d, 1H), 5.07 (d, 
1H), 5.07 (d, 1H), 5.15-5.22 (m, 2H), 6.11 (dd, 1H), 7.04-7.94 (m, 40H, aromatic) ppm; 
13C NMR (150 MHz, CDCl3): δ, -4.4, - 4.3, -4.2, -4.0, 18.1, 18.2, 26.0 (×6), 29.9, 55.5, 
67.9, 68.7, 70.4, 70.8, 71.1 (×2), 72.3, 72.5, 72.7, 73.4, 73.5, 74.9, 75.0, 75.3, 75.4, 75.8, 
79.4, 79.8, 81.5, 97.0, 98.4, 100.0, 127.7 (×2), 127.8 (×3), 127.9 (×2), 128.0 (×2), 128.1 
(×2), 128.4 (×11), 128.5 (×2), 129.4, 129.9 (×2), 130.0 (×2), 130.1 (×2), 130.3, 133.0, 
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133.1, 133.4, 138.3, 138.4, 138.5, 138.6, 139.1, 165.3, 165.9, 166.2 ppm; HR-FAB MS 
[M+Na]+ calcd for C87H106NaO118Si2
+ 1531.6608, found 1531.6576. 
 
2.4.7. X-ray structure determination of disaccharide 2.10 
A crystal of approximate dimensions 0.324 x 0.121 x 0.098 mm3 was mounted on 
MiTeGen cryoloops in a random orientation. Preliminary examination and data collection 
were performed using a Bruker X8 Kappa Apex II Charge Coupled Device (CCD) 
Detector system single crystal X-Ray diffractometer equipped with an Oxford 
Cryostream LT device. All data were collected using graphite monochromated Mo K 
radiation ( = 0.71073 Å) from a fine focus sealed tube X-Ray source. Preliminary unit 
cell constants were determined with a set of 36 narrow frame scans. Typical data sets 
consist of combinations of   and  scan frames with typical scan width of 0.5 and 
counting time of 15 seconds/frame at a crystal to detector distance of 4.0 cm. The 
collected frames were integrated using an orientation matrix determined from the narrow 
frame scans. Apex II and SAINT software packages (Bruker Analytical X-Ray, Madison, 
WI, 2010) were used for data collection and data integration. Analysis of the integrated 
data did not show any decay. Final cell constants were determined by global refinement 
of   reflections harvested from the complete data set. Collected data were corrected for 
systematic errors using SADABS (Bruker Analytical X-Ray, Madison, WI, 2010) based 
on the Laue symmetry using equivalent reflections. 
Crystal data and intensity data collection parameters are listed in Table 1S. 
Structure solution and refinement were carried out using the SHELXTL- PLUS software 
package.50  The structure was solved by direct methods and refined successfully in the 
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space group P21.  Full matrix least-squares refinements were carried out by minimizing 
w(Fo2-Fc2)2. The non-hydrogen atoms were refined anisotropically to convergence. All 
hydrogen atoms were treated using appropriate riding model (AFIX m3).  The final 
residual values and structure refinement parameters are listed in Table 1S. Several motifs 
are disordered in this structure. The disorder was modeled with partial occupancy atoms 
and rigid body restraints (RIGU). Absolute structure determination was confirmed with a 
Flack x of -0.02(11).  
Complete listings of positional and isotropic displacement coefficients for 
hydrogen atoms, anisotropic displacement coefficients for the non-hydrogen atoms are 
listed as supplementary material (Tables 2S and 4S). Table of calculated and observed 
structure factors are available in electronic format. The structural data have been 
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3.1. Introduction 
Carbohydrates are involved in many processes and are referred to as the “essential 
molecules of life”.1 Our life begins with fertilization, which takes place via carbohydrate-
protein recognition.2 Our journey with sugars continues with human milk that becomes the 
ideal first food.3 Glycans present in human milk can provide prebiotic effects,4 function as 
antimicrobial agents,5-13 and provide necessary nutrients for the development of the brain 
and cognition of infants.14 Thanks to advances in glycosciences, we already know that 
Human Milk Oligosaccharides (HMO) are a unique and diverse family of glycans.15-17 
Structures of 162 HMO have been elucidated,18-22 but our understanding of how HMO 
function is far from complete and is severely hampered by the lack of simple, efficient and 
cost effective methods for synthesizing glycans. Despite many efforts to prepare HMO 
enzymatically23-42 or chemically,43-54 their availability in pure form remains poor. Adding 
HMO to infant formulas could be beneficial for infants’ health,55-58 but HMO are 
challenging to produce and purify, and exact roles of individual HMO remain unknown.59-
61 Only two simple glycans have been approved for infant formulas in the US and Europe, 
and three more HMO entered clinical trials.62  
One of the two approved HMO structures is lacto-N-neotetraose 3.1 (LNnT), which 
is a linear tetrasaccharide comprising a Galβ1→4GlcNAcβ1→3Galβ1→4Glc sequence 
shown in Scheme 3.1. More specifically, LNnT contains lactose disaccharide 
(Galβ1→4Glc) at the reducing end elongated by N-acetyllactosamine (Galβ1→4GlcNAc). 
 
3.2. Results and discussion 
 During the incipient stage of the synthesis of LNnT 3.1, we decided to perform a 
convergent (2+2) synthetic strategy. Thus, per our retrosynthetic analysis, we chose the 
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protected lactosamine donor 3.2, containing a suitable leaving group (LG), and the 
regioselectively protected lactose acceptor 3.3. The latter was designed as a universal 
precursor for the synthesis of other HMO sequences elongated at C-2 and/or C-6 of the 
galactose unit. The access to those sequences is enabled by temporary protecting groups, 
benzoyl and picoloyl (Pico). Another key aspect in our design is the use of benzyl groups 
as semi-permanent protecting groups, whereas a majority of previous syntheses used acetyl 
groups that are prone to migration leading to side products.  
 
Scheme 3.1.  Retrosynthesis analysis of LNnT 3.1. 
 
The projected synthesis of lactosamine donor 3.2 involved coupling of galactosyl 
trichloroacetimidate donor 34 with glucosamine acceptor 3.5. To achieve the synthesis of 
lactose precursor 3.3, we projected the coupling between the orthogonally protected 
galactose donor 3.6 and tetrabenzylated glucose 4-OH acceptor 3.7. The protecting groups 
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in donor 3.6 were chosen to provide access to the universal lactose acceptor precursor that 
would be suitable for glycosylation at C-3 via Fmoc removal (like in case of acceptor 3.3), 
C-6 via OPico removal, or provide access to 3,6-branched HMO sequences. 
For the synthesis of lactosamine building block 3.2 we obtained known 
trichloroacetimidate donor 3.4.63 Also known glucosamine thioglycoside acceptor 3.5 was 
obtained following a seven-step protocol similar to that previously described method.64 
Unfortunately, coupling between donor 3.4 and acceptor 3.5 in the presence of TMSOTf 
was not straightforward as anticipated. Instead of the desired product 3.2, the major product 
was tetrabenzoylated ethylthio galactoside, presumably generated through an aglycone 
transfer side reaction. Gildersleeve et al. has done a careful mechanistic study on the 
aglycone transfer reactions.65 According to their mechanistic picture, several factors play 
a role in determining whether transfer occurs. One is the electronic, armed or disarmed, 
nature of the donor and the acceptor. Based on that, Gildersleeve et al. hypothesized that 
any thioglycoside could undergo transfer as long as the oxacarbenium ion or the glycosyl 
intermediate derived from the thioglycoside is more stable than the oxacarbenium ion 
derived from the glycosyl donor.  In further investigation of our coupling reaction, we came 
to realization that the aglycone transfer practically always takes place in reactions between 
disarmed galactose donors, regardless of the leaving group, and glucosamine acceptor 3.5.  
The same issue was reported by Wang,31 and the solution was found in applying galactosyl 
bromide as the donor that produced the respective lactosamine disaccharide with moderate 
yield of 70%. 
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Scheme 3.2.  Convergent synthesis of protected LNnT 3.12. 
 
In order to eliminate the aglycone transfer side reaction and to obtain the desired 
disaccharide 3.2 in high yield, we first investigated whether galactose trichloroacetimidate 
donor66 equipped with the superarming 2-benzoyl-3,4,6-tri-benzyl pattern67,68 would be 
advantageous. This reaction indeed produced disaccharide 3.2, and no aglycone transfer 
was detected in this case. However, multiple by-products have been detected that resulted 
in only a fair yield of disaccharide 3.2. At this point we decided to screen other leaving 
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groups and determined that the superarmed S-benzoxazolyl (SBox) thioimidate 3.867,68 
provides a superior combination of simplicity, efficiency and yields for the synthesis of 
lactosamine, which is a major constituent in many HMO. Thus, selective activation of the 
SBox leaving group in glycosyl donor 3.8 over thioethyl anomeric moiety of glycosyl 
acceptor 3.5 was achieved in the presence of silver trifluoromethanesulfonate (AgOTf). 
This glycosylation afforded the desired β-linked lactosamine disaccharide 3.2 in excellent 
yield of 98% (Scheme 3.2). 
Having achieved success in the synthesis of lactosamine disaccharide 3.2, we 
turned our attention to the synthesis of lactose derivative 3.3. The synthesis of galactose 
donor 3.6 started from known precursor 3.969 that was converted to the intermediate 3.10 
via the reductive regioselective opening of the benzylidene acetal by reaction with 1 M 
BH3 in THF in the presence of catalytic TMSOTf in 91% yield.  Subsequently, the 6-
hydroxyl derivative 3.10 was reacted with picolinic acid (PicoOH) in the presence of 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 4-dimethylaminopyridine 
(DMAP) to afford 6-picoloyl derivative 3.6 in 94% yield. The synthesis of the 4-OH 
acceptor 3.7 followed previously reported procedure.70 The coupling of donor 3.6 and 
acceptor 3.7 was carried out by the activation of the thioethyl leaving group with N-
iodosuccinimide (NIS) and TfOH in the presence of molecular sieves (3 Å). Subsequent 
deprotection of the Fmoc group with triethyl amine (Et3N) in one pot led to the desired 
disaccharide acceptor 3.3 in 84% yield. 
With the key disaccharide building blocks 3.2 and 3.3 in hand, we began to 
assemble the target tetrasaccharide sequence using the convergent strategy. The coupling 
of the disaccharide donor 3.2 bearing the SEt leaving group was very sluggish, and despite 
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all attempts to push the reaction to completion, significant amounts of both the donor and 
the acceptor remained. To increase the reactivity of the glycosyl donor counterpart, we 
converted thioglycoside 3.2 into a phosphate donor 3.11 in 97% yield via a one-step 
protocol developed by Seeberger.71 The coupling of phosphate donor 3.11 with lactose 
acceptor 3.2 was then conducted in the presence of TMSOTf as depicted in Scheme 3.2. 
As a result, tetrasaccharide 3.14 was obtained in a good yield of 70% with complete β-
stereoselectivity. 
With a very minimal strategic adjustment to our synthetic scheme, we were also 
able to investigate whether the linear synthetic approach is able to offer any advantage for 
the synthesis of the target tetrasaccharide sequence.  For this purpose, we converted 
building block 3.5 into its 4-O-Fmoc derivative 3.13 that was subsequently converted into 
phosphate donor 3.14. The linear synthesis started by glycosylation between donor 3.14 
and lactose acceptor 3.3 in the presence of TMSOTf to afford the intermediate trisaccharide 
3.15 in 70% yield. The Fmoc protecting group was removed with 30% Et3N in CH2Cl2 and 
glycosylation of the resulting trisaccharide acceptor 3.16 with SBox donor 3.8 in the 
presence of AgOTf afforded the desired β-linked tetrasaccharide 3.12 in 87% yield. 
With the key tetrasaccharide intermediate 3.12 which was obtained via both 
convergent and linear synthesis methods, we then endeavored a series of deprotection steps 
to obtain the target LNnT tetrasaccharide 3.1.  Deprotection of the phthalimido and the 
ester groups was achieved by refluxing with NH2NH2-H2O in MeOH, and the treatment 
with acetic anhydride in MeOH furnished tetrasaccharide 3.17 in 87% yield. Finally, the 
remaining benzyl groups were removed by hydrogenation the presence of 10% palladium 
on charcoal in wet ethanol to obtain the target trisaccharide 3.1 in 92% yield. 
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Scheme 3.3.  The linear synthesis of tetrasaccharide 3.12 and its deprotection to 
obtain LNnT 3.1. 
 
3.3. Conclusions 
In summary, the total synthesis of lacto-N-neotetraose has been completed using 
both linear and convergent synthesis approaches. Both approaches employed the universal 
W. M. Mithila D. Bandara | UMSL 2019 | Page  103 
 
lactose building block 3.3 and offered similar efficiency.  In accordance with the 
convergent approach, lactosamine building block 3.11 needed for glycosylation of acceptor 
3.3 was obtained in three steps from monosaccharide building blocks 3.5 and 3.8 followed 
by the introduction of the phosphate leaving group. As a result, the convergent assembly 
of tetrasaccharide 3.12 was achieved in 66% yield over three steps. The linear synthesis of 
3.12 involved glycosylation of acceptor 3.3 with donor 3.14, interim Fmoc deprotection, 
followed by glycosylation with 3.8. As a result, the linear assembly of tetrasaccharide 3.12 
was also achieved in three synthetic steps in 57% yield overall. Along the way, we have 
developed new synthetic protocols for different glycosidic linkages. Notably, the donor and 
acceptor protecting group and the leaving group combinations were found to be of 
paramount significance to successful coupling. The discovery of innovative methods and 
accessible technologies that will offer new capabilities for obtaining individual HMO will 
help to improve understanding their roles and boost practical applications. Further 
synthetic studies of HMO are underway in our laboratory. 
 
3.4. Experimental 
3.4.1. General methods   
The reactions were performed using commercial reagents and the ACS grade 
solvents were purified and dried according to standard procedures. Column 
chromatography was performed on silica gel 60 (70-230 mesh) and Sephadex G-25 size 
exclusion resin, reactions were monitored by TLC on Kieselgel 60 F254. The compounds 
were detected by examination under UV light and by charring with 10% sulfuric acid in 
methanol. Solvents were removed under reduced pressure at <40 oC. CH2Cl2 was distilled 
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from CaH2 directly prior to application. Molecular sieves (3Å), used for reactions, were 
crushed and activated in vacuo at 390 °C during 8 h in the first instance and then for 2-3 h 
at 390 °C directly prior to application. AgOTf was co-evaporated with toluene (3 x 10 mL) 
and dried in vacuo for 2-3 h directly prior to application. Optical rotations were measured 
using a Jasco polarimeter. 1H NMR spectra were recorded at 300 MHz or 600 MHz, and 
13C NMR spectra were recorded at 75 MHz or 151 MHz. The 1H chemical shifts are 
referenced to the signal of the residual TMS (δH = 0.00 ppm) for solutions in CDCl3 or the 
signal of the residual D2O (δH = 4.79 ppm) for solutions in D2O. The 
13C chemical shifts 
are referenced to the central signal of CDCl3 (δC = 77.16 ppm) for solutions in CDCl3 or 
the central signal of CD3COCD3 δC = 29.84 ppm) for solutions in D2O. Accurate mass 
spectrometry determinations were performed using Agilent 6230 ESI TOF LCMS mass 
spectrometer. 
 
3.4.2. Preparation of monosaccharide building blocks 3.10, 3.6, 3.13. 3.14 
Ethyl 2-O-benzoyl-4-O-benzyl-3-O-fluorenylmethoxycarbonyl-1-thio-β-D-
galactopyranoside (3.10).  A 1 M solution of BH3 in THF (48 mL, 48 mmol) was added 
to a solution of ethyl 2-O-benzoyl-3-O-fluorenylmethoxycarbonyl-4,6-O-benzylidene-1-
thio-β-D-galactopyranoside69 (6.15 g, 9.62 mmol) in CH2Cl2 (50 mL). The resulting 
mixture was cooled to 0 oC, TMSOTf (0.87 mL, 4.81 mmol) was added, and the resulting 
mixture was stirred under argon 2 h. During this time, the reaction was allowed to gradually 
increase to rt. After that, the reaction was quenched with Et3N (~2 mL) and MeOH (~5 
mL), and the resulting mixture was concentrated in vacuo. The residue was diluted with 
CH2Cl2 (~500 mL) and washed with sat. aq. NaHCO3 (50 mL) and water (2 x 50 mL).  The 
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organic phase was separated, dried over MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (ethyl acetate - hexane gradient 
elution) to afford the title compound as a white foam in 91% yield (5.61 g, 8.75 mmol). 
Analytical data for 3.10: Rf = 0.27 (ethyl acetate/hexane, 2/3, v/v); []D
22 +31.8 (c 1.0, 
CHCl3);
 1H NMR (300 MHz, CDCl3): δ, 1.23 (t, 3H, J = 7.5 Hz, CH2CH3), 2.75 (m, 2H, 
CH2CH3), 3.56 (m, 1H, J = 5.4, 8.4, 11.2 Hz, H-6a), 3.67 (m, 1H, J = 6.1 Hz, H-5), 3.85 
(m, 1H, H-6b), 4.04 (br d, 1H, H-4), 4.08 (d, 1H, J = 7.4 Hz, OCOCH2CH), 4.29 (m, 2H, 
OCOCH2CH), 4.60 (d, 1H, J1,2 = 10.0 Hz, H-1), 4.67 (dd, 2H, 
2J = 11.6 Hz, CH2Ph), 5.07 
(dd, 1H, J3,4 = 2.9 Hz, H-3), 5.76 (t, 1H, J2,3 = 10.0 Hz, H-2), 7.03-8.10 (m, 18H, aromatic) 
ppm; 13C NMR (75 MHz, CDCl3): δ, 14.9, 24.0, 46.5, 61.7, 68.5, 70.3, 73.5, 74.9, 79.0, 
79.2, 84.0, 120.1, 125.0, 125.2, 125.4, 127.2 (×2), 127.9, 128.2, 128.3 (×2), 128.6 (×4), 
129.1, 129.6, 130.0, 133.4, 137.6, 141.2, 141.3, 142.9, 143.3, 154.6, 165.4 ppm; ESI TOF 
LCMS [M+NH4]
+ calcd for C37H40NO8S 658.2475, found 658.2477. 
 
Ethyl 2-O-benzoyl-4-O-benzyl-3-O-fluorenylmethoxycarbonyl-6-O-picoloyl-1-thio-β-
D-galactopyranoside (3.6).  Picolinic acid (1.21 g, 9.83 mmol), EDC (0.90 g, 9.83 mmol), 
and DMAP (0.18 g, 1.31 mmol) were added to a stirring solution of 310 (4.20 g, 6.55 
mmol) in CH2Cl2 (60 mL) and the resulting mixture was stirred for 1 h at rt. After that, the 
reaction mixture was diluted with CH2Cl2 (~500 mL) and washed with water (50 mL), 1% 
aq. HCl (50 mL) and water (2 x 50 mL). The organic phase was separated, dried over 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate - hexane gradient elution) to afford the title compound as a white 
form in 94% yield (5.30 g, 6.14 mmol). Analytical data for 3.6: Rf = 0.41 (ethyl 
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acetate/hexane, 3/2, v/v); []D
23 +36.8 (c 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3): δ, 1.22 
(t, 3H, J = 7.5 Hz, CH2CH3), 2.73 (m, 2H, CH2CH3), 4.06 (m, 2H, H-5, OCOCH2CH), 4.15 
(d,1H, H-4), 4.28 (m, 2H, OCOCH2CH), 4.47 (dd, 1H, J5,6a = 11.2 Hz, J6a,6b = 6.5 Hz, H-
6a), 4.61 (dd, 1H, H-6b), 4.68 (d, 1H, J1,2 = 10.0 Hz, H-1) 4.73 (dd, 2H, 
2J = 11.4 Hz, 
CH2Ph), 5.13 (dd, 1H, J3,4 = 2.8 Hz, H-3), 5.79 (dd, 1H, J2,3 = 10.0 Hz, H-2), 7.00-8.82 (m, 
22H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, 15.0, 24.1, 46.5, 63.8, 68.5, 70.3, 
73.6, 75.2, 76.0, 79.0, 83.9, 120.1, 125.0, 125.2, 125.4, 127.2 (×3), 127.9 (×2), 128.0, 128.5 
(×5), 128.6 (×2), 129.5, 130.0 (×2), 133.4, 137.1, 137.4, 141.2, 141.3, 142.8, 143.3, 147.6, 
150.1, 154.6, 164.7, 165.3 ppm; ESI TOF LCMS [M+Na]+ calcd for C43H39NNaO9S 
768.2243, found 768.2247. 
 
Ethyl 3,6-di-O-benzyl-2-deoxy-4-O-fluorenylmethoxycarbonyl-2-phthalimido-1-thio-
β-D-glucopyranoside (3.13).  FmocCl (1.06 g, 4.12 mmol) was added to a solution of ethyl 
3,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside64 (3.5, 1.10 g, 2.06 
mmol) in CH2Cl2 (20 mL) and pyridine (0.42 mL), and the resulting mixture was stirred 
under argon for 2 h at rt. After that, the reaction mixture was diluted with CH2Cl2 (~250 
mL) and washed with 1% aq. HCl (40 mL) and water (2 x 40 mL). The organic phase was 
separated, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the 
title compound as a white form in 87% yield (1.35 g, 1.79 mmol). Analytical data for 3.13: 
Rf = 0.53 (ethyl acetate/hexane, 2/3, v/v); []D
23 +75.8 (c 1.0, CHCl3);
 1H NMR (300 MHz, 
CDCl3): δ, 1.17 (t, 3H, J = 7.4 Hz, CH2CH3), 2.54-2.75 (m, 2H, CH2CH3), 3.68 (br d, 2H, 
J6a,6b = 4.5 Hz, H-6a, 6b), 3.86 (m, 1H, J5,6a = J5,6b = 4.5 Hz, H-5), 4.13 (t, 1H, J = 7.1 Hz, 
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OCOCH2CH), 4.27-4.44 (m, 2H, OCOCH2CH), 4.30 (dd, 1H, J2,3 = 10.5 Hz, H-2), 4.44 
(dd, 2H, 2J = 12.2 Hz, CH2Ph), 4.50 (dd, 1H, J3,4 = 9.0 Hz, H-3), 4.55 (dd, 2H, 
2J = 12.0 
Hz, CH2Ph), 4.99 (dd, 1H, J4,5 = 10.0 Hz, H-4), 5.27 (d, 1H, J1,2 = 10.5 Hz, H-1), 6.78-7.83 
(m, 22H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, 15.1, 24.2, 46.9, 54.6, 69.9, 70.0, 
73.6, 74.4, 77.3 (×2), 77.8, 81.3, 120.2 (×2), 123.4, 123.7, 124.8, 125.1, 125.2, 127.2, 127.3 
(×2), 127.5, 127.7 (×3), 127.9 (×2), 128.0, 128.1 (×2), 128.4 (×2), 131.7, 134.1, 137.6, 
138.1, 141.4 (×2), 143.2, 143.4, 154.4, 167.3, 168.1 ppm;  ESI TOF LCMS [M+Na]+ calcd 
for C45H41NNaO8S; 778.2451, found 778.2457. 
 
Di-O-butyl 3,6-di-O-benzyl-2-deoxy-4-O-fluorenylmethoxy-carbonyl-2-phthalimido-
β-D-glucopyranosyl phosphate (3.14). A mixture of thioglycoside 3.13 (0.30 g, 0.39 
mmol), dibutyl hydrogen phosphate (0.23 mL, 1.19 mmol), and freshly activated molecular 
sieves (3 Å, 0.6 g) in CH2Cl2 (7.0 mL) was stirred under argon for 1 h at rt. The reaction 
mixture was cooled to 0 oC, NIS (0.17 g, 0.78 mmol) and TfOH (7.0 μL, 0.08 mmol) were 
added, and the resulting mixture was stirred for 20 min at 0 oC. After that, the solids were 
filtered off and rinsed successively with CH2Cl2. The combined filtrate (~100 mL) was 
washed with 10% aq. Na2S2O3 (15 mL) and sat. aq. NaHCO3 (15 mL), and water (2 x 15 
mL). The organic phase was separated, dried over MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (acetone - toluene gradient 
elution) to afford the title compound as a clear syrup in 90% yield (0.31 g, 0.35 mmol). 
Analytical data for 3.14: Rf = 0.45 (ethyl acetate/hexane, 1/4, v/v); []D
23 +55.8 (c 1.0, 
CHCl3);
 1H NMR (300 MHz, CDCl3): δ, 0.69, 0.83 (2 t, 6H, 2 x O(CH2)3CH3), 1.03 (m, 
2H, J = 7.3, 14.4 Hz, O(CH2)2CH2CH3), 1.18-1.34 (m, 4H, O(CH2)2CH2CH3, 
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OCH2CH2CH2CH3), 1.42-1.56 (m, 2H, OCH2CH2CH2CH3), 3.61-3.80 (m, 4H, H-6a, 6b, 
OCH2CH2CH2CH3), 3.84-4.03 (m, 3H, H-5, OCH2CH2CH2CH3), 4.13 (t, 1H, J = 7.0 Hz, 
OCOCH2CH), 4.29-4.43 (m, 3H, H-2, OCOCH2CH), 4.44 (dd, 2H, 
2J = 12.4 Hz, CH2Ph), 
4.51 (dd, 2H, 2J = 12.0 Hz, CH2Ph), 4.58 (m, 1H, J3,4 = 9.4 Hz, H-3), 5.08 (t, 1H, J4,5 = 9.4 
Hz, H-4), 5.84 (t, 1H, J1,2 = 7.5 Hz, H-1), 6.76-7.82 (m, 22H, aromatic) ppm; 
13C NMR (75 
MHz, CDCl3): δ, 13.5, 13.6, 18.4, 18.6, 31.9 (d, J = 7.1 Hz), 32.0 (d, J = 7.2 Hz), 46.8, 
55.9 (d, J = 8.2 Hz), 67.9 (d, J = 6.2 Hz), 68.1 (d, J = 6.3 Hz), 69.1, 70.1, 73.5, 73.6, 74.4, 
76.4, 76.5, 94.1 (d, J = 4.5 Hz), 120.2 (×2), 123.5, 125.0, 125.2, 127.3 (×2), 127.5, 127.7 
(×4), 127.8 (×3), 128.0 (×2), 128.1 (×3), 128.4 (×3), 131.6, 134.0 (×2), 137.6, 137.9, 141.4 
(×2), 143.1, 143.4, 154.3 ppm; ESI TOF LCMS [M+Na]+ calcd for C51H54NNaO12P 
926.3281, found 926.3286. 
 
3.4.3.  Synthesis of oligosaccharides 3.2, 3.3, 3.11, 3.15, 3.16, 3.12 
Ethyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→4)-4,6-di-O-
benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (3.2).  A mixture of 
benzoxazolyl 2-O-benzoyl-3,4,6-tri-O-benzyl-1-thio-β-D-galactopyranoside67,68 (3.8, 0.20 
g, 0.29 mmol), acceptor 3.5 (0.12 g, 0.22 mmol), and freshly activated molecular sieves 
(3Å, 600 mg) in CH2Cl2 (7.0 mL) was stirred under argon for 2 h at rt. The reaction mixture 
was cooled to -30 oC, freshly conditioned AgOTf (0.15 g, 0.58 mmol) was added, and the 
resulting mixture was stirred for 15 min. The solids were filtered-off rinsed successively 
with CH2Cl2. The combined filtrate (~50 mL) was washed with sat. aq. NaHCO3 (10 mL) 
and water (2 x 10 mL) The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
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(acetone - toluene gradient elution) to afford the title compound as a white foam in 98% 
yield (0.23 g, 0.22 mmol). Analytical data for 3.2: Rf = 0.54 (acetone/toluene, 1/9, v/v); 
[]D
23 +28.5 (c 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3): δ, 1.11 (t, 3H, J = 7.4 Hz, 
CH2CH3), 2.45-2.67 (m, 2H, CH2CH3), 3.34-3.70 (m, 7H, H-3ʹ, 5, 5ʹ, 6a, 6aʹ, 6b, 6bʹ), 4.03 
(m, 2H, H-4, 4ʹ), 4.15-4.66 (m, 11H, H-1ʹ, 2, 3, 8 x CHPh), 4.66 (d, 1H, J1ʹ,2ʹ = 7.9 Hz, H-
1ʹ), 4.91 (d, 1H, 2J = 12.1 Hz, CHPh), 4.97 (d, 1H, 2J = 11.6 Hz, CHPh), 5.13 (d, 1H, J1,2 
= 9.9 Hz, H-1), 5.65 (dd, 1H, J2ʹ,3ʹ = 10.1 Hz, H-2ʹ), 6.73-7.98 (m, 34H, aromatic) ppm; 
13C 
NMR (75 MHz, CDCl3): δ, 15.0. 24.0, 54.9, 68.0, 68.2, 71.4, 72.6 (×2), 73.4 (×2), 73.6, 
74.6, 74.8, 77.4, 78.1, 79.0, 79.8, 81.1, 100.8, 123.4, 123.5, 126.8, 127.4, 127.6 (×2), 127.7 
(×2), 127.8 (×7), 127.9 (×4), 128.0 (×2), 128.2 (×2), 128.4 (×6), 128.5 (×3), 129.9 (×2), 
131.7, 133.2, 133.9, 137.8, 138.1, 138.4, 138.8, 138.9, 165.2, 167.7, 168.0 ppm; ESI TOF 
LCMS [M+NH4]
+ calcd for C64H67N2O12S 1087.4415, found 1087.4426. 
 
Benzyl O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-galactopyranosyl)-(1→4)-2,3,6-
tri-O-benzyl-β-D-glucopyranoside (3.3).  A mixture of donor 3.6 (0.82 g, 0.96 mmol), 
benzyl 2,3,6-tri-O-benzyl-β-D-glucopyranoside70 (3.7, 0.40 g, 0.74 mmol), and freshly 
activated molecular sieves (3Å, 2.0 g) in CH2Cl2 (20 mL) was stirred under argon for 2 h 
at rt. The reaction mixture was cooled to 0 oC, NIS (0.43 g, 1.96 mmol) and TfOH (17 µL, 
0.19 mmol) were added, and the resulting mixture was stirred for 16 h. Over this time, the 
reaction temperature was allowed to reach rt. After that, Et3N (6.0 mL) was added, and the 
resulting mixture was stirred for 1 h at rt. The solid was filtered-off and rinsed successively 
with CH2Cl2. The combined filtrate (~100 mL) was washed with 10% aq. Na2S2O3 (15 mL) 
and water (2 x 15 mL). The organic phase was separated, dried over MgSO4, and 
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concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(acetone - toluene gradient elution) to afford the title compound as a white foam in 84% 
yield (0.61 g, 0.62 mmol). Analytical data for 3.3: Rf = 0.50 (acetone/toluene, 1/4, v/v); 
[]D
23 -7.8 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 2.39 (d, 1H, J = 9.4 Hz, OH), 
3.29 (m, 1H, J5,6a = 1.4 Hz, J5,6b = 3.8 Hz, H-5), 3.45 (dd, 1H, J2,3 = 9.0 Hz, H-2), 3.57 (dd, 
1H, J3,4 = 9.1 Hz, H-3), 3.62 (dd, 1H, J6a,6b = 10.8 Hz, H-6a), 3.65-3.72 (m, 3H, J3ʹ,4ʹ = 3.8 
Hz, H-3ʹ, 5ʹ, 6b), 3.93 (br d, 1H, H-4ʹ), 3.96 (dd, 1H, J4,5 = 9.1 Hz, H-4), 4.33-4.42 (m, 3H, 
H-6aʹ, 6bʹ, CHPh), 4.41 (d, 1H, J1,2 = 8.0 Hz, H-1), 4.58 (d, 1H, 
2J = 12.0 Hz, CHPh), 4.61 
(d, 1H, 2J = 12.2 Hz, CHPh), 4.70 (d, 1H, 2J = 11.0 Hz, CHPh), 4.82-4.75 (m, 4H, J1ʹ,2ʹ = 
8.0 Hz, H-1ʹ, 3 x CHPh), 4.86-4.89 (m, 2H, 2 x CHPh), 5.01 (d, 1H, 2J = 10.9 Hz, CHPh), 
5.27 (dd, 1H, J2ʹ,3ʹ = 10.0, H-2ʹ), 7.12-8.82 (m, 34H, aromatic) ppm; 
13C NMR (75 MHz, 
CDCl3): δ, 63.1, 68.2, 71.2, 72.1, 73.5, 73.5, 74.6, 74.7, 75.0, 75.4, 75.8, 76.4, 76.8, 81.9, 
82.8, 100.2, 102.6, 125.4, 124.4, 127.2, 127.4, 127.7, 127.8 (×3), 127.9 (×2), 128.0 (×2), 
128.2 (×6), 128.4 (×2), 128.5 (×2), 128.6 (×4), 128.7 (×2), 129.6, 129.9 (×2), 133.5, 137.1, 
137.5, 137.8, 138.3, 138.6, 139.1, 147.6, 150.1, 164.5, 166.7 ppm; ESI TOF LCMS 
[M+Na]+ calcd for C60H59NNaO13 1024.3884, found 1024.3878. 
 
Di-O-butyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→4)-4,6-di-
O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl phosphate (3.11).  A mixture of 
compound 3.2 (0.285 g, 0.282 mmol), dibutyl hydrogen phosphate (0.17 mL, 0.847 mmol), 
and freshly activated molecular sieves (3 Å, 0.5 g) in CH2Cl2 (5.0 mL) was stirred under 
argon for 1 h at rt. The mixture was cooled to 0 °C, NIS (0.126 g, 0.564 mmol) and TfOH 
(5.0 μL, 0.056 mmol) were added, and the resulting mixture was stirred for 20 min at 0 oC.  
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After that, the solids were filtered off and rinsed successively with CH2Cl2. The combined 
filtrate (~100 mL) was washed with 10% aq. Na2S2O3 (15 mL), sat. aq. NaHCO3 (15 mL), 
and water (2 x 15 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(acetone - toluene gradient elution) to afford the title compound as an oily syrup in 97% 
yield (0.33 g, 0.273 mmol). Analytical data for 3.11: Rf = 0.35 (acetone/toluene,1/9, v/v); 
[]D
23 +31.7 (c 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3): δ, 0.71, 0.86 (2 t, 6H, 2 x 
O(CH2)3CH3), 1.03 (m, 2H, O(CH2)2CH2CH3), 1.37-1.20 (m, 4H, O(CH2)2CH2CH3, 
OCH2CH2CH2CH3 ), 1.52 (m, 2H, OCH2CH2CH2CH3), 3.48-3.59 (m, 6H, H-3ʹ, 5, 6a, 6aʹ, 
6b, 6bʹ), 3.64-3.80 (m, 3H, H-5ʹ, OCOCH2CH), 3.84-4.00 (m, 2H, OCOCH2CH), 4.06 (br 
d, 1H, J3ʹ,4ʹ = 2.8 Hz, H-4ʹ), 4.13 (dd, 1H, J4,5 = 8.9 Hz, H-4), 4.21-4.63 (m, 8H, H-2, 3, 6 x 
CHPh), 4.66-4.74 (m, 3H, J1ʹ,2ʹ = 7.7 Hz, H-1ʹ, 2 x CHPh), 4.97 (d, 1H, 
2J = 12.2 Hz, CHPh), 
5.04 (d, 1H, 2J = 11.6 Hz, CHPh), 5.69 (dd, 1H, J2ʹ,3ʹ = 9.9 Hz, H-2ʹ), 5.75 (dd, 1H, J = 8.2, 
7.1 Hz, H-1), 6.80-8.05 (m, 34H, aromatic); 13C NMR (75 MHz, CDCl3): δ, 13.4, 13.6, 
18.3, 18.5, 31.8 (d, J = 7.0 Hz), 32.0 (d, J = 7.2 Hz), 56.0, 56.1, 67.4, 67.7 (d, J = 6.0 Hz), 
67.9 (d, J = 6.3 Hz), 68.2, 71.4, 72.4, 72.6, 73.4, 73.5 (x2), 74.5, 74.7, 75.1, 76.4, 76.8, 
79.7, 94.1 (d, J = 4.9 Hz), 100.7, 123.3, 125.4, 126.9, 127.4, 127.6 (×2), 127.7, 127.8 (×6), 
127.9, 128.0 (×6), 128.2 (×2), 128.3, 128.4 (×2), 128.5 (×6), 129.1, 129.8, 129.9, 131.6, 
133.2, 133.9, 137.8, 138.0, 138.1, 138.8 (x2), 165.1, 167.6 (×2) ppm; ESI TOF LCMS 
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galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (3.15). A mixture of 
donor 3.14 (0.20 g, 0.22 mmol), acceptor 3.2 (0.17 g, 0.17 mmol), and freshly activated 
molecular sieves (3Å, 600 mg) in CH2Cl2 (10 mL) was stirred under argon for 2 h at rt. 
The mixture was cooled to -30 oC, TMSOTf (80 μL, 0.44 mmol) was added, and the 
resulting mixture was stirred for 15 min. The reaction mixture was then diluted with 
CH2Cl2, the solid was filtered-off and rinsed successively with CH2Cl2. The combined 
filtrate (~50 mL) was washed with sat. aq. NaHCO3 (10 mL) and water (2 x 10 mL). The 
organic phase was separated, dried over MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (acetone - toluene gradient elution) 
to afford the title compound as an off-white amorphous solid in 70% yield (0.20 g, 0.12 
mmol). Analytical data for 3.15: Rf = 0.52 (acetone/toluene, 1/4 v/v); []D
23 +10.0 (c 1.0, 
CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 2.90 (m, 1H, J = 9.2 Hz, H-5), 3.25 (dd, 1H, J = 
10.0 Hz, H-6a), 3.32 (dd, 1H, J2,3 = 8.9 Hz, H-2), 3.36-3.39 (m, 2H, H-3, 6b), 3.63-3.72 
(m, 4H, H-3ʹ, 5ʹ, 6aʹʹ, 6bʹʹ), 3.81(dd, 1H, H-4), 3.88 (m, 1H, H-5ʹʹ), 4.03 (br d, 1H, J3ʹ,4ʹ = 
1.9 Hz, H-4ʹ), 4.11 (t, 1H, J = 6.9 Hz, OCOCH2CH), 4.15-4.27 (m, 5H, H-1, 2ʹʹ, 6aʹ, 2 x 
CHPh), 4.31-4.37 (m, 3H, H-6b, OCOCH2CH), 4.42 (d, 1H, J1ʹ,2ʹ = 8.0 Hz, H-1ʹ), 4.44-
4.49 (m, 4H, H-3ʹʹ, 3 x CHPh), 4.56-4.68 (m, 5H, 5 x CHPh), 4.78-4.82 (m, 2H, 2 x CHPh), 
4.89-4.94 (m, 2H, H-4ʹʹ, CHPh), 5.05 (d, 1H, 2J = 11.5 Hz, CHPh), 5.19 (d, 1H, J1ʹʹ,2ʹʹ = 8.4 
Hz, H-1ʹʹ), 5.30 (dd, 1H, J2ʹ,3ʹ = 9.8 Hz, H-2ʹ), 6.62-8.86 (m, 56H, aromatic) ppm; 
13C NMR 
(151 MHz, CDCl3): δ, 46.0, 55.6, 63.7, 67.4, 69.7, 69.9, 70.9, 71.9 (x2), 72.9, 73.4, 73.6 
(×2), 74.1, 74.2, 74.8, 74.9, 75.4, 75.7, 76.0, 76.3, 80.0, 81.5, 82.5, 99.4, 100.1, 102.4, 
120.0 (×2), 124.9, 125.0, 125.3, 126.7, 127.1 (×2), 127.2, 127.3 (×2), 127.4, 127.5, 127.6 
(×4), 127.7 (×3), 127.8, 127.9 (×11), 128.0 (×3), 128.1, 128.2 (×11), 128.4 (×3), 128.5 
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(×2), 128.6 (×3), 129.3, 129.6, 132.8, 136.8, 137.4 (×2), 137.6, 138.2, 138.4, 138.5, 138.9, 
141.2, 141.3, 143.0, 143.2, 147.7, 149.8, 154.2, 164.2, 164.3 ppm; ESI TOF LCMS 




β-D-glucopyranoside (3.16).  Compound 3.15 (200 mg, 0.118 mmol) was dissolved in a 
solution of Et3N in CH2Cl2 (7.0 mL, 1/165, v/v), and the resulting solution was stirred for 
2 h at rt. The resulting mixture was concentrated in vacuo, and the residue was purified by 
column chromatography on silica gel (acetone - toluene gradient elution) to afford the title 
compound as an off-white amorphous solid in 98% yield (170.3 mg, 0.116 mmol). 
Analytical data for 3.16: Rf = 0.55 (acetone/toluene, 1/4, v/v); []D
22 -5.7 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 2.92 (m, 1H, J = 1.8, 3.4, 10.0 Hz, H-5), 3.28 (dd, 1H, H-
6a), 3.34 (dd, 1H, J1,2 = 7.8 Hz, J2,3 = 9.2 Hz, H-2), 3.37-3.42 (m, 2H, H-3, 6b), 3.67-3.84 
(m, 7H, H-3ʹ, 4, 4ʹʹ, 5ʹ, 5ʹʹ, 6aʹʹ, 6bʹʹ), 4.02 (br d, 1H, J3ʹ,4ʹ = 2.2 Hz, H-4ʹ), 4.16-4.29 (m, 5H, 
H-1, 2ʹʹ, 6aʹ, 6bʹ, CHPh), 4.37 (dd, 1H, J = 6.2, 11.2 Hz, H-3ʹʹ), 4.41 (d, 1H, 2J = 12.1 Hz, 
CHPh), 4.45-4.70 (m, 9H, J1ʹ,2ʹ = 8.0 Hz, H-1ʹ, 8 x CHPh), 4.81 (d, 1H, 
2J = 12.0 Hz, 
CHPh), 4.82 (d, 1H, 2J = 11.4 Hz, CHPh), 4.93 (d, 1H, 2J = 10.4 Hz, CHPh), 5.08 (d, 1H, 
2J = 11.5 Hz, CHPh), 5.22 (d, 1H, J1ʹʹ,2ʹʹ = 8.2 Hz, H-1ʹʹ), 5.33 (dd, 1H, J2ʹ,3ʹ = 10.1 Hz, H-
2ʹ), 6.63-8.81 (m, 48H, aromatic) ppm; 13C NMR (151 MHz, CDCl3): δ, 55.7, 63.8, 67.6, 
70.7, 71.0, 72.0, 73.4, 73.9 (×4), 74.3, 74.5, 74.9, 75.0, 75.5, 75.9, 76.1, 78.6, 80.1, 81.6, 
82.6, 99.7, 100.3, 102.5, 122.8, 123.4, 125.4, 126.9, 127.2, 127.5, 127.5, 127.6 (×3), 127.7 
(×3), 127.8 (×2), 128.0 (×5), 128.1 (×4), 128.2 (×5), 128.3 (×6), 128.4 (×2), 128.6 (×2), 
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128.7 (×5), 129.4, 129.7, 130.9, 131.4, 132.9, 133.4, 133.5, 137.0, 137.5, 138.1, 138.3, 
138.6, 139.0, 147.8, 149.9, 164.4, 164.4, 167.2, 168.1 ppm; ESI TOF LCMS [M+Na]+ 





glucopyranoside (3.12).  A convergent (2+2) approach.  A mixture of donor 3.11 (128.3 
mg, 0.105 mmol), acceptor 3.3 (80.0 mg, 0.081 mmol), and freshly activated molecular 
sieves (3Å, 400 mg) in CH2Cl2 (7.0 mL) was stirred under argon for 2 h at rt. The mixture 
was cooled to -60 oC, TMSOTf (29 μL, 0.162 mmol) was added, and the resulting mixture 
was stirred for 30 min. During this time the reaction temperature was allowed to gradually 
increase to -30 oC. The reaction mixture was then diluted with CH2Cl2, the solid was 
filtered-off and rinsed successively with CH2Cl2. The combined filtrate (~50 mL) was 
washed with sat. aq. NaHCO3 (10 mL) and water (2 x 10 mL). The organic phase was 
separated, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (acetone - toluene gradient elution) to afford the title 
compound as an off-white amorphous solid in 70% yield (146.6 mg, 0.073 mmol).  A linear 
approach.  A mixture of donor 3.867,68 (42.5 mg, 0.062 mmol), acceptor 3.16 (70.0 mg, 
0.0475 mmol), and freshly activated molecular sieves (3Å, 250 mg) in CH2Cl2 (4.0 mL) 
was stirred under argon for 2 h at rt. The mixture was cooled to -30 oC, freshly conditioned 
AgOTf (31.8 mg, 0.124 mmol) was added, the external cooling was removed, and the 
resulting mixture was stirred for 15 min. During this time the reaction temperature was 
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allowed to gradually increase to -23 oC. The reaction mixture was then diluted with CH2Cl2, 
the solid was filtered-off and rinsed successively with CH2Cl2. The combined filtrate (~50 
mL) was washed with sat. aq. NaHCO3 (10 mL) and water (2 x 10 mL). The organic phase 
was separated, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (acetone - toluene gradient elution) to afford the title 
compound as an off-white amorphous solid in 84% yield (80.0 mg, 0.0398 mmol). 
Analytical data for 3.12: Rf = 0.50 (acetone/toluene, 1/4, v/v); []D
22 +11.5 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 2.89 (m, 1H, J = 1.9, 3.4, 9.9 Hz, H-5), 3.24 (dd, 1H, H-
6a), 3.28-3.46 (m, 7H, H-2, 3, 5ʹʹ, 5ʹʹʹ, 6aʹʹʹ, 6b, 6bʹʹʹ), 3.49 (dd, 1H, J = 2.8, 10.1 Hz, H-
3ʹʹʹ), 3.53 (dd, 1H, J5ʹʹ,6aʹʹ = 0.8 Hz, H-6aʹʹ), 3.56-3.61 (m, 2H, H-3ʹ, 5ʹ), 3.66 (dd, 1H, J5ʹʹ,6bʹʹ 
= 3.8 Hz, H-6bʹʹ, 3.78 (dd, 1H, J4,5 = 9.2 Hz, H-4), 3.95-3.99 (m, 3H, H-4ʹ, 4ʹʹ, 4ʹʹʹ), 4.12-
4.32 (m, 10H, H-1, 2ʹʹ, 3ʹʹ, 6aʹ, 6bʹ, 5 x CHPh), 4.40-4.49 (m, 4H, H-1ʹ, 3 x CHPh), 4.50-
4.58 (m, 4H, 4 x CHPh), 4.60-4.67 (m, 3H, J1ʹʹʹ,2ʹʹʹ = 7.9 Hz, H-1ʹʹʹ, 2 x CHPh), 4.79 (m, 2H, 
2 x CHPh), 4.85 (d, 1H, 2J = 12.0 Hz, CHPh), 4.90 (d, 1H, 2J = 10.4 Hz, CHPh), 4.95 (d, 
1H, CHPh), 5.08 (m, 2H, J1ʹʹ,2ʹʹ = 8.1 Hz, H-1ʹʹ, CHPh), 5.28 (dd, 1H, J2ʹ,3ʹ = 10.0, H-2ʹ), 
5.61 (dd, 1H, J2ʹʹʹ,3ʹʹʹ = 10.0 Hz, H-2ʹʹʹ), 6.59-8.70 (m, 68H, aromatic) ppm; 
13C NMR (151 
MHz, CDCl3): δ, 29.8, 56.0, 63.9, 67.6, 68.0, 68.3, 71.0, 71.4, 71.9, 72.0, 72.5, 72.6, 73.4, 
73.5, 73.6, 74.3, 74.6 (x2), 74.0, 75.0, 75.1, 75.6, 76.1, 76.2, 76.8, 77.8, 79.8, 80.1, 80.3, 
81.7, 82.6, 99.7, 100.4, 101.0, 102.5, 122.8, 123.3, 125.5, 126.7, 126.8, 127.2, 127.4 (×2), 
127.5 (×2), 127.6, 127.7 (×7), 127.8 (×8), 127.9 (×4), 128.0 (×4), 128.1 (×6), 128.3 (×6), 
128.4 (×5), 128.5 (×5), 128.6 (×3), 129.4, 129.7, 130.0 (×2), 131.0, 131.5, 132.9, 133.3, 
137.0, 137.6, 137.8, 138.0 (×2), 138.3, 138.7, 138.8 (×2), 138.9, 139.0, 147.8, 149.9, 164.3, 
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164.4, 165.2, 167.2, 167.8 ppm; ESI TOF LCMS [M+H]+ calcd for C122H117N2O25 
2010.7979, found 2010.7988. 
 
3.4.4. Deprotection of tetrasaccharide 3.12  
Benzyl O-(3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→4)-O-(2-acetamido-3,6-di-O-
benzyl-2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(4-O-benzyl-β-D-galactopyranosyl)-
(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (3.17).  Compound 3.12 (78.0 mg, 0.038 
mmol) was dissolved in MeOH (5.0 mL), NH2NH2-H2O (167 μL, 3.42 mmol) was added, 
and the resulting mixture was kept for 24 h at reflux. After that, the volatiles were removed 
under reduced pressure, and the residue was dried in vacuo for 3 h. The crude residue was 
dissolved in a mixture of Ac2O/MeOH (2.0 mL, 1/1, v/v) and the resulting mixture was 
stirred for 12 h at rt. After that, the volatiles were removed under reduced pressure. The 
residue was diluted with CH2Cl2 (50 mL), and washed with water (10 mL), 1 M HCl (10 
mL), and water (2 x 10 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(acetone - toluene gradient elution) to afford the title compound as an off-white amorphous 
solid in 87% yield (53.1 mg, 0.033 mmol). Analytical data for 3.17: Rf = 0.67 
(acetone/toluene, 2/3, v/v); []D
22 +12.0 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 
1.75 (s, 3H, CH3CO). 2.94-4.03 (m, 24H, H-2, 2ʹ, 2ʹʹ, 2ʹʹʹ, 3, 3ʹ, 3ʹʹ, 3ʹʹʹ, 4, 4ʹ, 4ʹʹ, 4ʹʹʹ, 5, 5ʹ, 
5ʹʹ, 5ʹʹʹ, 6a, 6aʹ, 6aʹʹ, 6aʹʹʹ, 6b, 6bʹ, 6bʹʹ, 6bʹʹʹ), 4.30 (dd, 2H, 2J = 11.7 Hz, CH2Ph), 4.43-4.50 
(m, 3H, H-1, 1ʹ, 1ʹʹʹ), 4.52-4.73 (m, 11H, 11 x CHPh), 4.80-4.96 (m, 7H, 7 x CHPh), 4.99 
(d, 1H, J1ʹʹ,2ʹʹ = 7.8 Hz, H-1ʹʹ), 5.61 (d, 1H, J = 7.4 Hz, NHCOCH3), 7.16-7.40 (m, 50H, 
aromatic) ppm; 13C NMR (151 MHz, CDCl3): δ, 23.6, 57.2, 61.8, 68.3, 68.8, 69.0, 71.3, 
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71.9, 72.1, 72.3, 72.8, 73.5, 73.6 (×3), 73.7, 74.3 (×2), 74.7, 74.8, 74.9, 75.0, 75.1, 75.3, 
77.1, 77.2, 80.2, 82.0, 82.2, 83.2 (×2), 102.2, 102.9, 103.2, 103.4, 127.4, 127.5 (×3), 127.6 
(×2), 127.7 (×3), 127.8 (×3), 127.9 (×5), 128.0 (×7), 128.1 (×2), 128.3 (×6), 128.4 (×5), 
128.5 (×4), 128.6 (×7), 137.6 (×2), 137.9 (×2), 138.1, 138.2, 138.4, 138.6, 138.8 (x2), 




(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose (LNnT, 3.1).  A 10% Pd on 
charcoal (150 mg) was added to a solution of 3.17 (53.0 mg, 0.033 mmol) in EtOH/H2O 
(5.0 mL, 4/1, v/v), and the resulting mixture was stirred under hydrogen atmosphere for 24 
h at rt. After that, the solids were filtered off and rinsed successively with methanol and 
water. The combined filtrate (~40 mL) was concentrated in vacuo, and the residue was 
purified by column chromatography on Sephadex G-25 (water elution) to afford the title 
compound as a white amorphous solid in 92% yield (21.4 mg, 0.030 mmol).  Selected 
analytical data for 3.1:72 Rf = 0.32 (chloroform/methanol/water, 2/1/0.4, v/v/v); 
1H NMR 
(600 MHz, D2O): δ, 2.01 (s, 3H), 3.24-3.28 (m, 1H), 3.88-3.49 (m, 29H), 3.89-3.96 (m, 
4H), 4.14 (d, 1H, J = 3.3 Hz), 4.42 (d, 1H, J = 7.9 Hz), 4.46 (d, J = 7.8 Hz, 1H), 4.64 (d, 
1H, J = 8.0 Hz), 4.68 (dd, 1H, J = 2.1, 8.4 Hz,), 5.20 (d, 1H, J = 3.8 Hz) ppm; 13C NMR 
(151 MHz, D2O): δ, 22.5, 55.5, 60.2, 60.3, 60.4, 61.3, 61.4, 68.7 (x2), 68.9, 70.3 (x2), 70.4, 
70.5, 71.3, 71.5 (×2), 71.7, 72.5, 72.8, 74.1, 74.7, 74.9, 75.1, 75.2, 75.7, 78.5, 78.6, 78.7, 
82.4, 92.2, 96.1, 103.1, 103.2 (x2), 103.3, 103.4, 175.2 ppm; ESI TOF LCMS [M+Na]+ 
calcd for C26H45NNaO21 730.2382, found 730.2392. 
W. M. Mithila D. Bandara | UMSL 2019 | Page  118 
 
3.5. References 
 (1) Stick, R. V.; Williams, S. J.: Carbohydrates: the essential molecules of 
life; Second ed.; Elsevier: Amsterdam - Boston - Heidelberg, 2009. 
 (2) Pang, P.-C.; Chiu, P. C. N.; Lee, C.-L.; Chang, L.-Y.; Panico, M.; Morris, 
H. R.; Haslam, S. M.; Khoo, K.-H.; Clark, G. F.; Yeung, W. S. B.; Dell, A. Human 
Sperm Binding Is Mediated by the Sialyl-Lewisx Oligosaccharide on the Zona Pellucida 
Science 2011, 333, 1761-1764. 
 (3) Eriksen, K. G.; Christensen, S. H.; Lind, M. V.; Michaelsen, K. F. Human 
milk composition and infant growth. Curr. Opin. Clin. Nutr. Metab. Care 2018, 21, 200-
206. 
 (4) Thomson, P.; Medina, D. A.; Garrido, D. Human milk oligosaccharides 
and infant gut bifidobacteria: Molecular strategies for their utilization. Food Microbiol. 
2018, 75, 37-46. 
 (5) Plaza-Diaz, J.; Fontana, L.; Gil, A. Human Milk Oligosaccharides and 
Immune System Development. Nutrients 2018, 10. 
 (6) Craft, K. M.; Townsend, S. D. The Human Milk Glycome as a Defense 
Against Infectious Diseases: Rationale, Challenges, and Opportunities. ACS Infect. Dis. 
2018, 4, 77-83. 
 (7) Andreas, N. J.; Kampmann, B.; Mehring Le-Doare, K. Human breast 
milk: A review on its composition and bioactivity. Early Hum. Dev. 2015, 91, 629-635. 
 (8) Newburg, D. S. Glycobiology of human milk. Biochemistry 2013, 78, 771-
785. 
W. M. Mithila D. Bandara | UMSL 2019 | Page  119 
 
 (9) Triantis, V.; Bode, L.; van Neerven, R. J. J. Immunological Effects of 
Human Milk Oligosaccharides. Front. Pediatr. 2018, 6, 190. 
 (10) Craft, K. M.; Gaddy, J. A.; Townsend, S. D. Human Milk 
Oligosaccharides (HMOs) Sensitize Group B Streptococcus to Clindamycin, 
Erythromycin, Gentamicin, and Minocycline on a Strain Specific Basis. ACS Chem. Biol. 
2018, 13, 2020-2026. 
 (11) Ayechu-Muruzabal, V.; van Stigt, A. H.; Mank, M.; Willemsen, L. E. M.; 
Stahl, B.; Garssen, J.; Van't Land, B. Diversity of Human Milk Oligosaccharides and 
Effects on Early Life Immune Development. Front. Pediatr. 2018, 6, 239. 
 (12) Lin, A. E.; Autran, C. A.; Szyszka, A.; Escajadillo, T.; Huang, M.; 
Godula, K.; Prudden, A. R.; Boons, G. J.; Lewis, A. L.; Doran, K. S.; Nizet, V.; Bode, L. 
Human milk oligosaccharides inhibit growth of group B Streptococcus. J. Biol. Chem. 
2017, 292, 11243-11249. 
 (13) Kulinich, A.; Liu, L. Human milk oligosaccharides: The role in the fine-
tuning of innate immune responses. Carbohydr. Res. 2016, 432, 62-70. 
 (14) Wu, S.; Grimm, R.; German, J. B.; Lebrilla, C. B. Annotation and 
Structural Analysis of Sialylated Human Milk Oligosaccharides. J. Proteome Res. 2011, 
10, 856-868. 
 (15) Bode, L. Human milk oligosaccharides: every baby needs a sugar mama. 
Glycobiology 2012, 22, 1147-1162. 
 (16) Wu, X.; Jackson, R. T.; Khan, S. A.; Ahuja, J.; Pehrsson, P. R. Human 
Milk Nutrient Composition in the United States: Current Knowledge, Challenges, and 
Research Needs. Curr. Dev. Nutr. 2018, 2, nzy025. 
W. M. Mithila D. Bandara | UMSL 2019 | Page  120 
 
 (17) Kunz, C.; Rudloff, S.; Baier, W.; Klein, N.; Strobe, S. Oligosaccharides in 
Human Milk: Structural, Functional, and Metabolic Aspects. Annu. Rev. Nutr. 2000, 20, 
699-722. 
 (18) Urashima, T.; Hirabayashi, J.; Sato, S.; Kobata, A. Human Milk 
Oligosaccharides as Essential Tools for Basic and Application Studies on Galectins. 
Trends Glycosci. Glycotechnol. 2018, 30, SE51-SE65. 
 (19) Remoroza, C. A.; Mak, T. D.; De Leoz, M. L. A.; Mirokhin, Y. A.; Stein, 
S. E. Creating a Mass Spectral Reference Library for Oligosaccharides in Human Milk. 
Anal. Chem. 2018, 90, 8977-8988. 
 (20) Chen, X. Human Milk Oligosaccharides (HMOS): Structure, Function, 
and Enzyme-Catalyzed Synthesis. Adv. Carbohydr. Chem. Biochem. 2015, 72, 113-190. 
 (21) Ruhaak, L. R.; Lebrilla, C. B. Advances in analysis of human milk 
oligosaccharides. Adv. Nutr. 2012, 3, 406S-414S. 
 (22) Wu, S.; Tao, N.; German, J. B.; Grimm, R.; Lebrilla, C. B. Development 
of an Annotated Library of Neutral Human Milk Oligosaccharides. J. Proteome Res. 
2010, 9, 4138-4151. 
 (23) Fischoder, T.; Cajic, S.; Reichl, U.; Rapp, E.; Elling, L. Enzymatic 
Cascade Synthesis Provides Novel Linear Human Milk Oligosaccharides as Reference 
Standards for xCGE-LIF Based High-Throughput Analysis. Biotechnol. J. 2018, 
1800305. 
 (24) Fischer, C.; Kleinschmidt, T. Synthesis of Galactooligosaccharides in 
Milk and Whey: A Review. Compr. Rev. Food Sci. Food Saf. 2018, 17, 678-697. 
W. M. Mithila D. Bandara | UMSL 2019 | Page  121 
 
 (25) Fang, J.-L.; Tsai, T.-W.; Liang, C.-Y.; Li, J.-Y.; Yu, C.-C. Enzymatic 
Synthesis of Human Milk Fucosides α1,2-Fucosyl para-Lacto-N-Hexaose and its 
Isomeric Derivatives. Adv. Synth. Catal. 2018, 360, 3213-3219. 
 (26) Zhu, H.; Wu, Z.; Gadi, M. R.; Wang, S.; Guo, Y.; Edmunds, G.; Guan, 
W.; Fang, J. Cation exchange assisted binding-elution strategy for enzymatic synthesis of 
human milk oligosaccharides (HMOs). Bioorg. Med. Chem. Lett. 2017, 27, 4285-4287. 
 (27) Prudden, A. R.; Liu, L.; Capicciotti, C. J.; Wolfert, M. A.; Wang, S.; Gao, 
Z.; Meng, L.; Moremen, K. W.; Boons, G. J. Synthesis of asymmetrical multiantennary 
human milk oligosaccharides. Proc. Nat. Acad. Sci. 2017, 114, 6954-6959. 
 (28) Yu, H.; Yan, X.; Autran, C. A.; Li, Y.; Etzold, S.; Latasiewicz, J.; 
Robertson, B. M.; Li, J.; Bode, L.; Chen, X. Enzymatic and Chemoenzymatic Syntheses 
of Disialyl Glycans and Their Necrotizing Enterocolitis Preventing Effects. J. Org. 
Chem. 2017, 82, 13152-13160. 
 (29) Zhao, C.; Wu, Y.; Yu, H.; Shah, I. M.; Li, Y.; Zeng, J.; Liu, B.; Mills, D. 
A.; Chen, X. The one-pot multienzyme (OPME) synthesis of human blood group H 
antigens and a human milk oligosaccharide (HMOS) with highly active 
Thermosynechococcus elongatus α1-2-fucosyltransferase. Chem. Commun. 2016, 52, 
3899-3902. 
 (30) Yu, H.; Zeng, J.; Li, Y.; Thon, V.; Shi, B.; Chen, X. Effective one-pot 
multienzyme (OPME) synthesis of monotreme milk oligosaccharides and other sialosides 
containing 4-: O -acetyl sialic acid. Org. Biomol. Chem. 2016, 14, 8586-8597. 
 (31) Xiao, Z.; Guo, Y.; Liu, Y.; Li, L.; Zhang, Q.; Wen, L.; Wang, X.; 
Kondengaden, S. M.; Wu, Z.; Zhou, J.; Cao, X.; Li, X.; Ma, C.; Wang, P. G. 
W. M. Mithila D. Bandara | UMSL 2019 | Page  122 
 
Chemoenzymatic Synthesis of a Library of Human Milk Oligosaccharides. J. Org. Chem. 
2016, 81, 5851-5865. 
 (32) Lezyk, M.; Jers, C.; Kjaerulff, L.; Gotfredsen, C. H.; Mikkelsen, M. D.; 
Mikkelsen, J. D. Novel α-L-fucosidases from a soil metagenome for production of 
fucosylated human milk oligosaccharides. PLoS ONE 2016, 11. 
 (33) Yao, W.; Yan, J.; Chen, X.; Wang, F.; Cao, H. Chemoenzymatic synthesis 
of lacto-N-tetrasaccharide and sialyl lacto-N-tetrasaccharides. Carbohydr. Res. 2015, 
401, 5-10. 
 (34) Chen, C.; Zhang, Y.; Xue, M.; Liu, X. W.; Li, Y.; Chen, X.; Wang, P. G.; 
Wang, F.; Cao, H. Sequential one-pot multienzyme (OPME) synthesis of lacto-N-
neotetraose and its sialyl and fucosyl derivatives. Chem. Commun. 2015, 51, 7689-7692. 
 (35) Baumgaertner, F.; Conrad, J.; Sprenger, G. A.; Albermann, C. Synthesis 
of the Human Milk Oligosaccharide Lacto-N-Tetraose in Metabolically Engineered, 
Plasmid-Free E. coli. Chem Bio Chem 2014, 15, 1896-1900. 
 (36) Hattie, M.; Debowski, A. W.; Stubbs, K. A. Development of Tools to 
Study Lacto-N-Biosidase: An Important Enzyme Involved in the Breakdown of Human 
Milk Oligosaccharides. Chembiochem : a European journal of chemical biology 2012, 
13, 1128-1131. 
 (37) Nishimoto, M.; Kitaoka, M. Practical preparation of lacto-N-biose I, a 
candidate for the bifidus factor in human milk. Biosci. Biotechnol. Biochem. 2007, 71, 
2101-2104. 
 (38) Matsuo, I.; Kim, S.; Yamamoto, Y.; Ajisaka, K.; Maruyama, J. I.; 
Nakajima, H.; Kitamoto, K. Cloning and overexpression of β-n-acetylglucosaminidase 
W. M. Mithila D. Bandara | UMSL 2019 | Page  123 
 
encoding gene naga from aspergillus oryzae and enzyme-catalyzed synthesis of human 
milk oligosaccharide. Biosci. Biotechnol. Biochem. 2003, 67, 646-650. 
 (39) Priem, B.; Gilbert, M.; Wakarchuk, W. W.; Heyraud, A.; Samain, E. A 
new fermentation process allows large-scale production of human milk oligosaccharides 
by metabolically engineered bacteria. Glycobiology 2002, 12, 235-240. 
 (40) Rencurosi, A.; Poletti, L.; Guerrini, M.; Russo, G.; Lay, L. Human milk 
oligosaccharides: An enzymatic protection step simplifies the synthesis of 3′- and 6′-O-
sialyllactose and their analogues. Carbohydr.  Res. 2002, 337, 473-483. 
 (41) La Ferla, B.; Lay, L.; Poletti, L.; Russo, G.; Panza, L. Easy chemo-
enzymatic synthesis of human milk trisaccharides from a common selectively protected 
lactose building block. J. Carbohydr. Chem. 2000, 19, 331-343. 
 (42) Nikrad, P. V.; Kashem, M. A.; Wlasichuk, K. B.; Alton, G.; Venot, A. P. 
Use of human-milk fucosyl-transferase in the chemoenzymic synthesis of analogs of the 
sialyl Lewis x and sialyl Lewis a tetrasaccharides modified at the C-2 position of the 
reducing unit. Carbohydr. Res. 1993, 250, 145-160. 
 (43) Arboe Jennum, C.; Hauch Fenger, T.; Bruun, L. M.; Madsen, R. One-Pot 
Glycosylation in the Synthesis of Human Milk Oligosaccharides. Eur. J. Org. Chem. 
2014, 2014, 3232-3241. 
 (44) Pereira, C. L.; McDonald, F. E. Synthesis of human milk oligosaccharides: 
2'- and 3'-fucosyllactose. Heterocycles 2012, 84, 637-655. 
 (45) Schmidt, D.; Thiem, J. Chemical synthesis using enzymatically generated 
building units for construction of the human milk pentasaccharides sialyllacto-N-tetraose 
and sialyllacto-N-neotetraose epimer. Beilstein J. Org. Chem. 2010, 6, 1-7. 
W. M. Mithila D. Bandara | UMSL 2019 | Page  124 
 
 (46) La Ferla, B.; Prosperi, D.; Lay, L.; Russo, G.; Panza, L. Synthesis of 
building blocks of human milk oligosaccharides. Fucosylated derivatives of the lacto- and 
neolacto-series. Carbohydr. Res. 2002, 337, 1333-1342. 
 (47) Knuhr, P.; Castro-Palomino, J.; Grathwohl, M.; Schmidt, R. R. Complex 
structures of antennary human milk oligosaccharides - Synthesis of a branched 
octasaccharide. Eur. J. Org. Chem. 2001, 4239-4246. 
 (48) Takamura, T.; Chiba, T.; Tejima, S. Chemical Modification of Lactose. 
XVI. Synthesis of Lacto-N-neohexaose. Chem. Pharm. Bull. 1981, 29, 2270-2276. 
 (49) Takamura, T.; Chiba, T.; Ishihara, H.; Tejima, S. Chemical Modification 
of Lactose. XIII. Synthesis of Lacto-N-tetraose. Chem. Pharm. Bull. 1980, 28, 1804-
1809. 
 (50) Aly, M. R. E.; Ibrahim, E. S. I.; El Ashry, E. S. H.; Schmidt, R. R. 
Synthesis of lacto-N-neotetraose and lacto-N-tetraose using the dimethylmaleoyl group 
as amino protective group. Carbohydr.  Res. 1999, 316, 121-132. 
 (51) Craft, K. M.; Townsend, S. D. Synthesis of lacto-N-tetraose. Carbohydr.  
Res. 2017, 440-441, 43-50. 
 (52) Roussel, F.; Takhi, M.; Schmidt, R. R. Solid-phase synthesis of a branched 
hexasaccharide using a highly efficient synthetic strategy. J. Org. Chem. 2001, 66, 8540-
8548. 
 (53) Roussel, F.; Knerr, L.; Schmidt, R. R. Solid-phase synthesis of lactose-
containing oligosaccharides. Eur. J. Org. Chem. 2001, 2067-2073. 
W. M. Mithila D. Bandara | UMSL 2019 | Page  125 
 
 (54) Nilsson, S.; Loenn, H.; Norberg, T. Synthesis of two tumor-associated 
oligosaccharides:  di- and trifucosylated para-lacto-N-hexaose. J. Carbohydr. Chem. 
1991, 10, 1023-1048. 
 (55) Sprenger, G. A.; Baumgartner, F.; Albermann, C. Production of human 
milk oligosaccharides by enzymatic and whole-cell microbial biotransformations. J. 
Biotechnol. 2017, 258, 79-91. 
 (56) Bych, K.; Miks, M. H.; Johanson, T.; Hederos, M. J.; Vigsnaes, L. K.; 
Becker, P. Production of HMOs using microbial hosts - from cell engineering to large 
scale production. Curr. Opin. Biotechnol. 2019, 56, 130-137. 
 (57) Puccio, G.; Alliet, P.; Cajozzo, C.; Janssens, E.; Corsello, G.; Sprenger, 
N.; Wernimont, S.; Egli, D.; Gosoniu, L.; Steenhout, P. Effects of Infant Formula With 
Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter 
Trial. J. Pediatr. Gastroenterol. Nutr. 2017, 64, 624-631. 
 (58) Vandenplas, Y.; Berger, B.; Carnielli, V. P.; Ksiazyk, J.; Lagstrom, H.; 
Sanchez Luna, M.; Migacheva, N.; Mosselmans, J. M.; Picaud, J. C.; Possner, M.; 
Singhal, A.; Wabitsch, M. Human Milk Oligosaccharides: 2'-Fucosyllactose (2'-FL) and 
Lacto-N-Neotetraose (LNnT) in Infant Formula. Nutrients 2018, 10. 
 (59) Xu, G.; Davis, J. C.; Goonatilleke, E.; Smilowitz, J. T.; German, J. B.; 
Lebrilla, C. B. Absolute Quantitation of Human Milk Oligosaccharides Reveals 
Phenotypic Variations during Lactation. J. Nutr. 2017, 147, 117-124. 
 (60) Smilowitz, J. T.; Lebrilla, C. B.; Mills, D. A.; German, J. B.; Freeman, S. 
L. Breast milk oligosaccharides: structure-function relationships in the neonate. Annu. 
Rev. Nutr. 2014, 34, 143-169. 
W. M. Mithila D. Bandara | UMSL 2019 | Page  126 
 
 (61) Bode, L.; Jantscher-Krenn, E. Structure-function relationships of human 
milk oligosaccharides. Adv. Nutr. 2012, 3, 383S-391S. 
 (62) Nguyen, T. Synthesizing mothers’ milk. Chem. Eng. News 2018, 96, 26. 
 (63) Mbadugha, B. N. A.; Menger, F. M. Sugar/Steroid/Sugar Conjugates:  
Sensitivity of Lipid Binding to Sugar Structure. Org. Lett. 2003, 5, 4041-4044. 
 (64) Nagorny, P.; Fasching, B.; Li, X.; Chen, G.; Aussedat, B.; Danishefsky, S. 
J. Toward Fully Synthetic Homogeneous β-Human Follicle-Stimulating Hormone (β-
hFSH) with a Biantennary N-Linked Dodecasaccharide. Synthesis of β-hFSH with 
Chitobiose Units at the Natural Linkage Sites. J. Am. Chem. Soc. 2009, 131, 5792-5799. 
 (65) Li, Z.; Gildersleeve, J. Mechanistic studies and methods to prevent 
aglycon transfer of thioglycosides. J. Am. Chem. Soc. 2006, 128, 11612-11619. 
 (66) Plé, K. Synthesis of the trisaccharide portion of soyasaponin βg: 
evaluation of a new glucuronic acid acceptor. Carbohydr.  Res. 2003, 338, 1441-1454. 
 (67) Mydock, L. K.; Demchenko, A. V. Superarming the S-benzoxazolyl 
glycosyl donors by simple 2-O-benzoyl-3,4,6-tri-O-benzyl protection. Org. Lett. 2008, 
10, 2103-2106. 
 (68) Mydock, L. K.; Demchenko, A. V. Application of the superarmed 
glycosyl donor to chemoselective oligosaccharide synthesis. Org. Lett. 2008, 10, 2107-
2110. 
 (69) Mondal, P. K.; Liao, G.; Mondal, M. A.; Guo, Z. Chemical Synthesis of 
the Repeating Unit of Type Ia Group B Streptococcus Capsular Polysaccharide. Org. 
Lett. 2015, 17, 1102-1105. 
W. M. Mithila D. Bandara | UMSL 2019 | Page  127 
 
 (70) Degenstein, J. C.; Murria, P.; Easton, M.; Sheng, H.; Hurt, M.; Dow, A. 
R.; Gao, J.; Nash, J. J.; Agrawal, R.; Delgass, W. N.; Ribeiro, F. H.; Kenttämaa, H. I. Fast 
Pyrolysis of 13C-Labeled Cellobioses: Gaining Insights into the Mechanisms of Fast 
Pyrolysis of Carbohydrates. J. Org. Chem. 2015, 80, 1909-1914. 
 (71) Palmacci, E. R.; Plante, O. J.; Seeberger, P. H. Oligosaccharide synthesis 
in solution and on solid support with glycosyl phosphates. Eur. J. Org. Chem. 2002, 595-
606. 
 (72) Strecker, G.; Wieruszeski, J.-M.; Michalski, J.-C.; Montreuil, J. 
Assignment of the 1H- and 13C-NMR Spectra of Eight Oligosaccharides of the Lacto-N-
tetraose and Neotetraose Series. Glycoconjugate J. 1989, 6, 67-83. 
 
M. D. Bandara, K. J. Stine, and A. V. Demchenko.  The chemical synthesis of 
human milk oligosaccharides: lacto-N-tetraose 
(Galβ1→3GlcNAcβ1→3Galβ1→4Glc). Carbohydr. Res., 2019, 486, 107824; 











W. M. Mithila D. Bandara | UMSL 2019 | Page  129 
 
4.1. Introduction 
Carbohydrates are essential biomolecules that become our first food.1 
Oligosaccharides present in human milk (HMO) can supply building blocks for the 
development of the infants’ cognition,2 act as prebiotics3 and antimicrobials.4,5 Thanks to 
advances in glycosciences, chemical structures of 162 HMO have been elucidated to 
date,6,7 but our understanding of how HMO function is incomplete.8,9 All HMO are 
composed of five monosaccharides: including glucose (Glc), galactose (Gal), N-
acetylglucosamine (GlcNAc), fucose, and sialic acid.10 Many efforts to prepare HMO 
enzymatically or chemically have been reported,11-13 and importance of including HMO in 
infant formulas has been acknowledged.14  
The total amount and composition of HMO varies between women and are 
dependent on maternal genetics, environment, and geographic location.15 Lacto-N-tetraose 
(LNT) 4.1 represents one of the most common and abundant core structures and is 
classified as a type I HMO. It comprises a Galβ1→3GlcNAcβ1→3Galβ1→4Glc sequence 
shown in Scheme 4.1. More specifically, LNT is a linear tetrasaccharide wherein the 
reducing end lactose disaccharide (Galβ1→4Glc) is elongated with lacto-N-biose 
disaccharide residue (Galβ1→3GlcNAc). Chemical16-18 and enzymatic syntheses19 of LNT 
have been reported, and several of its derivatives have been synthesized using chemical 
synthesis in solution and on solid phase.20-24 Despite being one of the most abundant HMO 
core structures in human milk, LNT is not yet available in large quantities and at reasonable 
prices for research and application.  
Previously, we reported the total synthesis of lacto-N-neotetraose that has been 
completed using both linear and convergent approaches (see Chapter 3).25 Along the way, 
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we developed the synthesis of key building blocks, accessed scalability, and refined 
coupling procedures to obtain different glycosidic linkages and sequences. Notably, the 
donor and acceptor protecting/leaving group combinations were found to be key 
parameters. In further synthetic studies of HMO in our lab reported herein is the synthesis 
of LNT 4.1.  
 
4.2. Results and discussion 
First, we decided to investigate a convergent (2+2) synthetic strategy, according to 
which we chose to converge the protected lacto-N-biose donor 4.2 and lactose acceptor 
4.3.25 Based on our previous synthetic endeavors and preliminary refinement of reaction 
conditions (Chapter 3),25 for the synthesis of disaccharide 4.2 we chose superarmed S-
benzoxazolyl (SBox) galactosyl donor 4.429,30 and glucosamine acceptor 4.5. SBox 
galactosyl donor 4.4 was very instrumental in avoiding the unwanted aglycone transfer side 
reaction12,26 that was taking place in other previously investigated building blocks.25  
 
Scheme 4.1.  Retrosynthesis analysis of LNT 4.1. 
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The synthesis of glucosamine thioglycoside acceptor 4.5 was achieved from known 
building block 4.6 as depicted in Scheme 4.2.27 First, precursor 4.6 was reacted with tert-
butyldimethylsilyl chloride (TBDMSCl) in the presence of imidazole in DMF at 90 oC to 
obtain compound 4.7 in 97% yield. The latter was then converted to intermediate 4.8 via 
the reductive regioselective opening of the benzylidene acetal by reaction with 1 M BH3 in 
THF in the presence of catalytic TMSOTf in 82% yield. Subsequently, 6-OH in compound 
4.8 was benzylated with BnBr in the presence of NaH in DMF to afford compound 4.9 in 
77% yield. In order to minimize the formation of side products, temperature control is 
highly important in this reaction (see the experimental part for further details). Finally, the 
silyl group of compound 4.9 was removed with BF3-Et2O in CH3CN at 0 
oC to afford the 
desired glucosamine thioglycoside acceptor 4.5 in 87% yield. 
We next turned our attention to the assembly of LNB disaccharide 4.2. Selective 
activation of the SBox leaving group in glycosyl donor 4.4 over thioethyl anomeric moiety 
of acceptor 4.5 was achieved in the presence of silver trifluoromethanesulfonate (AgOTf) 
to afford β-linked disaccharide 4.2 in excellent yield of 99%. Direct coupling of 
disaccharide 4.2 with acceptor 4.3 was proven inefficient, so we chose to employ the 
corresponding phosphate donor 4.10. This was accomplished in 90% yield via an efficient 
one-step protocol developed by Seeberger and co-workers.28 The coupling of phosphate 
donor 4.10 with lactose acceptor 4.3 in the presence of TMSOTf was more successful, and 
tetrasaccharide 4.11 was obtained in a moderate yield of 51% with complete β-
stereoselectivity.  
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Scheme 4.2.  Convergent synthesis of protected LNT 4.11. 
 
Despite numerous attempts involving modifying the reaction condition, and 
replacing the glycosyl donor with O- and S-imidoyl leaving groups, we failed to improve 
the outcome of this reaction. We were also unable to elucidate structures of by-products 
forming alongside the desired tetrasaccharide 4.11.  Not being satisfied with the outcome 
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of the convergent synthesis, we were curious to investigate whether the linear approach 
would be more successful in achieving a better outcome.  
 
Scheme 4.3.  The linear synthesis of tetrasaccharide 4.11 and its deprotection to 
obtain LNT 4.1. 
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Only a minimal strategic adjustment was required, and this involved conversion of 
building block 4.5 into its 4-O-Fmoc derivative 4.12 that was subsequently transformed 
into phosphate donor 4.13. Glycosylation between donor 4.13 and lactose acceptor 4.3 in 
the presence of TMSOTf afforded trisaccharide 4.14 in 86% yield. The Fmoc protecting 
group was removed with 30% Et3N in CH2Cl2 and glycosylation of the resulting 
trisaccharide acceptor 4,15 with SBox donor 4.4 in the presence of AgOTf afforded the 
desired β-linked tetrasaccharide 4.11 in 89% yield. Overall, the three-step linear assembly 
of 4.11 involving glycosylation of acceptor 4.3 with glycosyl donor 4.13, interim Fmoc 
deprotection, followed by glycosylation with donor 4.4 proceeded with 68% overall yield 
for the synthesis of tetrasaccharide 4.11. In contrast, the convergent approach was much 
less efficient, 45% over three steps, primarily due to the very low-yielding last coupling 
step between disaccharides 4.3 and 4.10.  
With the key tetrasaccharide intermediate 4.11 we endeavored to carry out its 
deprotection steps to obtain the target LNT tetrasaccharide 4.1. Deprotection of the 
phthalimido and the ester groups was performed in the presence of NH2NH2-H2O in 
refluxing MeOH. Subsequent N-acetylation with acetic anhydride in MeOH furnished 
tetrasaccharide intermediate 4.16 in 92% yield. Subsequently, benzyl ethers were 
hydrogenated the presence of 10% Pd/C in wet ethanol to afford the target trisaccharide 
4.1 in 81% yield. 
 
4.3. Conclusions 
In summary, the total synthesis of lacto-N-tetraose has been completed using both 
linear and convergent synthesis approaches. The linear approach was significantly more 
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effective in this application. Along the way, we have developed new synthetic protocols for 
different glycosidic linkages. Notably, the donor and acceptor protecting group and the 
leaving group combinations were found to be of paramount significance to successful 
glycosylations. The protecting groups in precursors used for the synthesis of the key 
building block 4.3 were chosen to provide access to variable glycosylation sites. In this 
application, 3’-OH acceptor 4.3 was achieved via the Fmoc group removal,25 but the same 
precursors could also be used to achieve 6’-OH via the OPico group removal, or provide 
access to 3’,6’-diol for the synthesis of branched HMO. We expect that new methods for 




4.4.1. General methods 
The reactions were performed using commercial reagents and the ACS grade 
solvents were purified and dried according to standard procedures. Column 
chromatography was performed on silica gel 60 (70-230 mesh) and Sephadex G-25 size 
exclusion resin, reactions were monitored by TLC on Kieselgel 60 F254. The compounds 
were detected by examination under UV light and by charring with 10% sulfuric acid in 
methanol. Solvents were removed under reduced pressure at <40 oC. CH2Cl2 was distilled 
from CaH2 directly prior to application. Molecular sieves (3Å), used for reactions, were 
crushed and activated in vacuo at 390 °C during 8 h in the first instance and then for 2-3 h 
at 390 °C directly prior to application. AgOTf was co-evaporated with toluene (3 x 10 mL) 
and dried in vacuo for 2-3 h directly prior to application. Optical rotations were measured 
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using a Jasco polarimeter. 1H NMR spectra were recorded at 300 MHz or 600 MHz, and 
13C NMR spectra were recorded at 75 MHz or 151 MHz. The 1H chemical shifts are 
referenced to the signal of the residual TMS (δH = 0.00 ppm) for solutions in CDCl3 or the 
signal of the residual D2O (δH = 4.79 ppm) for solutions in D2O. The 
13C chemical shifts 
are referenced to the central signal of CDCl3 (δC = 77.16 ppm) for solutions in CDCl3 or 
the central signal of CD3COCD3 δC = 29.84 ppm) for solutions in D2O. Accurate mass 
spectrometry determinations were performed using Agilent 6230 ESI TOF LCMS mass 
spectrometer. 
 
4.4.2. Preparation of monosaccharide building blocks 4.7, 4.8, 4.5, 4.12. 4.13 
Ethyl 4,6-O-benzylidene-3-O-tert-butyldimethylsilyl-2-deoxy-2-phthalimido-1-thio-β-
D-glucopyranoside (4.7).  TBDMSCl (0.37 g, 2.44 mmol) and imidazole (0.16 g, 2.44 
mmol) were added to a solution of ethyl 4,6-O-benzylidene-2-deoxy-2-phthalimido-1-thio-
β-D-glucopyranoside27 (4.6, 0.54 g, 1.22 mmol) in DMF (7.0 mL) and the resulting mixture 
was heated at 90 oC for 3 h. After that, the reaction mixture was cooled to rt, diluted with 
CH2Cl2 (~250 mL) and washed with water (40 mL), sat. aq. NaHCO3 (40 mL), and water 
(40 mL). The organic phase was separated, dried over MgSO4, and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
gradient elution) to afford the title compound as a white form in 97% yield (0.65 g, 1.18 
mmol). Analytical data for 4.7: Rf = 0.60 (ethyl acetate/hexane, 3/7, v/v); []D
23 -2.5 (c 1.0, 
CHCl3);
 1H NMR (300 MHz, CDCl3): δ, -0.28, -0.12 (2 s, 6H, 2 x SiCH3), 0.59 (s, 9H, 
SitBu), 1.19 (t, 3H, J = 7.4 Hz, CH2CH3), 2.69 (m, 2H, CH2CH3), 3.59 (t, 1H, J4,5 = 8.8 Hz, 
H-4), 3.71 (m, 1H, J5,6a = 10.0 Hz, J5,6b = 4.4 Hz, H-5), 3.81 (dd, 1H, J6a,6b = 10.0 Hz, H-
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6a), 4.32 (dd, 1H, J2,3 = 9.6 Hz, H-2), 4.39 (dd, 1H, H-6b), 4.67 (dd, 1H, J3,4 = 8.8 Hz, H-
3), 5.37 (d, 1H, J1,2 = 10.7 Hz, H-1), 5.54 (s, 1H, CHPh), 7.31-7.94 (m, 9H, aromatic) ppm; 
13C NMR (75 MHz, CDCl3): δ, -5.1, -4.0, 15.0, 17.8, 24.2, 25.5 (×3), 56.7, 68.8, 70.6, 70.7, 
81.9, 82.8, 102.1, 123.3, 123.8, 126.5 (×2), 128.3 (×2), 129.2, 131.7, 131.9, 134.3, 134.4, 




glucopyranoside (4.8).  A 1 M solution of BH3 in THF (43 mL, 43 mmol) was added to a 
solution of 4.7 (4.80 g, 8.66 mmol) in CH2Cl2 (45 mL). The resulting solution was cooled 
to 0 oC, TMSOTf (0.78 mL, 4.33 mmol) was added, and the resulting mixture was stirred 
for 5 h while the reaction temperature was allowed to gradually increase to rt. After that, 
the reaction was quenched with Et3N (~2 mL) and MeOH (~5 mL), and the volatiles were 
removed in vacuo. The residue was diluted with CH2Cl2 (~500 mL), washed with sat. aq. 
NaHCO3 (50 mL) and water (2 x 50 mL).  The organic phase was separated, dried over 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate - hexane gradient elution) to afford the title compound as a clear 
syrup in 82% yield (3.80 g, 7.06 mmol). Analytical data for 4.8: Rf = 0.80 (ethyl 
acetate/hexane, 2/3, v/v); []D
23 +27.4 (c 1.0, CHCl3);
 1H NMR (300 MHz, CDCl3): δ, -
0.38, 0.00 (2 s, 6H, 2 x SiCH3), 0.76 (s, 9H, Si
tBu), 1.20 (t, 3H, J = 7.4 Hz, CH2CH3), 2.21 
(m, 1H, OH), 2.68 (m, 2H, CH2CH3), 3.52-3.67 (m, 2H, H-4, 5), 3.73 (m, 1H, H-6a), 3.94 
(m, 1H, H-6b), 4.27 (dd, 1H, J2,3 = 10.6 Hz, H-2), 4.56 (dd, 1H, J3,4 = 8.0 Hz, H-3), 4.80 
(dd, 2H, 2J = 11.7 Hz, CH2Ph), 5.40 (d, 1H, J1,2 = 10.6 Hz, H-1), 7.27-7.95 (m, 9H, 
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aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, -4.6, -4.0, 15.0, 17.7, 24.3, 25.7 (×3), 56.8, 
62.0, 73.3, 74.7, 79.7 (×2), 81.2, 123.3, 123.7, 127.3 (×2), 127.6, 128.4 (×2), 131.7, 132.1, 
134.3 (×2), 138.1, 167.6, 168.8 ppm; ESI TOF LCMS [M+Na]+ calcd for C29H39NNaO6SSi 
580.2165, found 580.2163. 
 
Ethyl 4,6-di-O-benzyl-2-deoxy-2-phthalimido-3-O-tert-butyldimethylsilyl-1-thio-β-D-
glucopyranoside (4.9).  NaH (0.51 g, 0.021 mmol) was added portionwise to a cooled (-
20 oC) solution of 4.8 (3.80 g, 7.06 mmol) in DMF (30 mL) and the resulting mixture was 
stirred under argon at -20 oC until gas evolution has ceased. After that, BnBr (1.06 mL, 
9.18 mmol) was added and the resulting mixture was stirred for 6 h at -15 oC. The reaction 
mixture was cooled to -40 oC and glacial acetic acid (~2 mL) was added dropwise. The 
resulting mixture was allowed to attain rt, then diluted with EtOAc (~500 mL) and washed 
with water (50 mL), sat. aq. NaHCO3 (50 mL) and water (2 x 50 mL).  The organic phase 
was separated, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the 
title compound as a colorless syrup in 77% yield (3.65 g, 5.42 mmol). Analytical data for 
4.9: Rf = 0.80 (ethyl acetate/hexane,3/7, v/v); []D
23 +39.3 (c 1.0, CHCl3);
 1H NMR (300 
MHz, CDCl3): δ, -0.36, 0.00 (2 s, 6H, 2 x SiCH3), 0.79 (s, 9H, Si
tBu), 1.26 (t, 3H, J = 7.4 
Hz, CH2CH3), 2.73 (m, 2H, CH2CH3), 3.63-3.71 (m, 2H, H-4, 5), 3.77-3.86 (br d, 2H, H-
6a, 6b), 4.35 (dd, 1H, J2,3 = 10.0 Hz, H-2), 4.58 (dd, 1H, J3,4 = 7.6 Hz, H-3), 4.64 (d, 2H, 
2J 
= 9.6 Hz, CH2Ph), 4.79 (dd, 2H, 
2J = 12.0 Hz, CH2Ph), 5.38 (d, 1H, J1,2 = 10.5 Hz, H-1), 
7.21-7.99 (m, 14H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, -4.6, -4.1, 15.1, 17.7, 
23.9, 25.8 (×3), 56.8, 69.0, 73.4, 73.5, 74.6, 79.5, 80.0, 80.8, 123.2, 123.7, 127.1 (×2), 
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127.4, 127.6, 127.8 (×2), 128.4 (×4), 131.8, 132.2, 134.3 (×2), 138.3, 138.4, 167.7, 168.8 
ppm; ESI TOF LCMS [M+Na]+ calcd for C36H45NNaO6SSi 670.2635, found 670.2633. 
 
Ethyl 4,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (4.5).  BF3-
Et2O (1.05 mL, 8.29 mmol) was added to a solution of 4.9 (5.07 g, 7.54 mmol) in dry 
CH3CN (90 mL) and the resulting mixture was stirred under argon for 20 min at 0 
oC. After 
that, the reaction was quenched with sat. aq. NaHCO3 (5 mL), and the volatiles were 
removed in vacuo. The residue was diluted with CH2Cl2 (~500 mL) and washed with brine 
(2 x 50 mL). The organic phase was separated, dried over MgSO4, and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate - 
hexane gradient elution) to afford the title compound as a white amorphous solid in 87% 
yield (3.49 g, 6.54 mmol). Analytical data for 4.5: Rf = 0.30 (ethyl acetate/hexane, 3/7, v/v); 
[]D
22 +7.3 (c 1.0, CHCl3);
 1H NMR (300 MHz, CDCl3): δ, 1.20 (t, 3H, J = 7.4 Hz, 
CH2CH3). 2.36 (d, 1H, J = 4.5 Hz, OH), 2.67 (m, 2H, CH2CH3), 3.58-3.69 (m, 2H, H-4, 5), 
3.75-3.85 (m, 2H, H-6a, 6b), 4.24 (dd, 1H, J2,3 = 10.4 Hz, H-2), 4.48 (m, 1H, H-3), 4.63 
(dd, 2H, 2J = 12.1 Hz, CH2Ph), 4.70 (m, 2H, 
2J = 11.5 Hz, CH2Ph), 5.29 (d, 1H, J1,2 = 10.4 
Hz, H-1), 7.15-7.90 (m, 14H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, 15.1, 24.1, 
55.7, 69.0, 72.8, 73.6, 74.8, 79.3 (×2), 81.2, 123.4, 123.8, 127.8, 127.9 (×2), 128.0 (×2), 
128.1, 128.5 (×2), 128.7 (×2), 131.7, 131.8, 134.2 (×2), 138.2 (×2), 168.1, 168.3 ppm; ESI 
TOF LCMS [M+Na]+ calcd for C30H31NNaO6S 556.1770, found 556.1767. 
 
Ethyl 4,6-di-O-benzyl-2-deoxy-3-O-fluorenylmethoxycarbonyl-2-phthalimido-1-thio-
β-D-glucopyranoside (4.12).  FmocCl (3.88 g, 15.04 mmol) was added to a solution of 4.5 
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(2.08 g, 3.90 mmol) in CH2Cl2 (50 mL) and pyridine (1.72 mL) and the resulting mixture 
was stirred under argon for 2 h at rt. After that, the reaction mixture was diluted with 
CH2Cl2 (~500 mL) and washed with 1 M aq. HCl (50 mL) and water (2 x 50 mL). The 
organic phase was separated, dried over MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (ethyl acetate - hexane gradient 
elution) to afford the title compound as a white amorphous solid in 92% yield (2.70 g, 3.58 
mmol). Analytical data for 4.12: Rf = 0.40 (ethyl acetate/hexane,2/3, v/v); []D
23 +55.2 (c 
1.0, CHCl3);
 1H NMR (300 MHz, CDCl3): δ, 1.22 (t, 3H, J = 7.4 Hz, CH2CH3), 2.70 (m, 
2H, CH2CH3), 3.73-3.86 (m, 4H, H-5, 6a, 6b, OCOCH2CH), 3.91-4.16 (m, 3H, H-4, 
OCOCH2CH), 4.47 (dd, 1H, J2,3 = 10.5 Hz, H-2), 4.62 (dd, 2H, 
2J = 12.1 Hz, CH2Ph), 4.64 
(dd, 2H, 2J = 11.2 Hz, CH2Ph), 5.46 (d, 1H, J1,2 = 10.5 Hz, H-1), 5.75 (dd, 1H, J3,4 = 8.9 
Hz, H-3), 7.07-7.88 (m, 26H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, 15.1, 24.2, 
46.5, 54.1, 68.8, 70.3, 73.6, 75.0, 76.6, 78.5, 79.2, 81.0, 120.0 (×2), 123.7, 123.8, 125.1, 
125.3, 127.3 (×2), 127.8 (×4), 127.9 (×4), 128.4 (×2), 128.5 (×2), 131.3, 131.8, 134.1, 
134.4, 137.8, 138.2, 141.1, 141.2, 143.0, 143.3, 154.8, 167.5, 168.0 ppm; ESI TOF LCMS 
[M+Na]+ calcd for C45H41NNaO8S 778.2451, found 778.2451. 
 
Di-O-butyl 4,6-di-O-benzyl-2-deoxy-3-O-fluorenylmethoxycarbonyl-2-phthalimido-
β-D-glucopyranosyl phosphate (4.13).  A mixture containing thioglycoside 4.12 (0.50 g, 
0.66 mmol), dibutyl hydrogen phosphate (0.39 mL, 1.99 mmol), and molecular sieves (3 
Å, 1.0 g) in CH2Cl2 (10 mL) was stirred under argon for 1h. The mixture was cooled to 0 
°C, NIS (0.29 g, 1.32 mmol) and TfOH (10 μL, 0.13 mmol) were added, and the resulting 
mixture was stirred under argon for 20 min at 0 °C. After that, the solids were filtered off 
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and washed successively with CH2Cl2. The combined filtrate (~100 mL) was washed with 
10% aq. Na2S2O3 (15 mL), sat. aq. NaHCO3 (15 mL), and water (2 x 15 mL). The organic 
phase was separated, dried over MgSO4, and concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (acetone - toluene gradient elution) to 
afford the title compound as a white form in 94% yield (0.56 g, 0.62 mmol). Analytical 
data for 4.13: Rf = 0.45 (ethyl acetate/hexane,1/4, v/v); []D
23 +43.0 (c 1.0, CHCl3);
 1H 
NMR (300 MHz, CDCl3): δ, 0.71, 0.85 (2 t, 6H, 2 x O(CH2)3CH3), 1.07 (m, 2H, 
O(CH2)2CH2CH3), 1.22-1.37 (m, 4H, OCH2CH2CH2CH3), 1.48-1.60 (m, 2H, 
OCH2CH2CH2CH3), 3.67-4.17 (m, 11H, 2 x OCH2CH2CH2CH3, H-4, 5, 6a, 6b, 
OCOCH2CH, OCOCH2CH), 4.49 (dd, 1H, J2,3 = 10.6 Hz, H-2), 4.60 (dd, 2H, 
2J = 11.9 Hz, 
CH2Ph), 4.64 (dd, 2H, 
2J =11.2 Hz, CH2Ph), 5.80 (dd, 1H, J3,4  = 8.9 Hz, H-3), 6.02 (d, 1H, 
J1,2 = 8.3, H-1), 6.97-7.86 (m, 22H, aromatic) ppm; 
13C NMR (75 MHz, CDCl3): δ, 13.5, 
13.6, 18.4, 18.6, 31.9 (d, J = 7.0 Hz), 32.0 (d, J = 7.2 Hz), 46.4, 55.3 (d, J = 8.9 Hz). 67.9 
(d, J  6.1 Hz), 68.1 (d, J = 6.0 Hz), 70.3, 73.6, 74.9, 75.2, 76.0, 76.8, 77.3, 93.9 (d, J = 4.6 
Hz), 120.0 (×2), 123.6, 125.0, 125.2, 125.4, 127.2 (×2), 127.7 (×3), 127.8 (×3), 127.9 (×3), 
128.3, 128.4 (×3), 128.5 (×3), 129.1, 134.2, 137.6, 137.9, 141.1, 141.2, 143.0, 143.2, 154.6 
ppm; ESI TOF LCMS [M+Na]+ calcd for C51H54NNaO12P 926.3281, found 926.3285. 
 
4.4.3. Synthesis of oligosaccharides 4.2, 4.10, 4.14, 4.15, 4.11 
Ethyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→3)-4,6-di-O-
benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (4.2).  A mixture of 
benzoxazolyl 2-O-benzoyl-3,4,6-tri-O-benzyl-1-thio-β-D-galactopyranoside29,30 (4.4, 0.20 
g, 0.29 mmol), acceptor 5 (0.12 g, 0.22 mmol), and freshly activated molecular sieves (3Å, 
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600 mg) in CH2Cl2 (7 mL) was stirred under argon for 2 h. The reaction mixture was cooled 
to -30 oC, and freshly conditioned AgOTf (0.15 g, 0.58 mmol) was added. The resulting 
mixture was stirred for 15 min while the temperature was allowed to increase gradually. 
The reaction mixture was then diluted with CH2Cl2, the solids were filtered off, and rinsed 
successively with CH2Cl2. The combined filtrate (~50 mL) was washed with sat. aq. 
NaHCO3 (10 mL) and water (2 x 10 mL) The organic phase was separated, dried over 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (acetone - toluene gradient elution) to afford the title compound as a white 
foam in 99% yield (0.23 g, 0.22 mmol). Analytical data for 4.2: Rf = 0.55 (acetone/toluene, 
1/9 v/v); []D
23 +34.1 (c 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3): δ, 1.09 (t, 3H, J = 7.4 
Hz, CH2CH3). 2.56 (m, 2H, CH2CH3), 3.30-3.51 (m, 4H, H-3ʹ, 5ʹ, 6aʹ, 6bʹ), 3.57-3.72 (m, 
2H, H-4, 5), 3.77 (br d, 2H, J = 2.1 Hz, H-6a, 6b), 3.94 (br d, 1H, J3ʹ,4ʹ = 2.5 Hz, H-4ʹ), 4.26 
(dd, 2H, 2J = 11.6 Hz, CH2Ph), 4.29 (d, 1H, J = 12.0 Hz, CHPh), 4.30 (dd, 1H, J2,3 = 10.3, 
H-2), 4.44 (d, 1H, J1ʹ,2ʹ = 7.9 Hz, H-1ʹ), 4.454.64 (m, 5H, 5 × CHPh), 4.83 (dd, 1H, J3,4 = 
8.0 Hz, H-3), 4.91 (d, 1H, J = 11.3 Hz, CHPh), 5.06 (d, 1H, J1,2 = 10.4 Hz, H-1), 5.09 (d, 
1H, J = 10.5 Hz, CHPh), 5.52 (dd, 1H, J2ʹ,3ʹ = 9.9 Hz, H-2ʹ), 6.92-7.78 (m, 34H, aromatic) 
ppm; 13C NMR (75 MHz, CDCl3): δ, 14.9, 23.7, 54.8, 67.8, 69.2, 71.7, 72.5, 72.8, 73.3, 
73.4, 73.5, 74.8, 75.0, 77.4, 77.8, 79.5, 80.3, 81.0, 100.7, 127.2, 127.5 (×3), 127.6 (×2), 
127.8 (×4), 128.0 (×3), 128.1 (×6), 128.2 (×3), 128.3 (×3), 128.4 (×3), 128.5 (×3), 130.0 
(×2), 130.3, 131.5, 132.8, 134.0, 137.5, 138.0, 138.3, 138.7 (×2), 165.4 ppm; ESI TOF 
LCMS [M+Na]+ calcd for C64H63NNaO12S 1092.3969, found 1092.3981. 
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Di-O-butyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→3)-4,6-di-
O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl phosphate (4.10). A mixture of 
compound 2 (0.236 g, 0.234 mmol), dibutyl hydrogen phosphate (0.14 mL, 0.802 mmol), 
and freshly activated molecular sieves (3 Å, 0.5 g) in CH2Cl2 (5.0 mL) was stirred under 
argon for 1 h at rt. The mixture was cooled to 0 °C, NIS (0.104 g, 0.468 mmol) and TfOH 
(4.15 μL, 0.047 mmol) were added, and the resulting mixture was stirred for 20 min at 0 
oC. After that, the solids were filtered off and rinsed successively with CH2Cl2. The 
combined filtrate (~100 mL) was washed with 10% aq. Na2S2O3 (15 mL) and sat. aq. 
NaHCO3 (15 mL), and water (2 x 15 mL). The organic phase was separated, dried over 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (acetone - toluene gradient elution) to afford the title compound as an oily 
syrup in 94% yield (0.267 g, 0.219 mmol). Analytical data for 4.10: Rf = 0.35 
(acetone/toluene,1/9, v/v); []D
23 +26.2 (c 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3): δ, 
0.67 (t, 3H, J = 7.2 Hz, O(CH2)3CH3), 0.81 (t, 3H, J = 7.3 Hz, O(CH2)3CH3), 0.90-1.06 (m, 
2H, O(CH2)2CH2CH3), 1.11-1.31 (m, 4H, O(CH2)2CH2CH3, OCH2CH2CH2CH3), 1.38-1.53 
(m, 2H, OCH2CH2CH2CH3), 3.31-3.96 (m, 13H, H-3ʹ, 4, 4ʹ, 5, 5ʹ, 6a, 6b, 6aʹ, 6bʹ, 2 x 
OCOCH2(CH)2CH3), 4.20 (d, 1H, 
2J = 11.7 Hz, CHPh), 4.24-4.32 (m, 3H, H-2, 2 x CHPh), 
4.43-4.54 (m, 5H, H-1, 4 x CHPh), 4.59 (d, 1H, 2J = 12.0 Hz, CHPh), 4.91 (m, 2H, H-3, 
CHPh), 5.09 (d, 1H, 2J = 10.5 Hz, CHPh), 5.51 (dd, 1H, J2ʹ,3ʹ = 8.8 Hz, H-2ʹ), 5.69 (dd, 1H, 
J1,2 = 7.4 Hz, H-1) 6.94-7.74 (m, 36H, aromatic) ppm; 
13C NMR (75 MHz, CDCl3): δ, 13.5, 
13.6, 18.3, 18.6, 31.8 (d, J = 7.1 Hz). 32.0 (d, J = 7.2 Hz), 56.1, 56.2, 67.6, 67.8 (d, J = 4.5 
Hz), 68.0 (d, J = 6.4 Hz), 68.6, 71.7, 72.5, 72.8, 73.3, 73.5 (×2), 74.8, 74.9, 75.6, 76.2, 
80.2, 94.1 (d, J = 4.6 Hz), 100.8, 123.5, 127.3, 127.5 (×2), 127.6 (×3), 127.7, 127.8 (×3), 
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128.0 (×7), 128.1 (×4), 128.2 (×4), 128.3 (×2), 128.4 (×2), 128.5 (×2), 130.0, 130.2, 131.5, 
132.7, 134.0, 137.5, 138.0, 138.1, 138.6, 138.7, 165.3 ppm; ESI TOF LCMS [M+Na]+ 




galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (4.14).  A mixture of 
donor 4.13 (0.14 g, 0.15 mmol), acceptor 4.325 (0.12 g, 0.12 mmol) (reference from LNnT 
paper), and freshly activated molecular sieves (3Å, 450 mg) in CH2Cl2 (7.0 mL) was stirred 
under argon for 2 h. The mixture was cooled to -30 oC, TMSOTf (56 μL, 0.31 mmol) was 
added, and the resulting mixture was stirred for 15 min while the temperature was allowed 
to increase gradually. The reaction mixture was then diluted with CH2Cl2, the solids were 
filtered off and rinsed successively with CH2Cl2. The combined filtrate (~50 mL) was 
washed with sat. aq. NaHCO3 (10 mL) and water (2 x 10 mL) The organic phase was 
separated, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (acetone - toluene gradient elution) to afford the title 
compound as a white foam in 86% yield (0.17 g, 0.10 mmol). Analytical data for 4.14: Rf 
= 0.45 (acetone/toluene, 1/4 v/v); []D
23 +11.3 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): 
δ, 2.91 (ddd, 1H, J = 1.8, 3.0, 9.9 Hz, H-5), 3.27 (dd, 1H, J = 9.5 Hz, H-6a), 3.33 (dd, 1H, 
J2,3 = 8.4 Hz, H-2), 3.38-3.42 (m, 2H, H-3, 6b), 3.69-3.75 (m, 3H, H-3ʹ, 5ʹ, OCOCH2CH), 
3.79-3.85 (m, 4H, H-4, 5ʹʹ, 6aʹʹ, 6bʹʹ), 3.87-3.93 (m, 2H, H-4ʹʹ, OCOCH2CH), 4.02 (dd, 1H, 
J = 10.5, 7.2 Hz, OCOCH2CH), 4.11 (br d, 1H, J = 2.4 Hz, H-4ʹ), 4.18-4.24 (m, 2H, H-6aʹ, 
CHPh), 4.27 (d, 1H, J1,2 = 7.7 Hz, H-1), 4.34-4.40 (m, 2H, H-2ʹʹ, 6bʹ), 4.42-4.49 (m, 3H, 
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J1ʹ,2ʹ = 8.1 Hz, H-1ʹ, 2 x CHPh), 4.5-4.69 (m, 7H, 7 x CHPh), 4.80 (d, 1H, 
2J = 12.0 Hz, 
CHPh), 4.81 (d, 1H, 2J = 12.0 Hz, CHPh), 4.92 (d, 1H, 2J = 10.4 Hz, CHPh), 5.12 (d, 1H, 
2J = 11.5 Hz, CHPh), 5.36 (dd, 1H, J2ʹ,3ʹ = 10.1 Hz, H-2ʹ), 5.44 (d, 1H, J1ʹʹ,2ʹʹ = 8.3 Hz, H-
1ʹʹ), 5.66 (dd, 1H, J = 8.9, 10.7 Hz, H-3ʹʹ), 6.81-8.73 (m, 56H, aromatic) ppm; 13C NMR 
(151 MHz, cdcl3): δ, 46.4, 55.2, 63.8, 67.6, 68.9, 70.3, 71.0, 71.9, 72.0, 73.5 (×2), 73.6 
(×2), 74.4, 74.7, 75.0 (×2), 75.2, 75.6, 76.2, 76.6, 80.6, 81.7, 82.6, 99.4, 100.4, 102.6, 
120.0, 125.0, 125.3, 125.5, 126.9, 127.2 (×2), 127.3, 127.6 (×2), 127.7 (×3), 127.8 (×3), 
127.9 (×5), 128.0, 128.1 (×9), 128.3 (×6), 128.4 (×3), 128.5 (×3), 128.6 (×9), 128.7 (×3), 
129.4, 129.8, 132.9, 137.0, 137.6 (×2), 137.9, 138.3, 138.7 (×2), 139.0, 141.1, 141.2, 142.9, 
143.3, 147.8, 150.0, 154.6, 164.5, 164.5 ppm; ESI TOF LCMS [M+Na]+ calcd for 




β-D-glucopyranoside (4.15).  Compound 4.14 (135 mg, 0.0796 mmol) was dissolved in a 
mixture of Et3N in CH2Cl2 (5.0 mL, 3/7, v/v) and the resulting solution was stirred for 2 h 
at rt. After that, the reaction mixture was concentrated in vacuo, and the residue was 
purified by column chromatography on silica gel (acetone - toluene gradient elution) to 
afford the title compound as a white foam in 89% yield (104.8 mg, 0.0711 mmol). 
Analytical data for 4.15: Rf = 0.55 (acetone/toluene, 1/4 v/v); []D
22 -11.6 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 2.45 (d, 1H, J = 4.6 Hz, OH), 2.94 (ddd, 1H, J = 8.9 Hz, 
H-5), 3.29 (dd, 1H, J = 10.3 Hz, H-6a), 3.34 (dd, 1H, J2,3 = 9.0 Hz, H-2), 3.39-3.44 (m, 2H, 
H-3, 6b), 3.61 (dd, 1H, J3”,4” = 9.1 Hz, J4”,5” = 9.1 Hz, H-4ʹʹ), 3.67-3.76 (m, 3H, H-3ʹ, 5ʹʹ, 
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6aʹʹ), 3.78-3.88 (m, 3H, H-4, 5ʹ, 6bʹʹ), 4.11 (br s, 1H, H-4ʹ), 4.13-4.26 (m, 3H, H-2ʹʹ, 6aʹ, 
CHPh), 4.29 (d, 1H, J1.2 = 7.7 Hz, H-1), 4.36 (dd, 1H, J = 6.1, 11.0 Hz, H-6bʹ), 4.44-4.52 
(m, 4H, J1ʹ,2ʹ = 8.0 Hz, H-1ʹ, 3ʹʹ, 2 x CHPh), 4.55-4.70 (m, 6H, 6 x CHPh), 4.74 (d, 1H, 
2J 
= 11.4 Hz, CHPh), 4.82 (d, 2H, 2J = 12.0 Hz, CHPh × 2 ), 4.94 (d, 1H, 2J = 10.4 Hz, CHPh), 
5.14 (d, 1H, 2J = 11.5 Hz, CHPh), 5.22 (d, 1H, J1ʹʹ,2ʹʹ = 8.3 Hz, H-1ʹʹ), 5.34-5.39 (dd, 1H, 
J2ʹ,3ʹ = 9.9 Hz, H-2ʹ), 7.00-8.75 (m, 48H, aromatic) ppm; 
13C NMR (151 MHz, CDCl3): δ, 
56.8, 63.9, 67.5, 69.1, 71.0 (×2), 72.0 (×2), 73.4, 73.6 (×2), 74.3, 74.9 (×3), 75.1, 75.6, 
76.1, 79.2, 80.3, 81.6, 82.6, 99.7, 100.3, 102.5, 125.4, 126.9, 127.2, 127.5, 127.7 (×3), 
127.8 (×3), 127.9, 128.0 (×8), 128.1 (×4), 128.2 (×3), 128.3 (×6), 128.4 (×3), 128.5 (×3), 
128.6 (×6), 128.7 (×3), 129.4, 129.6, 132.9, 133.6, 137.0, 137.5, 137.9, 138.1, 138.2, 138.6, 
138.8, 139.0, 147.7, 149.9, 164.4 (×2) ppm; ESI TOF LCMS [M+H]+ calcd for 





glucopyranoside (4.11).  Convergent method.  A mixture of donor 4.10 (80.0 mg, 0.065 
mmol), acceptor 4.3 (49.8 mg, 0.050 mmol),25 and freshly activated molecular sieves (3Å, 
400 mg) in CH2Cl2 (7.0 mL) was stirred under argon for 2 h. The mixture was cooled to -
60 oC, TMSOTf (24 μL, 0.131 mmol) was added, and the resulting mixture was stirred for 
30 min while the temperature was allowed to increase gradually. The reaction mixture was 
then diluted with CH2Cl2, the solids were filtered off and rinsed successively with CH2Cl2. 
The combined filtrate (~50 mL) was washed with sat. aq. NaHCO3 (10 mL) and water (2 
W. M. Mithila D. Bandara | UMSL 2019 | Page  147 
 
x 10 mL) The organic phase was separated, dried over MgSO4, and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (acetone - toluene 
gradient elution) to afford the title compound as an off-white amorphous solid in 51% yield 
(66.6 mg, 0.033 mmol).  Linear method.  A mixture of benzoxazolyl 2-O-benzoyl-3,4,6-
tri-O-benzyl-1-thio-β-D-galactopyranoside29,30 (4.4, 13.3 mg, 0.0194 mmol), acceptor 4.15 
(22 mg, 0.0149 mmol), and freshly activated molecular sieves (3Å, 100 mg) in CH2Cl2 (2.0 
mL) was stirred under argon for 2 h. The reaction mixture was cooled to -30 oC, freshly 
conditioned AgOTf (10.0 mg, 0.0387 mmol) was added, and the resulting mixture was 
stirred for 15 min while the temperature was allowed to increase gradually. The reaction 
mixture was then diluted with CH2Cl2, the solids were filtered off and was rinsed 
successively with CH2Cl2. The combined filtrate (~30 mL) was washed with sat. aq. 
NaHCO3 (7 mL) and water (2 x 7 mL) The organic phase was separated, dried over MgSO4, 
and concentrated in vacuo. The residue was purified by column chromatography on silica 
gel (acetone - toluene gradient elution) to afford the title compound as a white foam in 89% 
yield (26.7 mg, 0.0132 mmol). Analytical data for 4.11: Rf = 0.45 (acetone/toluene, 1/4, 
v/v); []D
22 +2.5 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 2.85 (ddd, 1H, J = 9.6 
Hz, H-5), 3.19 (dd, 1H, J = 10.2 Hz, H-6a), 3.25-3.37 (m, 6H, H-2, 3, 3ʹʹʹ, 6aʹʹʹ, 6b, 6bʹʹʹ), 
3.43 (m, 1H, H-5ʹʹʹ), 3.58-3.66 (m, 3H, H-3ʹ, 4ʹʹ, 5ʹ), 3.70 (m, 1H, H-5ʹʹ), 3.84-3.75 (m, 3H, 
H-4, 6aʹʹ, 6bʹʹ), 3.88 (br d, 1 H, J = 1.9 Hz, H-4ʹʹʹ), 3.98 (s, 1H, H-4ʹ), 4.14-4.30 (m, 9H, H-
1, 1ʹʹʹ, 2ʹʹ, 6aʹ, 6bʹ, 4 x CHPh), 4.33 (d, 1H, J1ʹ,2ʹ = 8.0 Hz, H-1ʹ), 4.41-4.60 (m, 9H, 9 x 
CHPh), 4.66 (d, 1H, 2J = 11.0 Hz, CHPh), 4.78-4.82 (m, 3H, H-3ʹʹ, 2 x CHPh), 4.89 (d, 2H, 
2J = 11.0 Hz, 2 x CHPh), 4.95 (d, 1H, 2J = 11.7 Hz, CHPh), 5.00 (d, 1H, J1ʹʹ,2ʹʹ = 8.3 Hz, H-
1ʹʹ), 5.06 (d, 1H, 2J = 10.4 Hz, CHPh), 5.17 (dd, 1H, J2ʹ,3ʹ = 9.8 Hz, H-2ʹ), 5.45 (dd, 1H, J 
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2ʹʹ,3ʹʹ = 8.9 Hz, H-2ʹʹʹ), 6.75-8.69 (m, 68H, aromatic) ppm: 
13C NMR (151 MHz, CDCl3): δ, 
29.8, 31.1, 56.0, 63.8, 67.4, 67.8, 69.5, 71.0, 71.8, 72.0 (× 2), 72.6, 73.2, 73.5 (× 2), 73.6, 
74.4, 74.8, 74.9, 75.0, 75.1, 75.2, 75.6, 75.8 (× 2), 76.1, 79.4, 80.2, 81.6, 82.6, 99.3, 100.4, 
100.5, 102.6, 122.7, 123.7, 125.4, 126.8, 127.3, 127.4 (×2), 127.5 (×4), 127.6 (×2), 127.7, 
127.8 (×7), 127.9, 128.0 (×3), 128.1 (×7), 128.2 (×8), 128.3 (×4), 128.4 (×7), 128.5 (×6), 
128.6 (×2), 128.8 (×2), 129.6, 129.8, 130.0, 130.2, 130.9, 131.3, 132.7, 133.0, 133.4, 134.6, 
136.9, 137.5, 137.6, 138.0, 138.1, 138.2, 138.5, 138.7, 138.8, 139.0, 147.8, 150.0, 164.3, 
164.4, 165.5, 166.3, 168.4 ppm; ESI TOF LCMS [M+H]+calcd for C122H117N2O25 
2010.7979, found 2010.7963. 
 
4.4.4. Deprotection of tetrasaccharide 4.11  
Benzyl O-(3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→3)-O-(3,6-di-O-benzyl-2-
acetamido-2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(4-O-benzyl-β-D-
galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (4.16).  Compound 
4.11 (59.0 mg, 0.029 mmol) was dissolved in MeOH (3.0 mL), NH2NH2-H2O (130 μL, 
2.64 mmol) was added, and the resulting mixture was heated at 90 oC for 24 h. After that, 
the volatiles were removed under reduced pressure, and the residue was dried in vacuo for 
3 h. The crude residue was dissolved in a mixture of Ac2O and MeOH (2.0 mL, 1/1, v/v) 
and the resulting mixture was stirred for 12 h at rt. The volatiles were removed under 
reduced pressure, the residue was diluted with CH2Cl2 (50 mL), and washed with sat. aq. 
NaHCO3 (10 mL) and 1 M HCl (10 mL). The organic phase was separated, dried over 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (acetone - toluene gradient elution) to afford the title compound as an off-
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white amorphous solid in 92% yield (42.9 mg, 0.026 mmol). Analytical data for 4.16: Rf = 
0.50 (acetone/toluene, 3/7 v/v); []D
23 +70.8 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): 
δ, 1.81 (s, 3H, CH3CO), 2.95-4.03 (m, 24H, H-2, 2ʹ, 2ʹʹ, 2ʹʹʹ, 3, 3ʹ, 3ʹʹ, 3ʹʹʹ, 4, 4ʹ, 4ʹʹ, 4ʹʹʹ, 5, 
5ʹ, 5ʹʹ, 5ʹʹʹ, 6a, 6aʹ, 6aʹʹ, 6aʹʹʹ, 6b, 6bʹ, 6bʹʹ,6bʹʹʹ), 4.23 (d, 1H, 2J = 11.8 Hz, CHPh), 4.30-4.58 
(m, 10H, H-1, 1ʹ, 1ʹʹʹ, 7 x CHPh), 4.60-4.96 (m, 11H, 11 x CHPh), 5.01-5.04 (m, 2H, H-1ʹʹ, 
CHPh), 6.48 (d, 1H, J = 6.3 Hz, NHCOCH3), 7.12-7.37 (m, 50H, aromatic) ppm;  
13C NMR 
(151 MHz, CDCl3): δ, 23.7, 58.4, 61.9, 68.2, 68.8, 69.4, 71.3, 71.6, 71.9, 72.1, 72.8, 73.5, 
73.7 (×3), 73.8, 74.3, 74.7, 74.8, 74.9, 75.1 (×2), 75.2, 75.4, 76.6, 77.1, 81.9, 82.1, 83.0, 
83.1, 83.7, 101.8, 102.9, 103.1, 104.5, 127.4, 127.5, 127.6 (×3), 127.7 (×2), 127.8 (×3), 
127.9 (×4), 128.0 (×7), 128.2 (×8), 128.3 (×6), 128.4 (×4), 128.5 (×6), 128.7 (×3), 128.8 
(×2), 137.6, 138.0 (×2), 138.1, 138.2, 138.4, 138.6, 138.7, 138.9, 139.0, 172.3 ppm; ESI 
TOF LCMS [M+Na]+calcd for C96H105NNaO21 1631.7110, found 1631.7121. 
 
O-(β-D-Galactopyranosyl)-(1→3)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-
(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose (4.1, LNT).  10% Pd on 
carbon (125 mg) was added to a solution of tetrasaccharide 16 (40 mg, 0.025 mml) in 80% 
aq. EtOH (5.0 mL), and the resulting mixture was stirred under hydrogen atmosphere for 
24 h at rt. After that, the solids were filtered off and rinsed successively with methanol and 
water. The combined filtrate (~40 mL) was concentrated in vacuo. The residue was purified 
by size exclusion column chromatography on Sephadex G-25 using water as the eluent to 
afford the title compound as a white amorphous solid in 81% yield (14.3 mg, 0.020 mmol). 
Analytical data for 4.1: Rf = 0.30 (chloroform/methanol/water, 2/1/0.4, v/v/v); 
1H NMR 
(600 MHz, D2O): δ, 2.01 (s, 3H, CH3CO), 3.24-3.51 (m, 2H), 3.49-3.96 (m, 33H), 4.14 (d, 
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1H, J = 3.3 Hz), 4.43 (d, 2H, J = 7.8 Hz), 4.65 (d, 1H, J = 8.0 Hz), 4.72 (dd, 1H, J = 2.5, 
8.4 Hz), 5.21 (d, 1H, J = 3.8 Hz) ppm;  13C NMR (151 MHz, D2O): δ, 22.6, 55.0, 60.3, 
60.4, 60.8, 61.3, 61.4, 68.7, 68.8, 68.9, 70.4, 70.5, 71.0, 71.5, 71.8, 72.8, 74.1, 74.7, 75.1, 
75.2, 75.5, 75.6, 78.6, 78.7, 82.3, 82.4, 92.2, 96.0, 96.1, 102.9, 103.2, 103.3, 103.8, 175.3 
ppm; ESI TOF LCMS [M+Na]+calcd for C26H45NNaO21 730.2382, found 730.2361. 
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5.1. Introduction 
Thanks to advances in glycosciences in recent years, the importance of human milk 
oligosaccharides (HMO) as the essential source of antimicrobials1,2 and prebiotics3 has 
come to the fore. Biosynthesis of HMO follows a unique structural blue print. All glycan 
chains contain lactose (Galβ1→4Glc) at their reducing end, which can be elongated by the 
addition of a β1-3- or β1-6-linked lacto-N-biose (Galβ1→3GlcNAc, type 1 chain) or 
lactosamine (Galβ1→4GlcNAc, type 2 chain). Elongation of lactose via a β1-6 linkage 
introduces chain branching, and these structures are designated as iso-HMO, whereas linear 
structures are commonly designated as para-HMO. Lactose or the elongated 
oligosaccharide chain can also be fucosylated or sialylated.4 Structures of many HMO are 
known,5,6 many HMO sequences have already been prepared enzymatically and/or 
chemically,7-9 but the exact roles of a majority of individual HMO remain unknown.10,11  
With expectation that the development of reliable synthetic methods for obtaining 
individual HMO will boost our understanding the roles of these important biomolecules, 
we previously reported the total syntheses of lacto-N-neotetraose (LNnT, Chapter 3)12 and 
lacto-N-tetraose (LNT, Chapter 4).13 In further synthetic endeavors into the field of HMO, 
we became interested in studying more challenging, branched structures, such as lacto-N-
hexaose (LNH),14,15 whose exact biological roles are yet unknown. LNH 5.1 represents one 
of the most common core sequence and it is structurally derived from LNT 5.2 (Figure 
5.1).  
LNH comprises the reducing end lactose disaccharide (AB, Figure 5.1), common 
for all HMO, which is branched at the galactose residue (B). More specifically, it is 
elongated with lacto-N-biose disaccharide residue (CD) at C-3 of Gal, and also with N-
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acetyllactosamine residue (EF) at C-6 of Gal. While many chemical16-18 and enzymatic 
syntheses19 of LNT are known, to the best of our knowledge, neither chemical nor 
enzymatic synthesis of LNH have yet been reported. We came across an article by Schmidt 
and co-worker describing the synthesis of a “branched hexasaccharide related to lacto-N-
hexaose.”20 However, the actual molecule obtained therein is lacto-N-neohexaose, a 
different HMO core sequence. Human milk isolates of LNH are available on the market, 
but this common HMO is not yet available in large quantities and at accessible cost for 
mainstream research and application. Reported herein as an efficient and versatile method 
for the scalable synthesis of LNH 5.1 and, by extension, LNT 5.2. 
 
Figure 5.1. Chemical structures of LNH 5.1 and LNT 5.2. 
 
5.2. Results and discussion 
In the previous Chapter, we described the syntheses of LNT 5.2 via convergent and 
linear approaches.13 The protecting groups in the tetrasaccharide intermediate 5.313 were 
strategically placed to allow for the synthesis of other derivatives. Thus, we assumed that 
selective removal of 6ʹ-O-picoloyl (Pico) substituent in 5.3 would provide a 
straightforward access to acceptor 5.4 suitable for subsequent branching. To pursue this 
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route, the deprotection of 6ʹ-O-Pico in 5.3 was affected in the presence of Cu(OAc)2-H2O 
in MeOH/CH2Cl2 and tetrasaccharide 5.4 was obtained in 96% yield. To our 
disappointment, all attempts to glycosylate acceptor 5.4 with lactosamine thioglycoside 
donor 5.512 were largely unsuccessful and practically no desired hexasaccharide was 
formed. Instead, a large number of unidentified side products derived from the donor have 
been isolated, and the acceptor remained practically intact. 
 
Scheme 5.1.  First attempted assembly of LNH 5.1. 
 
Recalling our previous endeavors with the synthesis of HMO wherein the nature of 
glycosyl donor and acceptor was found to be of paramount significance, we attempted to 
employ the corresponding lactosamine phosphate and trichloroacetimidate donors. Despite 
extended study, these attempts to access the backbone of LNH were also unsuccessful. In 
further attempts to enhance the efficiency of this coupling we applied less bulky 
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glucosamine thioglycoside donor 5.6 and its phosphate and trichloroacetimidate analogues. 
Although the formation of minor amounts of the desired pentasaccharide were observed by 
mass spectroscopy, these glycosylations were deemed unsuccessful. Having explored all 
possibilities available to us, we came to a conclusion that the bulky benzyl group at the 4′-
OH position of acceptor 5.4 is hindering the glycosylation at the 6′-OH position. 
In order to decrease the steric hindrance, we changed our strategy and employed 
building block 5.7 protected with 4,6-O-benzyliene acetal instead.21 We envisaged that if 
the benzylidene acetal is removed at the tetrasaccharide stage, the resulting 4,6-diol will 
offer a far more accessible glycosyl acceptor site for glycosylation with donor 5.5.  
 
Scheme 5.2.  Convergent synthesis of acceptor 5.14. 
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With this strategic adjustment, we coupled donor 5.7 with 4-OH acceptor 5.822 in 
the presence of N-iodosuccinimide (NIS) and TfOH. The resulting disaccharide was 
subjected to deprotection of the Fmoc group with triethylamine in one pot affording the 
desired disaccharide acceptor 5.9 in 87% yield over two steps. We then attempted to 
glycosylate acceptor 5.9 with thioglycoside donor 5.10. This reaction was sluggish and 
inefficient, and despite all attempts to push the reaction to completion, significant amounts 
of acceptor remained. After a quick screening of other leaving groups, we discovered that 
trichloroacetimidate donor 5.12 offers an effective building block to glycosylation acceptor 
5.9. Glycosyl donor 5.12 was prepared from thioglycoside precursor 5.10 that was first 
converted into the corresponding hemiacetal 5.11 via anomeric bromination using Br2 in 
CH2Cl2 followed by the hydrolysis of the bromide using Ag2O in wet acetone in 81% over 
two steps. Next, the installation of the trichloroacetimidate group was performed using 
trichloroacetonitirle (CCl3CN) in the presence of 1,8-diazabicylco[5.4.0]undec-7-ene 
(DBU) to afford the lacto-N-biose trichloroacetimidate 5.12 in 93% yield. Glycosylation 
of acceptor 5.9 with donor 5.12 was conducted in the presence of catalytic TMSOTf and 
the desired tetrasaccharide 5.13 was obtained in a good yield of 83% with complete β-
stereoselectivity. It is noteworthy that the corresponding glycosyl phosphate donor gave a 
comparable result in this application. 
Subsequent deprotection of the 4′,6′-O-benzylidene acetal in intermediate 5.13 was 
somewhat low-yielding in the presence of TFA in wet DCM, traditional conditions for 
benzylidene cleavage. Inspired by work by Williams and Sit, wherein isopropylidene ketal 
was removed using p-toluenesulfonic acid (TsOH) and ethanedithiol in chloroform,23 we 
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conducted this reaction in the presence of TsOH and EtSH in MeOH/CH2Cl2. As a result, 
tetrasaccharide diol 5.14 was obtained in 96% yield.  
Next, we attempted glycosylation of tetrasaccharide diol 5.14 with lactosamine 
thioglycoside donor 5.5. Even this coupling with a more accessible glycosyl acceptor was 
not as straightforward as we had initially hoped for. Standard reaction conditions 
employing NIS/TfOH as promoters produced the desired hexasaccharide 5.14 in a modest 
yield of 51%. Although this result was significantly better than our previous attempt of 
glycosylation of acceptor 5.4, we wanted to make an effort to further improve the outcome 
of this challenging coupling. With this intention, we identified the major side reactions 
hampering the yield of the product: fairly rapid hydrolysis of lactosamine donor 5.5 and 
the formation of the 1-4-linked hexasaccharide 5.18 alongside the anticipated 1-6-linked 
counterpart. To suppress these side reactions, we employed milder promoters 
dimethyl(thiomethyl)sulfonium triflate (DMTST)24,25 and NIS/AgOTf.26 The former 
promoter provided a comparable result that that achieved with NIS/TfOH. With the latter 
promoter, known for providing a slower release of the iodonium ion, minimal side products 
resulting from hydrolysis of donor 5.5 were observed. After careful refinement of the 
reaction conditions, we achieved the desired protected LNH precursor 5.15 in a 
commendable yield of 80%. This result was obtained by conducting the reaction at -40 oC 
for 30 min, and then allowing the reaction temperature to gradually increase over the course 
of the additional 30 min period.  
With the protected intermediate 5.15 in hand, we then endeavored a series of 
deprotection steps to obtain the target LNH hexasaccharide. Deprotection of the 
phthalimido and NH2NH2-H2O in MeOH to afford intermediate 5.16 in 74% yield. Column 
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purification was found necessary before the subsequent step: N-acetylation of 5.16 with 
acetic anhydride in MeOH. Finally, the benzyl groups were removed by hydrogenation in 
the presence of 10% palladium on charcoal in wet ethanol to obtain target LNH 5.1 in 80% 
over two steps.  
 
Scheme 5.3.  Convergent synthesis of LNH 5.1 and LNT 5.2 
 
We also performed deprotection of the key tetrasaccharide intermediate 5.14 to 
obtain LNT 5.2. This was achieved via deprotection of the phthalimido and ester groups in 
the presence of NH2NH2-H2O in refluxing MeOH followed by N-acetylation with acetic 
anhydride in MeOH to furnish partially protected tetrasaccharide intermediate 5,17 in 84% 
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yield. Subsequently, benzyl ethers were removed by hydrogenation in the presence of 10% 
Pd/C in wet ethanol to afford target LNT 5.2 in 87% yield. 
 
5.3. Conclusions  
The first total synthesis of lacto-N-hexaose has been completed using a convergent 
2+2+2 strategy. This approach employed preassembled lactose, lactosamine, and lacto-N-
biose building blocks. Along the way, we have also obtained lacto-N-tetraose core 
sequence. It has been acknowledged that including HMO to infant formulas could be 
beneficial for infants’ health,27-30 but HMO are challenging to produce and purify, and exact 
roles of individual HMO remain unknown.10,11,31 Only two simple HMO have been 
approved for infant formulas, and three more entered clinical trials.32  With expectation 
that new methods for reliable synthesis of individual HMO will boost practical applications 




5.4.1. General methods 
Reactions were performed using commercial reagents and the ACS grade solvents 
were purified and dried according to standard procedures.  Column chromatography was 
performed on silica gel 60 (70-230 mesh) and Sephadex G-25 size exclusion resin, 
reactions were monitored by TLC on Kieselgel 60 F254. The compounds were detected by 
examination under UV light and by charring with 10% sulfuric acid in methanol. Solvents 
were removed under reduced pressure at <40 oC. CH2Cl2 was distilled from CaH2 directly 
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prior to application. Molecular sieves (3Å), used for reactions, were crushed and activated 
in vacuo at 390 °C during 8 h in the first instance and then for 2-3 h at 390 °C directly prior 
to application. AgOTf was co-evaporated with toluene (3 x 10 mL) and dried in vacuo for 
2-3 h directly prior to application. Optical rotations were measured using a Jasco 
polarimeter. 1H NMR spectra were recorded at 300 MHz or 600 MHz, and 13C NMR 
spectra were recorded at 75 MHz or 151 MHz. The 1H chemical shifts are referenced to the 
signal of the residual TMS (δH = 0.00 ppm) for solutions in CDCl3 or the signal of the 
residual D2O (δH = 4.79 ppm) for solutions in D2O. The 
13C chemical shifts are referenced 
to the central signal of CDCl3 (δC = 77.16 ppm) for solutions in CDCl3 or the central signal 
of CD3COCD3 δC = 29.84 ppm) for solutions in D2O. Accurate mass spectrometry 
determinations were performed using an Agilent 6230 ESI TOF LCMS mass spectrometer. 
 
5.4.2. Synthesis of oligosaccharides 5.4, 5.9, 5.11, 5.12, 5.13, 5.14, 5.15, 5.18. 
Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→3)-O-(4,6-di-O-
benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-
benzyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (5.4).  
Cu(OAc)2-H2O (15.3 mg, 0.084 mmol) was added to a solution of benzyl O-(2-O-benzoyl-
3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→3)-O-(4,6-di-O-benzyl-2-deoxy-2-
phthlimido-β-D-glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-
galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside13 (5.3, 113.0 mg, 0.056 
mmol) in MeOH/CH2Cl2 (8.0 mL, 1/3, v/v) and the resulting mixture was stirred for 20 
min at rt. Next, the reaction mixture was diluted with CH2Cl2 (~100 mL) was washed with 
H2O (15 mL), sat. aq. NaHCO3 (15 mL) and water (2 x 15 mL). The organic phase was 
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separated, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (acetone - toluene gradient elution) to afford the title 
compound as an off-white amorphous solid in 96% yield (102.3 mg, 0.053 mmol). 
Analytical data for 5.4: Rf = 0.60 (ethyl acetate/hexane, 1/1, v/v); []D
21 +5.8 (c 1.0, 
CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 2.84 (ddd, 1H, J = 8.9 Hz, H-5), 3.10-3,45 (m, 
11H, H-2, 3, 3ʹʹʹ, 5ʹʹ, 5ʹʹʹ, 6a, 6aʹʹ, 6aʹʹʹ, 6b, 6bʹʹ, 6bʹʹʹ), 3.54-3.60 (m, 2H, H-3ʹ, 4ʹʹ), 3.69-
3.77 (m, 3H, 4, 5ʹʹ, 6aʹʹ), 3.80 (br d, 1H, J3ʹ,4ʹ = 2.2 Hz, H-4ʹ), 3.87-3.89 (m, 2H, H-4ʹʹʹ, 6bʹ), 
4.13-4.18 (m, 2H, H-1ʹ, 2ʹʹ), 4.20-4.30 (m, 6H, H-1, 1ʹʹʹ, 2 x CH2Ph), 4.42-4.59 (m, 10H, 5 
x CH2Ph), 4.67 (d, 1H, 
2J = 11.1 Hz, CHPh), 4.78-4.91 (m, 6H, H-3ʹʹ, 5 x CHPh), 4.98 (d, 
1H, J1”,2” = 8.4 Hz, H-1ʹʹ), 5.08 (d, 1H, 
2J = 10.5 Hz, CHPh), 5.12 (dd, 1H, J1ʹ,2ʹ = 8.1, J2ʹ,3ʹ 
= 10.0 Hz, H-2ʹ), 5.46 (dd, 1H, J1ʹʹʹ,2ʹʹʹ = 8.7, J2ʹʹʹ,3ʹʹʹ = 9.4 Hz, H-2ʹʹʹ), 6.73-7.66 (m, 64H, 
aromatic) ppm; 13C NMR (151 MHz, CDCl3): δ, 56.0, 62.0, 67.3, 67.8, 69.7, 71.0, 71.7, 
72.0, 72.5, 72.7, 73.2, 73.5 (×2), 73.6 (×2), 74.3, 74.6, 74.8, 74.9, 75.0, 75.2, 75.4, 75.8, 
75.9, 76.0, 77.6, 79.8, 80.2, 81.2, 82.7, 99.3, 100.5 (×2), 102.6, 114.0, 122.7 (×2), 127.5 
(×3), 127.6 (×4), 127.7 (×2), 127.8 (×5), 127.9 (×4), 128.0 (×2), 128.1 (×6), 128.2 (×9), 
128.3 (×9), 128.4 (×2), 128.5 (×4), 128.6 (×5), 129.0 (×2), 129.6, 129.8, 130.0, 130.1, 
130.8, 131.3, 132.7, 133.0, 133.4, 133.6, 137.5, 137.6, 138.0, 138.2, 138.5, 138.6, 138.7, 
138.8, 164.3, 165.5, 166.3, 168.4 ppm; ESI TOF LCMS [M+Na]+ calcd for 
C116H113NNaO24 1927.7584, found 1927.7613. 
 
Benzyl O-(2-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-
benzyl-β-D-glucopyranoside (5.9).  A mixture of ethyl 2-O-benzoyl-4,6-O-benzylidene-
3-O-fluorenylmethyloxycarbonyl-1-thio-β-D-galactopyranoside21 (5.7, 0.30 g, 0.45 
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mmol), benzyl 2,3,6-tri-O-benzyl-β-D-gulcopyranoside33 (5.8, 0.19 g, 0.36 mmol), and 
freshly activated molecular sieves (3 Å, 1.0 g) in CH2Cl2 (10 mL) was stirred under argon 
for 2 h at rt. The reaction mixture was cooled to 0 oC, NIS (0.21 g, 0.94 mmol) and TfOH 
(18 µL, 0.09 mmol) were added, and the resulting mixture was stirred for 30 min. After 
that, the reaction mixture was warmed to rt, Et3N (~ 4.5 mL) was added, and the resulting 
mixture was stirred for 1 h at rt to achieve complete deprotection of the Fmoc group. Next, 
the solids were filtered-off and rinsed successively with CH2Cl2. The combined filtrate 
(~100 mL) was washed with sat. aq. NaHCO3 (15 mL), 10% aq. Na2S2O3 (15 mL), and 
water (2 x 15 mL). The organic phase was separated, dried over MgSO4, and concentrated 
in vacuo. The residue was purified by column chromatography on silica gel (acetone - 
toluene gradient elution) to afford the title compound as a white foam in 87% yield (0.28 
g, 0.31 mmol). Analytical data for 5.9: Rf = 0.35 (acetone/toluene, 1/4, v/v); []D
23 -15.3 (c 
1.0, CHCl3); 
1H NMR (300 MHz, CDCl3); δ, 2.51 (d, 1H, J = 11.4 Hz, OH), 3.11 (br s, 1H, 
H-5ʹ), 3.28 (ddd, 1H, H-5), 3.49 (dd, 1H, J2,3 = 9.1 Hz, H-2), 3.59-3.67 (m, 3H, H-3, 3ʹ, 
6a), 3.71 (dd, 1H, J5,6b = 4.2, J6a,6b = 11.0, Hz, H-6b), 3.87 (dd, 1H, J5ʹ,6aʹ = 1.5, J6aʹ,6bʹ = 
12.5 Hz, H-6aʹ), 3.96 (dd, 1H, J3,4 = J4,5 = 9.0 Hz, H-4), 4.11 (br d, 1H, J3ʹ,4ʹ = 3.6 Hz, H-
4ʹ), 4.21 (d, 1H, J6aʹ,6bʹ = 12.5 Hz, H-6bʹ), 4.45 (dd, 2H, 
 2J = 12.2 Hz, CH2Ph), 4.43 (d, 1H, 
J1,2 = 7.8 Hz, H-1), 4.45 (dd, 2H, 
2J = 12.2 Hz, CH2Ph), 4.74 (dd, 2H, 
2J = 12.0 Hz, CH2Ph), 
4.76 (d, J1ʹ,2ʹ = 8.1 Hz, H-1ʹ), 4.81 (dd, 2H, 
2J = 10.9 Hz, CH2Ph), 4.97 (dd, 2H, 
2J = 10.8 
Hz, CH2Ph), 5.32 (dd, 1H, J2ʹ,3ʹ = 9.9 Hz, H-2ʹ), 5.51 (s, 1H, CHPh), 7.16-8.05 (m, 30H, 
aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, 66.7, 68.4, 68.8, 71.2, 72.0, 72.2, 72.4, 
73.4, 73.6, 74.6, 75.0, 75.6, 75.8, 77.8, 100.8, 101.6, 102.5, 126.6 (×2), 127.4, 127.6, 127.8 
(×2), 127.9 (×2), 128.0 (×2), 128.1 (×2), 128.2 (×2), 128.3 (×4), 128.4 (×2), 128.5 (×4), 
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128.6 (×2), 129.3, 129.8, 129.9 (×2), 133.4, 137.5, 137.6, 138.4, 138.6, 139.1, 166.0 ppm; 
ESI TOF LCMS [M+Na]+ calcd for C54H54NaO12 917.3513, found 917.3521. 
 
O-(2-O-Benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→3)-4,6-di-O-benzyl-2-
deoxy-2-phthalimido-α/β-D-glucopyranose (5.11).  A freshly prepared solution of Br2 in 
DCM (6.5 mL, 1/165, v/v) was added to a pre-chilled solution of ethyl O-(2-O-benzoyl-
3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-
phthalimido-1-thio-β-D-glucopyranoside13 (5.10, 0.73 g, 0.68 mmol) in CH2Cl2 (9.0 mL) 
and the resulting mixture was stirred for 15 min at 0 oC. After that, the volatiles were 
evaporated under reduced pressure. The residue was co-evaporated with CH2Cl2 (3 × 10 
mL) and dried in vacuo for 2 h. The crude residue was dissolved in acetone (20 mL), water 
(1.0 mL) and Ag2CO3 (0.09 g, 0.34 mmol) were added, and the resulting mixture was stirred 
in the absence of light for 16 h at rt. After that, the solids were filtered-off and rinsed 
successively with CH2Cl2. The combined filtrate was concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (acetone - toluene gradient elution) 
to afford the title compound as a white foam in 81% yield (0.56 g, 0.55 mmol). Analytical 
data for β-5.11: Rf = 0.35 (acetone/toluene, 1/4, v/v); 
1H NMR (600 MHz, CDCl3): δ, 2.86 
(d, 1H, J = 8.8 Hz, OH), 3.30 (m, 1H, H-5ʹ), 3.38-3.45 (m, 3H, H-3ʹ, 6aʹ, 6bʹ), 3.60-3.65 
(m, 2H, H-4, 5) 3.72-3.74 (m, 2H, H-6a, 6b), 3.94 (br d, 1H, H-4ʹ), 4.06 (dd, 1H, J = 8.7, 
10.7 Hz, H-2), 4.19 (d, 1H, 2J = 11.6 Hz, CHPh), 4.26-4.33 (m, 2H, CH2Ph), 4.36-4.61 (m, 
7H, H-1ʹ, 3 × CH2Ph), 4.85 (dd, 1H, H-3), 4.90 (d, 1H, 
2J = 11.4 Hz, CHPh), 5.07 (m, 1H, 
H-1), 5.47-5.52 (dd, 1H, H-2ʹ), 6.94-7.70 (m, 34H, aromatic) ppm; 13C NMR (151 MHz, 
CDCl3): δ, 57.8, 67.8, 68.9, 71.7, 72.6, 73.3, 73.6, 73.7, 74.8 (×2), 75.0, 75.2, 76.4, 77.2, 
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80.2, 93.0, 100.7, 127.3, 127.5 (×2), 127.6 (×2), 127.8, 127.9, 128.0 (×3), 128.1 (×11), 
128.3 (×5), 128.5 (×3), 128.6 (×3), 130.0, 130.2, 131.5, 132.8, 134.1, 137.6, 138.0, 138.1, 




deoxy-2-phthalimido-β-D-glucopyranosyl trichloroacetimidate (5.12).  CCl3CN (1.01 
mL, 10.14 mmol) and DBU (7.15 μL, 0.05 mmol) were added to a solution of compound 
11 (0.52 g, 0.51 mmol) in CH2Cl2 (15 mL) and the resulting mixture was stirred under argon 
for 1 h at rt. After that, the reaction mixture was concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (acetone - toluene gradient elution) to 
afford the title compound as a white foam in 93% yield (0.47 g, 0.40 mmol). Analytical 
data for 5.12: Rf = 0.60 (acetone/toluene, 1/4, v/v); []D
24 +52.1 (c 1.0, CHCl3); 
1H NMR 
(300 MHz, CDCl3): δ, 3.27-3.50 (m, 4H, H-3ʹ, 5ʹ, 6aʹ, 6bʹ), 3.79 (m, 4H, H-4, 5, 6a, 6b), 
3.94 (dd, 1H, J = 2.6 Hz, H-4ʹ), 4.25 (dd, 2H, 2J = 11.5 Hz, CH2Ph), 4.30 (d, 1H, 
2J = 12.0 
Hz, CHPh), 4.43-4.53 (m, 5H, H-1ʹ, 2, 3 × CHPh), 4.58 (dd, 2H, 2J = 12.2 Hz, CH2Ph), 
4.88-4.97 (m, 2H, H-3, CHPh), 5.10 (d, 1H, 2J = 10.7 Hz, CHPh), 5.53 (dd, 1H, J1ʹ,2ʹ = 7.9, 
J2ʹ,3ʹ = 10.0 Hz, H-2ʹ), 6.22 (d, 1H, J1,2 = 8.9 Hz, H-1), 6.83-7.87 (m, 34H, aromatic), 8.48 
(s, 1H, NH) ppm; 13C NMR (75 MHz, CDCl3): δ, 54.7, 67.8, 68.4, 71.7, 72.5, 72.8, 73.3, 
73.4, 73.5, 74.8, 74.9, 76.1, 76.6, 76.8, 80.1, 90.4, 94.0, 100.8, 123.5, 127.3, 127.5 (×3), 
127.6 (×2), 127.7, 127.9, 128.0 (×4), 128.1 (×6), 128.2 (×3), 128.3 (×3), 128.4 (×3), 128.5 
(×3), 129.1, 130.0, 130.2, 131.3, 132.8, 134.1, 137.5, 138.0, 138.1, 138.6 (×2), 160.8, 
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(5.13).  A mixture of donor 5.12 (0.23 g, 0.19 mmol), acceptor 5.9 (0.13 g, 0.15 mmol), 
and freshly activated molecular sieves (3 Å, 600 mg) in CH2Cl2 (7.0 mL) was stirred under 
argon for 2 h at rt. The reaction mixture was cooled to -30 oC, TMSOTf (8.20 μL, 0.04 
mmol) was added, and the resulting mixture was stirred for 10 min while the reaction 
temperature was allowed to increase gradually. After that, the solids were filtered-off and 
rinsed successively with CH2Cl2. The combined filtrate (~50 mL) was washed with sat. aq. 
NaHCO3 (10 mL) and water (2 x 10 mL). The organic phase was separated, dried over 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (acetone - toluene gradient elution) to afford the title compound as a white 
foam in 83% yield (0.27 g, 0.12 mmol). Analytical data for 5.13: Rf = 0.55 (acetone/toluene, 
¼, v/v); []D
22 -4.0 (c 1.0, CHCl3):
 1H NMR (600 MHz, CDCl3): δ, 2.89 (m, 1H, J = 8.8 
Hz, H-5), 3.04 (br s, 1H, H-5ʹ), 3.21-3.58 (m, 11H, H-2, 3, 3ʹ, 3ʹʹʹ, 5ʹʹʹ, 6a, 6aʹʹ, 6aʹʹʹ, 6b, 
6bʹʹ, 6bʹʹʹ), 3.70-3.84 (m, 3H, H-4, 4ʹʹ, 5ʹʹ), 3.89-3.90 (m, 2H, H-4ʹ, 4ʹʹʹ), 4.11-4.32 (m, 8H, 
H-1ʹʹʹ, 2ʹʹ, 3ʹʹ, 6aʹ, 6bʹ, 3 x CHPh), 4.34 (d, 1H, 2J = 11.6 Hz, CHPh), 4.40 (d, 1H, 2J = 8.1 
Hz, CHPh), 4.43-4.49 (m, 2H, H-1ʹ, CHPh), 4.51 (d, 1H, 2J = 12.0 Hz, CHPh), 4.55-4.70 
(m, 5H, 5 x CHPh), 4.77-4.88 (m, 4H, H-1, 3 x CHPh), 4.91 (d, 1H, 2J = 11.4 Hz, CHPh), 
5.02 (d, 1H, 2J = 10.7 Hz, CHPh), 5.06-5.09 (m, 2H, H-1ʹʹ, CHPh), 5.17 (dd, 1H, J1ʹ,2ʹ = 
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8.2, J2ʹ,3ʹ = 10.0 Hz, H-2ʹ), 5.44-5.51 (m, 2H, H-2ʹʹʹ, CHPh), 6.93-7.72 (64H, m, aromatic) 
ppm; 13C NMR (151 MHz, CDCl3): δ, 55.5, 66.7, 67.7 (×2), 68.5, 70.0, 71.0, 71.1, 71.7, 
72.5, 73.2, 73.4, 73.5 (×2), 73.6, 74.3, 74.8 (×2), 74.9, 75.2, 75.7, 75.8, 75.9, 76.7, 77.6, 
77.8, 80.0, 81.7, 83.0, 99.2, 100.3, 100.6, 100.7, 102.4, 125.4, 126.5 (×2), 127.2, 127.4 
(×2), 127.5 (×3), 127.7, 127.8 (×6), 127.9 (×2), 128.0 (×8), 128.1 (×4), 128.2 (×10), 128.3 
(×3), 128.4 (×4), 128.5 (×8), 128.6 (×2), 129.1 (×2), 129.5, 129.6 (×2), 130.0 (×2), 130.1, 
132.7, 132.8, 137.5 (×2), 137.9, 138.0 (×2), 138.2, 138.3, 138.4, 138.6 (×2), 139.0, 163.3, 





galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (5.14).  TsOH 
(15.49 mg, 0.09 mmol) and EtSH (57 μL, 0.81 mmol) were added to a solution of 
compound 5.13 (0.25 g, 0.13 mmol) in MeOH/CH2Cl2 (10 mL, 1/1, v/v) and the reaction 
mixture was stirred for 3 h at rt. The reaction was then quenched with triethylamine (~0.5 
mL) and the volatiles were removed under reduced pressure. The residue was purified by 
column chromatography on silica gel (acetone - toluene gradient elution) to afford the title 
compound as a white amorphous solid in 96% yield (0.23 g, 0.12 mmol). Analytical data 
for 5.14: Rf = 0.55 (acetone/toluene, 1/4, v/v); []D
22 +23.4 (c 1.0, CHCl3); 
1H NMR (600 
MHz, CDCll3): δ, 2.66 (br s,1H, H-5ʹ), 2.87 (m, 1H, H-5), 3.19-3.38 (m, 9H, H-2, 3, 3ʹʹʹ, 
5ʹʹʹ, 6a, 6aʹ, 6aʹʹ, 6b, 6bʹ), 3.42-3.46 (m, 3H, H-3ʹ, 6aʹʹʹ, 6bʹʹʹ), 3.50 (dd, 1H, J2ʹʹ,3ʹʹ = 9.1 Hz, 
H-2ʹʹ), 3.61-3.71 (m, 3H, H-3ʹʹ, 5ʹʹ, 6bʹʹ), 3.76-3.78 (m, 2H, H-4, 4ʹʹ), 3.87 (br d, 1H, J = 
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1.5 Hz, H-4ʹʹʹ), 3.96 (br s, 1H, H-4ʹ), 4.12-4.31 (m, 9H, H-1, 1ʹ, 1ʹʹʹ, 3 x CH2Ph), 4.42-4.68 
(m, 6H, 3 x CH2Ph), 4.77-4.89 (m, 5H, H-1ʹʹ, 2 x CH2Ph), 5.00-5.05 (m, 2H, CH2Ph), 5.08 
(dd, 1H, J2ʹ,3ʹ = 8.9 Hz, H-2ʹ), 5.45 (1H, dd, J2ʹʹʹ,3ʹʹʹ = 8.9 Hz, H-2ʹʹʹ) 6.89-7.74 (m, 59 H, 
aromatic) ppm; 13C NMR (151 MHz, CDCl3): δ, 55.5, 62.2, 67.4, 67.8, 69.0, 69.4, 71.0, 
71.3, 71.8, 72.6, 73.3, 73.5, 73.6 (×2), 73.7 (×2), 74.3, 74.8, 74.9, 75.0, 75.2, 75.6, 76.0, 
76.3, 77.3, 80.1, 80.2, 81.4, 82.6, 98.8, 100.3 (×2), 102.6, 127.5 (×3), 127.6 (×4), 127.7, 
127.8 (×3), 127.9 (×4), 128.0, 128.1 (×7), 128.2 (×10), 128.3 (×8), 128.4 (×8), 128.5 (×3), 
128.6 (×5), 129.4, 129.6 (×2), 130.0 (×2), 130.2, 132.8, 137.5, 137.6, 138.0 (×2), 138.2, 
138.4, 138.6, 138.7, 164.2, 165.4 ppm; ESI TOF LCMS [M+2Na]+2 calcd for 






(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (5.15).  A mixture of donor 5.512 (15.3 
mg, 0.0143 mmol), acceptor 5.14 (20.0 mg, 0.011 mmol), and freshly activated molecular 
sieves (3 Å, 100 mg) in CH2Cl2 (2.0 mL) was stirred under argon for 2 h at rt. The reaction 
mixture was cooled to -40 oC, NIS (4.95 mg, 0.022 mmol) and freshly conditioned AgOTf 
(1.4 mg, 0.005 mmol) were added, and the resulting mixture was stirred for 30 min at -40 
oC. The external cooling was removed, and the reaction mixture was stirred for additional 
30 min during which the reaction temperature was allowed to increase gradually. After that, 
the solids were filtered-off and rinsed successively with CH2Cl2. The combined filtrate 
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(~30 mL) was washed with sat. aq. NaHCO3 (7 mL), Na2S2O3 (7 mL), and water (2 x 7 
mL). The organic phase was separated, dried over MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (acetone - toluene gradient 
elution) to afford the title compound as a white foam in 80% yield (24.8 g, 0.0088 mmol). 
Analytical data for 5.15: Rf = 0.65 (acetone/toluene, 1/4  v/v); []D
22 +22.9 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3, monosaccharide residues A-F are designated in the order 
shown in Figure 5.1; the assignment of signals for terminal galactose residues D and F can 
be interchanged): δ, 2.67 (br d,  1H, J = 1.5 Hz, H-5B), 2.70-2.76 (ddd, 1H, 5C), 2.85 (ddd, 
1H, J = 9.8, J = 2.8 Hz, H-5A), 3.02 (ddd, 1H, J = 9.6 Hz, H-5E), 3.14-3.18 (m, 2H, H-6aA, 
6bA), 3.23-3.77 (m, 20H, H-2A, 3A, 3B, 3D, 3F, 4A, 4B, 4C, 5D, 5F, 6aB, 6aC, 6aD, 6aE, 6aF, 
6bB, 6bC, 6bD, 6bE, 6bF), 3.86 (br d, 1H, J = 2.4 Hz, H-4D), 3.97-4.08 (m, 5H, H-2C, 2E, 3E, 
4E, 4F), 4.20-4.36 (m, 11H, H-1A, 1B, 1D, 4 x CH2Ph), 4.39-4.68 (m, 16H, H-1
C, 1F, 3C, 13 
x CHPh), 4.74 (d, 1H, 2J = 10.4 Hz, CHPh), 4.80 (m, 2H, CH2Ph), 4.88 (m, 3H, H-1
E, 
CH2Ph), 4.96 (m, 2H, CH2Ph), 5.05 (dd, 1H, J = 8.3, 9.5 Hz, H-2
B), 5.42 (dd, 1H, J = 8.4, 
9.3 Hz, H-2D), 5.63 (dd, 1H, J = 8.0, 10.0 Hz, H-2F), 6.75-7.98 (m, 93H, aromatic) ppm; 
13C NMR (151 MHz, CDCl3): δ, 55.3, 55.8, 65.9, 67.1, 67.6, 67.8, 67.9, 68.2, 68.8, 71.0, 
71.5, 71.6, 71.8 (×2), 72.6, 72.7 (×2), 73.3 (×3), 73.6 (×6), 74.3, 74.6 (×4), 74.7, 74.8, 74.2 
(×2), 75.4, 75.7, 75.9, 77.6, 79.9, 80.2 (×2), 81.7, 82.8, 97.8, 98.2, 100.0, 100.2, 100.8, 
102.6, 123.2, 123.8, 126.8, 127.2, 127.3, 127.4, 127.5 (×2), 127.6, 127.7 (4), 127.8(×10), 
127.9 (×4), 128.0 (×6), 128.1 (×16), 128.2 (×13), 128.3 (×6), 128.4 (×6), 128.5 (×6), 128.6 
(×9), 129.5, 130.0 (×2), 130.2, 131.4, 132.1, 132.6, 132.7, 133.3, 134.0, 134.5, 137.5, 
137.8, 137.9 (×2), 138.1, 138.2 (×2), 138.4, 138.7 (×2), 138.9, 139.0 (×2), 139.1, 164.0, 
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165.2, 165.4, 167.6, 168.0 ppm; ESI TOF LCMS [M+Na]+ calcd for C171H164N2NaO36 
2845.0995, found 2845.0975.  





(5.18). Analytical data for 5.18: Rf = 0.55 (acetone/toluene, 1/4, v/v); []D
22 +40.4 (c 1.0, 
CHCl3);
 1H NMR (600 MHz, CDCl3, monosaccharide residues A-F are designated as in 
15; the assignment of signals for terminal galactose residues D and F can be interchanged): 
δ, 2.78 (ddd, 1H, J = 1.4, 8.1 Hz, H-5A), 3.04-3.68 (m, 24H, H-2A, 2C, 3A, 3B, 3D, 3F, 4C, 
5B, 5C, 5D, 5E, 5F, 6aA, 6bA, 6aB, 6bB, 6aC, 6bC, 6aD, 6bD, 6aE, 6bE, 6aF, 6bF), 3.73 (dd, 1H, 
J3A,4A = 9.2 Hz, H-4A), 3.77-3.81 (m, 2H, H-4
D, 4E), 3.98 (d, 1H, J1D,2D = 7.8 Hz, H-1
D) 
4.05 (br d, 1H, J3F,4F = 1.1 Hz, H-4
F), 4.04 (d, 1H, 2J = 11.8 Hz, CHPh), 4.10-4.14 (m, 2H, 
CH2Ph), 4.16-4.24 (m,7H, H-1
A, 1B, 2E, 2 x CH2Ph), 4.25-4.34 (m, 4H, H-4
B, 3 x CHPh), 
4.36-4.47 (m, 6H, 3 x CH2Ph), 4.50-4.57 (m, 3H, H-3
C, CH2Ph), 4.60-4.71 (m, 5H, H-1
F, 
3E, 3 x CHPh), 4.75-4.84 (m, 3H, H-2B, CH2Ph), 4.86-4.95 (m, 3H, H-1
C, CH2Ph), 4.96-
5.02 (m, 3H, 3 x CHPh), 5.44 (dd, 1H, J2D,3D = 10.1 Hz, H-2
D), 5.46 (d, 1H, J1E,2E = 8.5 Hz, 
H-1E), 5.64 (dd, 1H, J1F,2F = 8.4, J2F,3F = 9.5 Hz, H-2
F), 6.66-7.91 (m, 93H, aromatic); 13C 
NMR (151 MHz, CDCl3): δ, 55.3, 55.9, 67.7, 67.8, 68.2, 68.7, 69.1, 71.0, 71.1, 71.4, 71.6, 
72.4, 72.5 (×3), 72.8, 73.9, 73.4 (×2), 73.6 (×4), 73.8, 74.2, 74.3, 74.4, 74.7, 74.8, 75.0 
(×2), 75.6, 75.7, 75.9, 77.2, 77.3, 77.6, 78.6, 80.0, 80.1, 81.6, 82.1, 82.6, 98.8, 99.9, 100.0 
(×2), 101.2, 102.6, 122.3 (×2), 122.8 (×2), 126.6 (×2), 127.0, 127.3 (×4), 127.5 (×2), 127.6 
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(×3), 127.7 (×2), 127.8 (×4), 127.9 (×4), 128.0 (11), 128.1 (×9), 128.2 (×7), 128.3 (×5), 
128.4 (×12), 128.5 (×5), 128.6 (×6), 129.2, 129.5, 129.9, 130.0, 130.3, 130.6, 130.7, 132.2, 
132.7, 133.1, 133.2, 133.4, 133.5, 137.5, 137.7, 137.8, 138.0 (×2), 138.3, 138.5, 138.7, 
138.9 (×2), 139.4 (×2), 163.1, 164.6, 165.0, 165.3, 168.4 ppm; ESI TOF LCMS 
[M+Na]+calcd for C171H164N2NaO36 2845.0995, found 2845.1057. 
 





(5.16).  Compound 5.15 (65.0 mg, 0.023 mmol) was dissolved in NH2NH2-H2O/MeOH 
(3.0 mL, 1/2, v/v) and the resulting mixture was kept for 36 h at reflux. After that, the 
volatiles were removed under reduced pressure. The residue was purified by column 
chromatography on silica gel (methanol - dichloromethane gradient elution) to afford the 
title compound as an off-white amorphous solid in 74% yield (37.2 mg, 0.016 mmol). 
Selected analytical data for 5.16: Rf = 0.50 (MeOH/CH2Cl2, 1/9, v/v); []D
22 +9.3 (c 1.0, 
CHCl3); 
1H NMR (600 MHz, CDCl3, monosaccharide residues A-F are designated in the 
order shown in Figure 1; the assignment of signals for terminal galactose residues D and F 
can be interchanged): δ, 2.65-4.11 (m, 37H, H-1A, 2A, 2B, 2C, 2D, 2E, 2F, 3A, 3B, 3C, 3D, 3E, 
3F, 4A, 4B, 4C, 4D, 4E, 4F, 5A, 5B, 5C, 5D, 5E, 5F, 6aA, 6aB, 6aC, 6aD, 6aE, 6aF, 6bA, 6bB, 6bC, 
6bD, 6bE, 6bF), 4.17-4.23 (m, 3H, 3 x CHPh), 4.28 (d, 1H, CHPh), 4.43-4.51 (m, 9H, H-1B, 
1C, 1D, 1E, 1F, 2 x CH2Ph), 4.55-4.74 (m, 12H, 6 x CH2Ph), 4.79-4.93 (m, 6H, 3 x CH2Ph), 
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5.02-5.08 (m, 4H, 2 x CH2Ph), 7.11-7.38 (m, 70H, aromatic) ppm; 
13C NMR (151 MHz, 
CDCl3): δ, 56.8, 57.3, 67.4, 68.1 (×2), 68.4, 68.6, 68.8, 71.3, 72.2, 72.3 (×3), 72.6, 73.0, 
73.6 (×2), 73.4 (×2), 73.5 (×3), 73.7, 73.8, 74.6 (×3), 74.7 (×3), 74.7 (×2), 75.0, 75.1, 75.2, 
75.7, 76.5, 76.8, 82.1 (×3), 82.4, 83.6, 83.9, 102.8, 103.0, 103.2 (×2), 103.8, 107.2, 127.3 
(×3) 127.4 (×3), 127.5 (×3), 127.6 (×3), 127.8 (×17), 127.9 (×3), 128.0 (×8), 128.1 (×3), 
128.2 (×8), 128.4 (×9), 128.5 (×8), 128.6 (×4), 137.7, 137.9, 138.0, 138.1 (×2), 138.4, 
138.7, 138.8, 138.9, 139.0, 139.3 (×2) ppm; ESI TOF LCMS [M+Na]+calcd for 




glucopyranosyl)-(1→6)]-O-(β-D-galactopyranosyl)-(1→4)-β-D-glucopyranose (5.1).  
Compound 5.16 (23.0 mg, 0.009 mmol) was dissolved in a mixture of Ac2O/MeOH (2.0 
mL, 1/1, v/v) and the resulting mixture was stirred for 16 h at rt. Then, the volatiles were 
removed under the reduced pressure. The residue was diluted with CH2Cl2 (~50 mL) and 
washed with sat. aq. NaHCO3 (10 mL), and water (2 x 10 mL). The organic phase was 
separated, dried over MgSO4, concentrated under reduced pressure and dried in vacuo for 
3 h. The crude residue was dissolved in EtOH/H2O (3.0 mL, 4/1, v/v), 10% Pd on charcoal 
(75 mg) was added, and the resulting mixture was stirred under hydrogen for 24 h at rt. 
After that, the solids were filtered off and rinsed successively with methanol and water. 
The combined filtrate (~40 mL) was concentrated in vacuo. The residue was purified by 
column chromatography on Sephadex G-25 (water elution) to afford the title compound as 
a white amorphous solid in 80% yield (7.6 mg, 0.007 mmol). The spectral data for LNH 
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5.1 was in agreement with that reported previously.15 Selected analytical data for 5.1: Rf = 
0.50 (chloroform/methanol/water, 2/1/0.4, v/v/v); 1H NMR (600 MHz, D2O): δ, 2.00, 2.03 
(2 s, 6H, 2 x CH3CO), 3.27 (dd, 1H, J = 8.1, 9.0 Hz), 3.43-3.99 (m, 46H), 4.12 (d, 1H, J = 
3.3 Hz), 4.41 (dd, 2H, J = 5.8, 7.8 Hz), 4.44 (d, 1H, J = 7.8 Hz), 4.62 (dd, 1H, J = 4.2, 7.9 
Hz), 4.64 (d, 1H, J = 8.0 Hz), 4.70 (dd, 1H, J = 2.7, 8.4 Hz), 5.19 (d, 1H, J = 3.7 Hz) ppm; 
13C NMR (151 MHz, D2O): δ, 22.58, 22.77, 55.06, 55.37, 60.38, 60.86, 61.38, 68.75, 68.80, 
68.89, 69.05, 70.23, 70.25, 70.35, 71.03, 71.31, 71.55, 71.77, 72.82, 72.85, 73.82, 74.20, 
74.74, 75.07, 75.10, 75.55, 75.63, 75.70, 78.72, 79.25, 79.35, 82.02, 82.40, 92.15, 96.07, 
101.33, 102.87, 103.24, 103.34, 103.84, 174.85, 175.29 ppm; ESI TOF LCMS 




tri-O-benzyl-β-D-glucopyranoside (5.17).  Compound 5.14 (30.0 mg, 0.016 mmol) was 
dissolved in NH2NH2-H2O/MeOH (2.5 mL, 1/4, v/v) and the resulting mixture was kept 
for 24 h at reflux. After that, the volatiles were removed under the reduced pressure. The 
residue was dissolved in MeOH/CH2Cl2 (~5 mL, 1/9, v/v) and filtered through a pad of 
silica gel eluting with MeOH/CH2Cl2 (1/9, v/v). The combined filtrate (~50 mL) was 
concentrated under the reduced pressure and dried in vacuo for 3 h. The crude residue was 
dissolved in Ac2O/MeOH (2.0 mL, 1/1, v/v) and the resulting mixture was stirred for 12 h 
at rt. Then, the volatiles were removed under reduced pressure. The residue was diluted 
with CH2Cl2 (50 mL) and washed with sat. aq. NaHCO3 (10 mL) and brine (2 x 10 mL). 
The organic phase was separated, dried over MgSO4, and concentrated in vacuo. The 
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residue was purified by column chromatography on silica gel (acetone - toluene gradient 
elution) to afford the title compound as an off-white amorphous solid in 84% yield (20.3 
mg, 0.013 mmol). Analytical data for 5.17: Rf = 0.65 (acetone/toluene, 2/3, v/v); []D
22 
+28.2 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 1.91 (3H, s, CH3CO), 3.15-4.13 (m, 
24H, H-2, 2ʹ, 2ʹʹ, 2ʹʹʹ, 3, 3ʹ, 3ʹʹ, 3ʹʹʹ, 4, 4ʹ, 4ʹʹ, 4ʹʹʹ, 5, 5ʹ, 5ʹʹ, 5ʹʹʹ, 6a, 6aʹ, 6aʹʹ, 6aʹʹʹ, 6b, 6bʹ, 6bʹʹ, 
6bʹʹʹ), 4.20 (dd, 2H, 2J = 11.7 Hz, CH2Ph), 4.35-4.49 (m, 7H, H-1, 1ʹ, 1ʹʹʹ, 2 x CH2Ph), 4.52-
4.74 (m, 7H, 7 x CHPh), 4.82 (d, 1H, 2J = 12.1 Hz, CHPh), 4.85-4.94 (m, 4H, H-1ʹʹ, 3 x 
CHPh), 4.98 (d, 1H, 2J = 10.6 Hz, CHPh), 6.44 (d, 1H, J = 7.0 Hz, NH), 7.04-7.37 (m, 
45H, aromatic) ppm; 13C NMR (151 MHz, CDCl3): δ, 23.7, 56.6, 62.4, 68.3, 68.4, 68.7, 
69.5, 70.5, 71.1, 71.5, 72.5, 73.0, 73.4, 73.5, 73.6, 73.8, 74.2 (×2), 74.7, 74.8, 74.9, 75.1, 
75.5, 77.9, 80.4, 82.3 (×2), 83.1, 83.8, 100.7, 102.8, 103.0, 104.3, 127.3, 127.5 (×2), 127.7 
(×2), 127.8 (×8), 127.9 (×4), 128.0 (×3), 128.1 (×2), 128.2 (×6), 128.3 (×2), 128.4 (×4), 
128.5 (×7), 128.6 (×4), 137.8, 138.0, 138.1, 138.3 (×2), 138.4, 138.6, 138.7, 139.2, 172.2 
ppm; ESI TOF LCMS [M+Na]+calcd for C89H99NNaO21 1540.6607, found 1540.6627. 
 
O-(β-D-Galactopyranosyl)-(1→3)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-
(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose (5.2).  10% Pd on charcoal 
(75 mg) was added to a solution of 5.17 (20.0 mg, 0.013 mmol) in EtOH/H2O (3.0 mL, 4/1, 
v/v), and the resulting mixture was stirred under hydrogen for 24 h at rt. After that, the 
solids were filtered off and rinsed successively with methanol and water. The combined 
filtrate (~40 mL) was concentrated in vacuo, and the residue was purified by column 
chromatography on Sephadex G-25 (water elution) to afford the title compound as a white 
amorphous solid in 87% yield (7.9 mg, 0.011 mmol). Analytical data for 5.2 was in 
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agreement with that reported previously:13 Rf = 0.30 (chloroform/methanol/water, 2/1/0.4, 
v/v/v); ESI TOF LCMS [M+Na]+ calcd for C26H45NNaO21 730.2382, found 730.2392.  
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6.1. Introduction 
Human milk oligosaccharides (HMO) are complex glycans that are highly abundant 
in human milk that have been associated with many beneficial effects via various 
mechanisms. A woman can secrete a distinct HMO composition profile that varies 
geographically and may even substantially vary between different mothers.1 All HMO 
sequences are variations of the specific structural blueprint, but all glycans composed of 
lactose (Galβ1→4Glc) at their reducing end. The lactose unit can be elongated at the 
galactose moiety at the C-3 position with lacto-N-biose (Galβ1→3GlcNAc, type 1 chain), 
which prevents further elongation in this direction. The galactose moiety of the reducing-
end lactose can also be elongated by lactosamine (Galβ1→4GlcNAc, type 2 chain) units. 
And this elongation, which can take place either at the C-3 or C-6 position of galactose, is 
open for further oligosaccharide chain extension. In addition, the HMO core structures can 
be fucosylated and/or sialylated.2 Structures of many HMO are known, and many have 
already been prepared enzymatically and/or chemically, but the exact biological 
mechanisms of action of a majority of individual HMO remain unknown due to the lack of 
well-defined HMO in sufficient quantities.3 
With the expectation that developing reliable synthetic methods for obtaining 
individual HMO will boost further innovations in this area, we have reported the total 
syntheses of a number of glycans. Our initial efforts included syntheses of two linear 
tetrasaccharide structures (para-HMO): lacto-N-neotetraose (LNnT) (Chapter 3)4 and 
lacto-N-tetraose (LNT) (Chapter 4).5 In Chapter 5, we communicated the first synthesis of 
branched (iso-HMO) hexasaccharide, lacto-N-hexaose (LNH).6 Reported herein is our 
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further advancement in the field of HMO dedicated to the synthesis of another branched 
hexasaccharide, lacto-N-neohexaose (LNnH).  
 
Figure 6.1.  Chemical structures of LNH 6.1 and LNT 6.2. 
 
LNnH 6.1 is structurally derived from LNnT 6.2, and represents one of the most 
common HMO core structures.7 LNnH comprises the reducing end lactose disaccharide 
(AB, Figure 6.1), common for all HMO, which is branched at the galactose residue (B). 
More specifically, it is elongated with N-acetyllactosamine disaccharide residue (CD) at 
C-3 of Gal, and also again with N-acetyllactosamine residue (EF) at C-6 of Gal. Many 
chemical4,8,9 and enzymatic syntheses3,10,11 of LNnT are known. LNnH has been 
synthesized enzymatically,3,12 and some spacer-containing, protected LNnH sequences 
have been chemically synthesized using polymer supports.13 However, to the best of our 
knowledge, no chemical synthesis of LNnH has yet emerged. Human milk isolates of 
LNnH are available from a variety of commercial vendors, but this common HMO is not 
yet available in large quantities and at accessible cost for mainstream research and 
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application. Reported herein as an efficient method for the scalable chemical synthesis of 
LNnH 6.1 and, by extension, LNnT 6.2. 
 
6.2. Results and discussion 
Recently we have synthesized LNnT 6.2 using convergent and linear assembly 
strategies.4 The protecting groups in the tetrasaccharide 6.3 obtained over the course of our 
previous work4 were strategically placed to allow for the synthesis of other derivatives. For 
instance, during the incipient stage of the synthesis we assumed that selective removal of 
6ʹ-O-picoloyl (Pico) substituent in 6.3 would provide a straightforward access to acceptor 
6.4 suitable for subsequent branching. Indeed, this would have offered a very 
straightforward access to LNnH.  
 
 
Scheme 6.1.  First attempted assembly of LNnH 6.1. 
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To follow this lead, the deprotection of 6ʹ-O-Pico in 6.3 was affected in the presence 
of Cu(OAc)2-H2O in MeOH/CH2Cl2, and tetrasaccharide 6.4 was obtained in 97% yield. 
To our disappointment, all attempts to glycosylate acceptor 6.4 with lactosamine 
thioglycoside donor 6.54 were largely unsuccessful and practically no desired 
hexasaccharide was formed. Instead, a large number of unidentified side products derived 
from the donor have been isolated, and the acceptor remained practically intact.  
Recalling our previous endeavors with the synthesis of HMO wherein the nature of 
glycosyl donor and acceptor was found to be of paramount significance, we attempted to 
employ the corresponding lactosamine phosphate and trichloroacetimidate donors. Despite 
extended study, these attempts to access the backbone of LNnH were also unsuccessful. In 
further attempts to enhance the efficiency of this coupling we applied less bulky 
glucosamine thioglycoside donor 6.6 and its phosphate and trichloroacetimidate analogues. 
Although the formation of minor amounts of the desired pentasaccharide were observed by 
mass spectroscopy, these glycosylations were largely unsuccessful. Having explored all 
possibilities available to us, we came to a conclusion that the bulky benzyl group at the 4′-
OH position of acceptor 6.4 is hindering the glycosylation at the 6′-OH position.  
It should be noted that a similar conclusion was made over the course of our 
preliminary attempts to synthesize LNH.6 In order to decrease the steric hindrance, we 
decided to follow the same strategy as that developed for the modified synthesis of LNH, 
in which we employed the lactose building block 6.7 protected with 4,6-O-benzyliene 
acetal.6 Over the course of our previous work with similar sequences, we observed that if 
the benzylidene acetal is removed at the tetrasaccharide stage, the resulting 4,6-diol will 
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offer a far more accessible glycosyl acceptor site for glycosylation. This would be essential 
for our route employing the glycosylation with bulky disaccharide donor 6.5.  
With this strategic adjustment, we attempted to glycosylate acceptor 6.7 with 
thioglycoside donor 6.5. This reaction was sluggish and inefficient, and despite all attempts 
to push the reaction to completion, significant amounts of the acceptor remained. After a 
quick screening of other leaving groups, we discovered that trichloroacetimidate donor 6.9 
offers an effective building blocks to glycosylate acceptor 6.7.  
 
 
Scheme 6.2.  Convergent synthesis of acceptor 6.11. 
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Glycosyl donor 6.9 was prepared from thioglycoside precursor 6.5 that was first 
converted into the corresponding hemiacetal 6.8 in 83% over two steps involving the 
anomeric bromination with Br2 in CH2Cl2 followed by hydrolysis of the bromide in the 
presence of Ag2CO3 in wet acetone. Next, installation of the trichloroacetimidate group 
was performed using trichloroacetonitirle (CCl3CN) in the presence of 1,8-
diazabicylco[5.4.0]undec-7-ene (DBU) to afford lacto-N-biose trichloroacetimidate donor 
6.9 in 87% yield. Glycosylation of acceptor 6.7 with donor 6.9 was conducted in the 
presence of catalytic TMSOTf and the desired tetrasaccharide 6.10 was obtained in a good 
yield of 83% with complete β-stereoselectivity. It is noteworthy that the corresponding 
glycosyl phosphate donor4 gave a comparable result in this application. However, the 
activation of the glycosyl phosphate donor demanded 2 equiv of TMSOTf along with 
prolonged reaction time. As a result, product 6.10 was contaminated with tetrasaccharide 
6.11, which was the result of benzylidene cleavage. While this offers a possibility of 
obtaining 6.11 directly from disaccharide building blocks in one pot, we have not explored 
this potential advantage. 
The deprotection of the 4′,6′-O-benzylidene acetal in intermediate 6.10 was 
somewhat low-yielding in the presence of TFA in wet DCM, hence we did the reaction in 
the presence of TsOH and EtSH in MeOH/CH2Cl2, an approach adapted in our previous 
work.6 As a result, tetrasaccharide diol 6.11 was obtained in 87% yield.  
Next, we attempted glycosylation of tetrasaccharide diol 6.11 with lactosamine 
thioglycoside donor 6.5. Even glycosylation of this more accessible glycosyl acceptor was 
not as straightforward as we had hoped for. Standard reaction condition employing 
NIS/TfOH as promoters produced the desired hexasaccharide 6.12 in an unremarkable 
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yield of 57%. Although this result was a significant improvement in respect to our initial 
attempts to glycosylate acceptor 6.4, wherein the yields rarely exceeded 25%, we 
endeavored to pursue further improvement the outcome of this challenging reaction. With 
this intention, we identified the major side reactions hampering the yield of the product: 
fairly rapid hydrolysis of lactosamine donor 6.5 and the formation of the 1→4-linked 
hexasaccharide alongside the desired 1→6-linked counterpart 6.12. The formation of 
somewhat unexpected 1→4-linked hexasaccharide was the main reason we were unable to 
introduce lactosamine units at C-3 and C-6 positions concomitantly. To suppress these side 
reactions, we investigated milder promoters, dimethyl(thiomethyl)sulfonium triflate 
(DMTST)14,15 and NIS/AgOTf.16 The former promoter provided a comparable result that 
that achieved with NIS/TfOH. With the latter promoter, known for providing a slower 
release of the iodonium ion, minimal side products were observed. After careful refinement 
of the reaction conditions, we achieved the desired protected LNnH precursor 6.12 in a 
commendable yield of 82%. This result was obtained by conducting the reaction at -40 oC 
for 30 min, and then allowing the reaction temperature gradually increase over the course 
of the additional 30 min period.  
With the protected intermediate 6.12 in hand, we then endeavored to carry out a 
series of deprotection steps to obtain the target LNnH hexasaccharide 6.1. Deprotection of 
the phthalimido and ester groups was achieved by refluxing compound 6.12 with NH2NH2-
H2O in MeOH, followed by N-acetylation affected with acetic anhydride in MeOH/Et3N 
to furnish hexasaccharide 6.13 in 92% yield. Finally, the benzyl groups were removed by 
hydrogenation in the presence of 10% palladium on charcoal in wet ethanol to obtain target 
LNnH 6.1 in 91% yield.  




Scheme 6.3.  Convergent synthesis of LNnH 6.1 and LNnT 6.2. 
 
We also performed deprotection of the key tetrasaccharide intermediate 6.11 to 
obtain LNnT 6.2. This was achieved via deprotection of the phthalimido and ester groups 
in the presence of NH2NH2-H2O in refluxing MeOH followed by N-acetylation with acetic 
anhydride in MeOH to furnish partially protected tetrasaccharide intermediate 6.14 in 94% 
yield. Subsequently, benzyl ethers were removed by hydrogenation in the presence of 10% 
Pd/C in wet ethanol to afford LNnT 6.2 in 82% yield.  
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6.3. Conclusions 
In summary, the first chemical synthesis of lacto-N-neohexaose has been completed 
using a convergent 2+2+2 strategy. This approach employed preassembled lactose and 
lactosamine building blocks. Along the way, we have also obtained the lacto-N-neotetraose 
core sequence. With expectation that new methods for reliable synthesis of individual 
HMO will boost practical applications of these important biomolecules, further synthetic 
studies of HMO are underway in our laboratory.  
 
6.4. Experimental 
6.4.1. General methods 
  Reactions were performed using commercial reagents and the ACS grade solvents 
were purified and dried according to standard procedures.  Column chromatography was 
performed on silica gel 60 (70-230 mesh) and Sephadex G-25 size exclusion resin, 
reactions were monitored by TLC on Kieselgel 60 F254. The compounds were detected by 
examination under UV light and by charring with 10% sulfuric acid in methanol. Solvents 
were removed under reduced pressure at <40 oC. CH2Cl2 was distilled from CaH2 directly 
prior to application. Molecular sieves (3Å), used for reactions, were crushed and activated 
in vacuo at 390 °C during 8 h in the first instance and then for 2-3 h at 390 °C directly prior 
to application. AgOTf was co-evaporated with toluene (3 x 10 mL) and dried in vacuo for 
2-3 h directly prior to application. Optical rotations were measured using a Jasco 
polarimeter. 1H NMR spectra were recorded at 300 MHz or 600 MHz, and 13C NMR 
spectra were recorded at 75 MHz or 151 MHz. The 1H chemical shifts are referenced to the 
signal of the residual TMS (δH = 0.00 ppm) for solutions in CDCl3 or the signal of the 
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residual D2O (δH = 4.79 ppm) for solutions in D2O. The 
13C chemical shifts are referenced 
to the central signal of CDCl3 (δC = 77.16 ppm) for solutions in CDCl3 or the central signal 
of CD3COCD3 δC = 29.84 ppm) for solutions in D2O. Accurate mass spectrometry 
determinations were performed using Agilent 6230 ESI TOF LCMS mass spectrometer 
 
6.4.2. Synthesis of oligosaccharides 6.4, 6.8, 6.9, 6.11, 6.12 
Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→4)-O-(3,6-di-O-
benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-
benzyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (6.4).  
Cu(OAc)2-H2O (15.3 mg, 0.084 mmol) was added to a solution of benzyl O-(2-O-benzoyl-
3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→4)-O-(3,6-di-O-benzyl-2-deoxy-2-
phthlimido-β-D-glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-
galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside4 (6.3, 22.0 mg, 0.011 
mmol) in MeOH/CH2Cl2 (3.0 mL, 1/3, v/v) and the resulting mixture was stirred for 20 
min at rt. Next, the reaction mixture was diluted with CH2Cl2 (~50 mL) was washed with 
H2O (10 mL), sat. aq. NaHCO3 (10 mL) and water (2 x 10 mL). The organic phase was 
separated, dried over MgSO4, and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) 
to afford the title compound as an off-white amorphous solid in 97% yield (20.9 mg, 0.011 
mmol). Analytical data for 6.4: Rf = 0.60 (ethyl acetate/hexane, 1/1, v/v); []D
21 +14.9 (c 
1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 2.88 (m, 1H, J = 9.5 Hz, H-5), 3.09-3.63 (m, 
15H, 2, 3, 3ʹ, 3ʹʹʹ, 5ʹ, 5ʹʹ, 5ʹʹʹ, 6a, 6aʹ, 6aʹʹ, 6aʹʹʹ, 6b, 6bʹ, 6bʹʹ, 6bʹʹʹ), 3.74-3.78 (m, 2H, H-4, 
4ʹ), 3.89-3.95 (dd, 1H, J4ʹʹ,5ʹʹ = 8.9 Hz, H-4ʹʹ), 3.98 (d, 1H, J3ʹʹʹ.4ʹʹʹ = 1.6 Hz, H-4ʹʹʹ), 4.14-4.30 
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(m, 9H, H-1, 1ʹ, 2ʹʹ, 3ʹʹ, 5 × CHPh), 4.42-4.59 (m, 7H, 7 × CHPh), 4.61-4.70 (m, 3H, H-1ʹʹʹ, 
CH2Ph), 4.79-4.82 (dd, 2H, CH2Ph), 4.84-4.88 (dd, 2H, CH2Ph), 4.98 (dd, 2H, CH2Ph), 
5.06 (d, 1H, J1ʹʹ,2ʹʹ = 8.4 Hz, H-1ʹʹ), 5.24 (dd, 1H, J1ʹ,2ʹ = 8.2, J2ʹ,3ʹ = 9.9 Hz, H-2ʹ), 5.64 (dd, 
1H, J1ʹʹʹ,2ʹʹʹ = 8.1, J2ʹʹʹ,3ʹʹʹ = 9.8 Hz, H-2ʹʹʹ), 6.57-8.12 (m, 64H, aromatic) ppm; 
13C NMR (151 
MHz, CDCl3): δ, 56.1, 61.9, 67.5, 68.1, 68.5, 71.0, 71.4, 71.9, 72.5, 72.7, 73.4 (×2), 73.5, 
73.6, 74.3, 74.5, 74.6, 74.7 (×2), 74.8, 74.9, 75.8, 76.0, 76.3, 77.0, 78.4, 79.8, 80.5, 81.4, 
82.7, 99.7, 100.6, 101.2, 102.5, 122.8, 123.2, 126.7, 127.4 (×2), 127.5, 127.6 (×2), 127.7 
(×3), 127.8 (×8), 127.9 (×5), 128.0 (×4), 128.1 (×5), 128.2 (×3), 128.3 (×6), 128.4 (×8), 
128.5 (×4), 128.6 (×3), 128.9 (×2), 129.4, 129.7, 130.0, 130.1, 130.9, 131.5, 132.9, 133.2, 
133.4, 137.6, 137.8, 138.0, 138.1, 138.2, 138.6, 138.8 (×2), 138.9, 164.4, 165.2, 167.3, 




deoxy-2-phthalimido-D-glucopyranose (6.8).  A freshly prepared solution of Br2 in DCM 
(2.5 mL, 1/165, v/v) was added to a pre-chilled solution of ethyl O-(2-O-benzoyl-3,4,6-tri-
O-benzyl-β-D-galactopyranosyl)-(1→4)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-
β-D-glucopyranoside4 (6.5, 0.28 g, 0.27 mmol) in CH2Cl2 (4.0 mL) and the resulting 
mixture was stirred for 15 min at 0 oC. After that, the volatiles were removed under reduced 
pressure. The residue was co-evaporated with CH2Cl2 (3 × 10 mL) and dried in vacuo for 
2 h. The crude residue was dissolved in acetone (5.0 mL), water (0.25 mL) and Ag2CO3 
(0.04 g, 0.14 mmol) were added, and the resulting mixture was stirred in the absence of 
light for 16 h at rt. After that, the solids were filtered-off and rinsed successively with 
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CH2Cl2. The combined filtrate (~150 mL) was concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel (acetone - toluene gradient 
elution) to afford the title compound as a white foam in 83% yield (0.23 g, 0.22 mmol). 
Analytical data for β-6.8: Rf = 0.35 (acetone/toluene, 1/4, v/v); 
1H NMR (300 MHz, 
CDCl3): δ, 3.34 (d, 1H, J = 8.4 Hz, OH), 3.36-3.65 (m, 7H, H-3ʹ, 5, 5ʹ, 6a, 6aʹ, 6b, 6bʹ), 
3.97-4.08 (m, 3H, H-2, 4, 4ʹ), 4.22-4.63 (m, 10H, J1ʹ,2ʹ = 7.9 Hz, H-1ʹ, 3, 3 × CH2Ph, 2 × 
CHPh), 4.91 (d, 1H, 2J = 12.1 Hz, CHPh), 4.97 (d, 1H, 2J = 11.6 Hz, CHPh), 5.19 (dd, 1H, 
J1,2 = 8.4 Hz, H-1), 5.62 (dd, 1H, J2ʹ,3ʹ = 10.1 Hz, H-2ʹ), 6.73-7.99 (m, 34H, aromatic) ppm; 
13C NMR (75 MHz, CDCl3): δ, 57.6, 67.8, 68.2, 71.4 (×2), 72.5, 72.6, 73.4, 73.6 (×2), 74.6 
(×2), 74.7, 77.4, 79.8, 93.0, 100.7, 123.6, 126.8, 127.5, 127.6 (×2), 127.8 (×7), 127.9 (×3), 
128.0 (×2), 128.1 (×2), 128.2 (×2), 128.3, 128.4 (×2), 128.5 (×5), 129.1, 129.9 (×2), 130.0 
(×2), 131.7, 133.2, 133.9, 137.8, 138.0, 138.1, 138.8, 139.0, 168.2 (×3) ppm; ESI TOF 
LCMS [M+Na]+ calcd for C62H59NNaO13 1048.3884, found 1048.3875. 
 
O-(2-O-Benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl)-(1→4)-3,6-di-O-benzyl-2-
deoxy-2-phthalimido-β-D-glucopyranosyl trichloroacetimidate (6.9).  CCl3CN (0.86 
mL, 8.58 mmol) and DBU (5.63 μL, 0.04 mmol) were added to a solution of compound 
6.8 (0.44 g, 0.43 mmol) in CH2Cl2 (8.0 mL) and the resulting mixture was stirred under 
argon for 1 h at rt. After that, the volatiles were removed under reduced pressure. The 
residue was purified by column chromatography on silica gel (acetone - toluene gradient 
elution) to afford the title compound as a white foam in 87% yield (0.43 g, 0.37 mmol). 
Analytical data for 6.9: Rf = 0.65 (acetone/toluene, 1/4, v/v); []D
22 +52.6 (c 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3): δ, 3.44-3.73 (m, 7H, H-3ʹ, 5, 5ʹ, 6a, 6aʹ, 6b, 6bʹ), 4.01 (br d, 
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1H, J3ʹ,4ʹ = 2.4 Hz, H-4ʹ), 4.16 (dd, 1H, J3,4 = J4,5 = 8.8 Hz, H-4), 4.27-4.75 (m, 11H, H-1ʹ, 
2, 3, 4 × CH2Ph), 4.92 (d, 1H, 
2J = 12.2 Hz, CHPh), 4.98 (d, 1H, 2J = 11.6 Hz, CHPh), 5.65 
(dd, 1H, J1ʹ,2ʹ = 8.1 Hz, J2ʹ,3ʹ = 9.8 Hz, H-2ʹ), 6.28 (d, 1H, J = 8.5 Hz, H-1), 6.73-8.00 (m, 
34H, aromatic), 8.46 (s, 1H, NH) ppm; 13C NMR (75 MHz, CDCl3): δ, 54.7, 67.2, 68.2, 
71.4, 72.4, 72.7, 73.4, 73.5, 73.6, 74.6, 74.8, 75.4, 76.6, 76.9, 79.8, 90.5, 94.2, 100.6, 123.4 
(×2), 125.4, 126.9, 127.4, 127.6 (×2), 127.7, 127.8 (×4), 127.9 (×3), 128.0 (×3), 128.2 (×4), 
128.3, 128.4 (×2), 128.5 (×3), 128.6 (×2), 129.1, 129.9 (×3), 131.5, 133.2, 133.9, 137.8, 
138.0, 138.2, 138.8 (×2), 160.9, 165.1, 167.6 ppm; ESI TOF LCMS [M+Na]+ calcd for 





(6.10).  A mixture of donor 6.9 (0.15 g, 0.13 mmol), acceptor 6.76 (0.09 g, 0.01 mmol), and 
freshly activated molecular sieves (3 Å, 450 mg) in CH2Cl2 (5.0 mL) was stirred under 
argon for 2 h at rt. The mixture was cooled to -30 oC, TMSOTf (5.50 μL, 0.03 mmol) was 
added, and the resulting mixture was stirred for 10 min while the reaction temperature was 
allowed to increase gradually. After that, the solids were filtered-off and rinsed 
successively with CH2Cl2. The combined filtrate (~50 mL) was washed with sat. aq. 
NaHCO3 (10 mL) and water (2 x 10 mL). The organic phase was separated, dried over 
MgSO4, and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel (acetone - toluene gradient elution) to afford the title 
compound as a white foam in 83% yield (0.21 g, 0.11 mmol). Analytical data for 6.10: Rf 
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= 0.55 (acetone/toluene, 1/4, v/v); []D
22 +7.9 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): 
δ, 2.92-3.00 (m, 2H, H-5, 5ʹ), 3.28-3.65 (m, 13H, H-2, 3, 3ʹ, 3ʹʹʹ, 4ʹ, 5ʹʹ, 5ʹʹʹ, 6a, 6aʹʹ, 6aʹʹʹ, 
6b, 6bʹʹ, 6bʹʹʹ), 3.78-3.89 (m, 2H, H-4, 4ʹʹ), 4.01 (br s, 1H, H-4ʹʹʹ), 4.09 (br d, 1H, J = 11.9 
Hz, H-6aʹ), 4.12-4.28 (m, 6H, H-2ʹʹ, 3ʹʹ, 6bʹ, 3 × CHPh), 4.29-4.34 (m, 3H, H-1, CH2Ph), 
4.39 (d, 1H, 2J = 11.5 Hz, CHPh), 4.45-4.59 (m, 5H, H-1ʹ, 2 × CH2Ph ), 4.63- 4.72 (m, 4H, 
H-1ʹʹʹʹ, 3 × CHPh ), 4.81-4.89 (m, 3H, 3 × CHPh), 5.01 (dd, 2H, CH2Ph ), 5.20 (d, 1H, J = 
7.6 Hz, H-1ʹʹ), 5.26-5.32 (dd, 1H, J2ʹ,3ʹ = 8.7 Hz, H-2ʹ), 5.39 (s, 1H, >CHPh), 5.64-5.71 (dd, 
1H, J2ʹʹʹ,3ʹʹʹ = 8.7 Hz, H-2ʹʹʹ), 6.72-8.13 (m, 64H, aromatic) ppm; 
13C NMR (151 MHz, 
CDCl3): δ, 55.6, 66.7, 68.0, 68.2, 68.6, 69.2, 71.0, 71.1, 71.5, 72.6, 72.8, 73.3, 73.5, 73.6 
(×2), 74.3, 74.6 (×4), 74.9, 75.3, 75.6, 75.7, 77.0, 78.5, 79.0, 80.0, 81.8, 83.1, 99.6, 100.6, 
100.8, 101.2, 102.5, 126.4 (×2), 126.7, 127.1, 127.5 (×4), 127.7 (×6), 127.8 (×3), 127.9 
(×7), 128.0 (×6), 128.1 (×6), 128.2 (×3), 128.3 (×6), 128.4 (×5), 128.5 (×5), 128.6 (×4), 
129.4, 129.5 (×2), 130.0, 130.1 (×2), 132.7, 133.3 (×2), 137.6, 137.8, 138.0, 138.1, 138.2, 
138.4, 138.7, 138.8 (×2), 139.2, 164.1, 165.2 ppm; ESI TOF LCMS [M+2Na]+2 calcd for 




galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (6.11).  TsOH (10.8 
mg, 0.06 mmol) and EtSH (38 μL, 0.54 mmol) were added to a solution of compound 6.10 
(0.17 g, 0.09 mmol) in MeOH/CH2Cl2 (7.0 mL, 1/1, v/v). and the resulting mixture was 
stirred for 3 h at rt. The reaction was then quenched with triethylamine (~0.5 mL) and the 
volatiles were removed under reduced pressure. The residue was purified by column 
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chromatography on silica gel (acetone - toluene gradient elution) to afford the title 
compound as a white amorphous solid in 87% yield (0.14 g, 0.08 mmol). Analytical data 
for 6.11: Rf = 0.50 (acetone/toluene, 1/4  v/v); []D
22 +36.1 (c 1.0, CHCl3); 
1H NMR (600 
MHz, CDCl3): δ, 2.85 (br s, 1H, H-5ʹ), 2.95 (br d, 1H, J = 9.6 Hz, H-5), 3.21-3.65 (m, 14H, 
H-2, 3, 3ʹ, 3ʹʹʹ, 5ʹʹ, 5ʹʹʹ, 6a, 6aʹ, 6aʹʹ, 6aʹʹʹ, 6b, 6bʹ, 6bʹʹ, 6bʹʹʹ), 3.80 (dd, 1H, J4,5 = 9.3 Hz, H-
4), 3.85 (dd, 1H, J4ʹʹ,5ʹʹ = 9.0 Hz, H-4ʹʹ), 3.90 (s, 1H, H-4ʹ), 4.00 (s, 1H, H-4ʹʹʹ), 4.10-4.59 
(m, 14H, H-1, 1ʹ, 2ʹʹ, 3ʹʹ, 5 × CH2Ph), 4.61-4.71 (m, 4H, H-1ʹʹʹ, 3 × CHPh), 4.80-4.87 (m, 
3H, 3 × CHPh), 4.90 (d, 1H, 2J = 10.3 Hz, CHPh), 4.97 (d, 1H, 2J = 11.7 Hz, CHPh), 5.13 
(d, 1H, J1ʹʹ,2ʹʹ = 8.4 Hz, H-1ʹʹ), 5.23 (dd, 1H, J2ʹʹ,3ʹʹ = 10.0 Hz, H-2ʹ), 5.65 (dd, 1H, J2ʹʹ,3ʹʹ  = 
9.6 Hz, H-2ʹʹʹ), 6.66-8.07 (m, 59H, aromatic) ppm; 13C NMR (151 MHz, CDCl3): δ, 55.5, 
62.0, 67.6, 68.2, 68.3, 68.4, 71.0, 71.1, 71.5, 72.6, 72.7, 73.4 (×2), 73.6 (×3), 74.3 (×2), 
74.6, 74.7, 74.8, 74.9, 75.7, 76.4, 78.3, 79.8, 81.4, 81.6, 82.7, 99.0, 100.3, 101.2, 102.5, 
126.8, 127.5 (×3), 127.6, 127.7 (×3), 127.8 (×8), 127.9 (×6), 128.0 (×2), 128.1 (×3), 128.2 
(×7), 128.3 (×6), 128.4 (×6), 128.5 (×3), 128.6 (×7), 129.2, 129.4, 130.0 (×2), 132.7, 133.4, 
137.6, 137.7, 138.0 (×2), 138.2, 138.6, 138.7, 138.8, 138.9, 164.2, 165.2 ppm; ESI TOF 






(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (6.12).  A mixture of donor 6.54 (38.3 
mg, 0.035 mmol), acceptor 6.11 (50.0 mg, 0.0275 mmol), and freshly activated molecular 
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sieves (3 Å, 100 mg) in CH2Cl2 (4.0 mL) was stirred under argon for 2 h at rt. The mixture 
was then cooled to -40 oC, NIS (12.3 mg, 0.055 mmol) and freshly conditioned AgOTf (3.5 
mg, 0.013 mmol) were added, and the resulting mixture was stirred for 30 min at -40 oC. 
After that, the reaction mixture was stirred for additional 30 min during which the reaction 
temperature was allowed to increase gradually. The solids were then filtered-off and rinsed 
successively with CH2Cl2. The combined filtrate (~50 mL) was washed with sat. aq. 
NaHCO3 (10 mL), Na2S2O3 (10 mL), and water (2 x 10 mL). The organic phase was 
separated, dried over MgSO4, and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel (acetone - toluene gradient elution) to 
afford the title compound as a white foam in 82% yield (63.6 mg, 0.0227 mmol). Analytical 
data for 6.12: Rf = 0.60 (acetone/toluene, 1/4 v/v); []D
22 +34.5 (c 1.0, CHCl3); 
1H NMR 
(600 MHz, CDCl3): δ, 3.93 (m, 1H, OH), 4.78 (br s, 1H, H-5
B), 5.00 (m, 1H, H-5E), 5.06 
(m, 1H, J = 9.3 Hz, H-5C), 5.24-5.72 (m, 22H, H-2A, 3B, 3D, 3F, 4A, 4B, 4E, 5A, 5D, 5F, 6aA, 
6aB, 6aC, 6aD, 6aE, 6aF, 6bA, 6bB, 6bC, 6bD, 6bE, 6bF), 5.78 (dd, 1H, J = 8.7, 10.7 Hz, H-3E), 
5.91-6.15 (m, 9H, H-2C, 2E, 3A, 3C, 4C, 4D, 4F, CH2Ph), 6.28-6.39 (m, 7H, H-1
A, 1F, 5 × 
CHPh), 6.43-6.61 (m, 14H, 1B, 1D, 1E, 11 × CHPh), 6.66-6.69 (dd, 2H, CH2Ph), 6.77 (dd, 
2H, CH2Ph), 6.83-6.89 (m, 4H, 2 × CH2Ph), 6.96 (d, 1H, J1C,2C = 8.4 Hz, H-1C), 7.01 (dd, 
2H, CH2Ph), 7.24 (dd, 1H, J1B,2B = 8.3, J2B,3B = 9.5 Hz, H-2
B), 7.66-7.69 (m, 2H, H-2D, 2F), 
8.77-10.14 (m, 93H, aromatic) ppm; 13C NMR (151 MHz, CDCl3): δ, 55.2, 55.6, 64.6, 
65.9, 67.3, 67.9, 68.1, 68.2, 70.6, 71.0, 71.2, 71.4 (×2), 72.4, 72.5, 72.6, 72.7, 73.3, 73.4, 
73.5, 73.6 (×5), 73.7, 73.8, 74.2, 74.3, 74.6 (×2), 74.7 (×3), 75.0, 75.6, 75.9, 76.3, 77.1, 
77.3, 79.8, 81.6, 81.9, 82.8, 97.3, 97.9, 100.2, 100.6 (×2), 102.5, 123.2, 123.9, 126.9 (×2), 
127.4 (×2), 127.5 (×2), 127.6 (×2), 127.7 (×3), 127.8 (×11), 127.9 (×12), 128.1 (×5), 128.2 
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(×6), 128.3 (×9), 128.4 (×8), 128.5 (×10), 128.6 (×8), 129.0, 129.2, 129.4, 129.9 (×2), 
130.0 (×2), 130.9, 131.2 (×2), 131.9, 132.5, 133.1, 133.4, 133.7, 133.9, 134.6 (×3), 137.7, 
137.9, 138.0, 138.1, 138.2 (×2), 138.4, 138.7, 138.8 (×3), 138.9, 139.0, 164.0, 165.2, 165.4, 
166.6, 167.0, 168.0, 168.1 ppm;  ESI TOF LCMS [M+Na]+ calcd for C171H164N2NaO36 
2845.0995, found 2845.0944. 
 





glucopyranoside (6.13).  Compound 6.12 (72.0 mg, 0.025 mmol) was dissolved in 
NH2NH2-H2O/MeOH (3.0 mL, 1/2, v/v), and the resulting mixture was kept for 36 h at 
reflux. After that, the volatiles were removed under reduced pressure. The residue was 
dissolved in MeOH/CH2Cl2 (~5 mL, 1/9, v/v) and filtered through a pad of silica gel eluting 
with MeOH/CH2Cl2 (1/9, v/v). The combined eluate (~50 mL) was concentrated under 
reduced pressure and dried in vacuo for 3 h. The crude residue was dissolved in 
Ac2O/MeOH/Et3N (2.0 mL, 1/1/0.1, v/v/v) and the resulting mixture was stirred for 12 h 
at rt. The volatiles were then removed under reduced pressure. The residue was diluted 
with CH2Cl2 (~50 mL), and washed with sat. aq. NaHCO3 (10 mL) and brine (2 x 10 mL). 
The organic phase was separated, dried over MgSO4, and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel (acetone - 
toluene gradient elution) to afford the title compound as an off-white amorphous solid in 
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92% yield (54.7 mg, 0.023 mmol). Analytical data for 6.13: Rf = 0.60 (acetone/toluene, 2/3, 
v/v); []D
24 +11.8 (c 1.0, CHCl3); 1.74, 1.78 (2 s, 6H, 2 x COCH3), 2.96-3.97 (m, 36H, H-
2A, 2B, 2C, 2D, 2E, 2F, 3A, 3B, 3C, 3D, 3E, 3F, 4A, 4B, 4C, 4D, 4E, 4F, 5A, 5B, 5C, 5D, 5E, 5F, 6aA, 
6aB, 6aC, 6aD, 6aE, 6aF, 6bA, 6bB, 6bC, 6bD, 6bE, 6bF), 4.20-4.98 (m, 34H, H-1A, 1B, 1C, 1D, 
1E, 1F, 14 x CH2Ph), 5.34, 5.62 (2 d, 2H, 2 x NH), 7.12-7.38 (m, 70H, aromatic) ppm;
 13C 
NMR (151 MHz, CDCl3): δ, 23.6, 23.7, 55.4, 56.0, 67.8, 68.0, 68.2 (×2), 68.6, 68.7, 70.8, 
71.2, 71.9, 72.2, 72.3 (×3), 72.9, 73.0, 73.3, 73.4 (×4), 73.5 (×6), 73.9, 74.0, 74.3, 74.6, 
74.7, 74.8, 75.0, 75.1, 75.6, 76.8, 77.0, 79.6, 80.3, 81.9, 82.4, 83.4, 101.0, 101.3, 102.7, 
102.8, 103.3, 103.4, 127.2, 127.5 (×2) 127.6 (×4), 127.7 (×6), 127.8 (×6), 127.9 (×8), 128.0 
(×12), 128.2 (×5), 128.3 (×3), 128.4 (×6), 128.5 (×15), 128.6 (×2), 137.5, 137.8, 137.9, 
138.0 (×2), 138.1, 138.2, 138.4 (×2), 138.8 (×2), 139.0, 139.1, 139.2, 170.3, 171.2 ppm; 





LNnH).  10% Pd on charcoal (200 mg) was added to a solution of 6.13 (70.0 mg, 0.030 
mmol) in EtOH/H2O (7.0 mL, 4/1, v/v), and the resulting mixture was stirred under 
hydrogen atmosphere for 24 h at rt. After that, the solids were filtered off and rinsed 
successively with methanol and water. The combined filtrate (~50 mL) was concentrated 
under reduced pressure. The residue was purified by size-exclusion chromatography on 
Sephadex G-25 (water elution) to afford the title compound as a white amorphous solid in 
91% yield (29.2 mg, 0.027 mmol).  Selected analytical data for 6.1:12 Rf = 0.50 
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(chloroform/methanol/water, 2/1/0.4, v/v/v); 1H NMR (600 MHz, D2O): δ, 1.99, 2.02 (2 s, 
6H, COCH3), 3.25 (dd, 1H, J = 8.1, 9.1 Hz), 3.47-3.59 (m, 9H), 3.61-3.64 (m, 2H), 3.65-
3.84 (m, 22H), 3.92 (m, 7H), 4.11 (d, 1H, J = 3.3 Hz), 4.39 (d, 1H, J = 7.9 Hz), 4.43 (m, 
2H), 4.59 (d, 1H, J = 7.9 Hz), 4.62 (d, 1H, J = 8.0 Hz), 4.66 (d, 1H, J  = 8.3 Hz ), 5.18 (d, 
0.5H, J = 3.7 Hz) ppm; 13C NMR (151 MHz, D2O): δ, 22.5, 22.8, 55.3, 55.5, 60.2 (×2), 
60.4, 61.4, 68.7, 68.9, 69.0, 70.2 (×2), 70.3, 71.3, 71.5, 71.7, 72.5, 72.8 (×2), 73.8 (×2), 
74.2, 74.7, 74.9, 75.0, 75.1, 75.7, 78.4, 78.6, 79.2, 79.3, 82.1, 92.1, 96.0, 101.3, 103.1, 
103.2 (×2), 103.3, 174.9, 175.2 ppm; ESI TOF LCMS [M+H]+calcd for C40H69N2O31 




tri-O-benzyl-β-D-glucopyranoside (6.14).  Compound 6.11 (47.0 mg, 0.026 mmol) was 
dissolved in NH2NH2-H2O/MeOH (2.5 mL, 1/4, v/v), and the resulting mixture was kept 
for 24 h at reflux. After that, the volatiles were removed under reduced pressure. The 
residue was dissolved in MeOH/CH2Cl2 (~5 mL, 1/9, v/v) and filtered through a pad of 
silica gel eluting with MeOH/CH2Cl2 (1/9, v/v). The combined eluate (~50 mL) was 
concentrated under reduced pressure and dried in vacuo for 3 h. The crude residue was 
dissolved in Ac2O/MeOH (2.0 mL, 1/1, v/v), and the resulting mixture was stirred for 12 h 
at rt. The volatiles were then removed under reduced pressure. The residue was diluted 
with CH2Cl2 (~50 mL) and washed with sat. aq. NaHCO3 (10 mL) and brine (2 x 10 mL). 
The organic phase was separated, dried over MgSO4, and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel (acetone - 
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toluene gradient elution) to afford the title compound as an off-white amorphous solid in 
94% yield (37.0 mg, 0.024 mmol). Analytical data for 6.14: Rf = 0.65 (acetone/toluene, 
2/3, v/v); []D
20 +20.4 (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCl3): δ, 1.73 (s, 3H, 
COCH3), 2.85-4.01 (m, 24H, H-2, 2ʹ, 2ʹʹ, 2ʹʹʹ, 3, 3ʹ, 3ʹʹ, 3ʹʹʹ, 4, 4ʹ, 4ʹʹ, 4ʹʹʹ, 5, 5ʹ, 5ʹʹ, 5ʹʹʹ, 6a, 
6aʹ, 6aʹʹ, 6aʹʹʹ, 6b, 6bʹ, 6bʹʹ, 6bʹʹʹ), 4.30 (dd, 2H, 2J = 11.7 Hz, CH2Ph), 4.43-4.61 (m, 9H, H-
1, 1ʹ, 1ʹʹʹ, 3 x CH2Ph), 4.62-4.71 (m, 4H, 2 x CH2Ph), 4.82-4.95 (m, 7H, H-1ʹʹ, 3 x CH2Ph), 
5.64 (d, 1H, J = 7.5 Hz, NH), 7.19-7.37 (m, 45H, aromatic) ppm; 13C NMR (151 MHz, 
CDCl3): δ, 23.6, 56.7, 62.6, 68.3, 68.6, 68.7, 68.8, 70.9, 71.3, 71.9, 72.4, 72.8, 73.4, 73.6 
(×2), 73.7, 74.1, 74.3 (×2), 74.7, 74.8, 75.0, 75.1, 75.3, 77.1, 79.6, 82.0, 82.1, 82.9, 83.1, 
101.5, 102.8 (×2), 103.4, 127.5 (×3), 127.6 (×2), 127.8 (×4), 127.9, 128.0 (×15), 128.3 
(×6), 128.4 (×5), 128.5 (×7), 128.6 (×2), 137.6, 137.8, 137.9, 138.1 (×2), 138.4, 138.8 (×2), 




(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose (6.2, LNnT).  10% Pd on 
charcoal (75 mg) was added to a solution of 6.14 (30.0 mg, 0.019 mmol) in EtOH/H2O (4.0 
mL, 4/1, v/v), and the resulting mixture was stirred under hydrogen atmosphere for 24 h at 
rt. After that, the solids were filtered off and rinsed successively with methanol and water. 
The combined filtrate (~50 mL) was concentrated under reduced pressure. The residue was 
purified by size exclusion chromatography on Sephadex G-25 (water elution) to afford the 
title compound as a white amorphous solid in 82% yield (11.0 mg, 0.015 mmol). Analytical 
data for 6.2 was in agreement with that reported previously:4 Rf = 0.30 
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(chloroform/methanol/water, 2/1/0.4, v/v/v); ESI TOF LCMS [M+Na]+ calcd for 
C26H45NNaO21 730.2382, found 730.2381.  
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CDCl3 300 MHz 
Figure A-1: 1H NMR spectrum of Ethyl 2-O-benzoyl-6-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.5)   
 
CDCl3 75 MHz 
Figure A-2: 13C NMR spectrum of Ethyl 2-O-benzoyl-6-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.5)   
 





CDCl3 300 MHz 
Figure A-3: 2-D NMR COSY spectrum of Ethyl 2-O-benzoyl-6-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.5)   
  





CDCl3 300 MHz 
Figure A-4: 1H NMR spectrum of Ethyl 2,6-di-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.6) 
 
CDCl3 75 MHz 
Figure A-5: 13C NMR spectrum of Ethyl 2,6-di-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.6) 
 






CDCl3 300 MHz 









CDCl3 300 MHz 
Figure A-7: 1H NMR spectrum of Ethyl 2,6-di-O-benzoyl-3,4-di-O-tert-
butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.8) 
 
CDCl3 75 MHz 
Figure A-8: 13C NMR spectrum of Ethyl 2,6-di-O-benzoyl-3,4-di-O-tert-
butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.8) 
  





CDCl3 300 MHz 
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CDCl3 300 MHz 
Figure A-10: 1H NMR spectrum of Ethyl 6-O-benzoyl-2-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.9)   
 
CDCl3 75 MHz 
Figure A-11: 13C NMR spectrum of Ethyl 6-O-benzoyl-2-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.9)    





CDCl3 300 MHz 
Figure A-12: 2-D NMR COSY spectrum of Ethyl 6-O-benzoyl-2-O-benzyl-3,4-di-O-
tert-butyldimethylsilyl-1-thio-β-D-glucopyranoside (2.9)   
  




CDCl3 600 MHz 
Figure A-13: 1H NMR spectrum of Methyl 6-O-(2-O-benzoyl-6-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.10)  
 
 
CDCl3 150 MHz 
Figure A-14: 13C NMR spectrum of Methyl 6-O-(2-O-benzoyl-6-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.10)  






 CDCl3 600 MHz 
Figure A-15: 2-D NMR COSY spectrum of Methyl 6-O-(2-O-benzoyl-6-O-benzyl-3,4-
di-O-tert-butyldimethylsilyl-β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-








CDCl3 600 MHz 
Figure A-16: 1H NMR spectrum of Methyl 6-O-(2,6-di-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-α/β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.11)   
 
 
CDCl3 150 MHz 
Figure A-17: 13C NMR spectrum of Methyl 6-O-(2,6-di-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-α/β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.11)   





CDCl3 600 MHz  
Figure A-18: 2-D NMR COSY spectrum of Methyl 6-O-(2,6-di-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-α/β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.11)    




CDCl3 600 MHz 




CDCl3 150 MHz 
Figure A-20: 13C NMR spectrum of Methyl 6-O-(2,6-di-O-benzoyl-3,4-di-O-tert-
butyldimethylsilyl-β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (2.13) 




CDCl3 600 MHz 
Figure A-21: 2-D NMR COSY spectrum of Methyl 6-O-(2,6-di-O-benzoyl-3,4-di-O-
tert-butyldimethylsilyl-β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside 
(2.13) 




CDCl3 600 MHz 












































CDCl3 300 MHz 
Figure A-24: 2-D NMR COSY spectrum of Methyl O-(2-O-benzoyl-6-O-benzyl-3,4-di-
O-tert-butyldimethylsilyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzyl-α/β-D-
glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-α-D-glucopyranoside (2.16) 




CDCl3 300 MHz 
Figure A-25: 1H NMR spectrum of Methyl O-(2-O-benzoyl-6-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzyl-α/β-D-























CDCl3 150 MHz 
Figure A-26: 13C NMR spectrum of 3 Methyl O-(2-O-benzoyl-6-O-benzyl-3,4-di-O-tert-
butyldimethylsilyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzyl-α/β-D-




















CDCl3 600 MHz 
Figure A-27: 2-D NMR COSY spectrum of Methyl O-(2-O-benzoyl-6-O-benzyl-3,4-di-
O-tert-butyldimethylsilyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzyl-α/β-D-
glucopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-α-D-glucopyranoside (2.18)   




CDCl3 300 MHz 
























CDCl3 150 MHz 
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CDCl3 600 MHz 











D2O 600 MHz 
Figure A-31: 1H NMR spectrum of O-(β-D-Galactopyranosyl)-(1→4)-O-(2-acetamido-
2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose 
(3.1, LNnT)   
 
D2O 151 MHz 
Figure A-32: 13C NMR spectrum of O-(β-D-Galactopyranosyl)-(1→4)-O-(2-acetamido-
2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose 
(3.1, LNnT)   





D2O  600 MHz 
Figure A-33: 2-D NMR COSY spectrum of O-(β-D-Galactopyranosyl)-(1→4)-O-(2-
acetamido-2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-
glucopyranose (3.1, LNnT)   




Figure A-34: 1H NMR spectrum of Ethyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-
glucopyranoside (3.2)   
CDCl3 75 MHz 
Figure A-35: 13C NMR spectrum of Ethyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-










CDCl3 300 MHz 
Figure A-36: 2-D NMR COSY spectrum of Ethyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-
D-galactopyranosyl)-(1→4)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-
glucopyranoside (3.2)   
  






CDCl3 600 MHz 
Figure A-37: 1H NMR spectrum of Benzyl O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-
D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (3.3)   
 
 
CDCl3 75 MHz 
Figure A-38: 13C NMR spectrum of Benzyl O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-
D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (3.3)   
 
 






 CDCl3 600 MHz 
Figure A-39: 2-D NMR COSY spectrum of Benzyl O-(2-O-benzoyl-4-O-benzyl-6-O-
picoloyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (3.3)   
  





CDCl3 300 MHz 
Figure A-40: 1H NMR spectrum of Ethyl 2-O-benzoyl-4-O-benzyl-3-O-
fluorenylmethoxycarbonyl-6-O-picoloyl-1-thio-β-D-galactopyranoside (3.6)  
 
CDCl3 75 MHz 
Figure A-41: 13C NMR spectrum of spectrum of Ethyl 2-O-benzoyl-4-O-benzyl-3-O-
fluorenylmethoxycarbonyl-6-O-picoloyl-1-thio-β-D-galactopyranoside (3.6)   







CDCl3 300 MHz 
Figure A-42: 2-D NMR COSY spectrum of spectrum of Ethyl 2-O-benzoyl-4-O-benzyl-
3-O-fluorenylmethoxycarbonyl-6-O-picoloyl-1-thio-β-D-galactopyranoside (3.6) 
  





CDCl3 300 MHz 
 
Figure A-43: 1H NMR spectrum of Di-O-butyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl 
phosphate (3.11)  
 
CDCl3 75 MHz 
Figure A-44: 13C NMR spectrum of Di-O-butyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl 
phosphate (3.11)  





CDCl3 300 MHz 
Figure A-45: 2-D NMR COSY spectrum of Di-O-butyl O-(2-O-benzoyl-3,4,6-tri-O-
benzyl-β-D-galactopyranosyl)-(1→4)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl phosphate (3.11) 
  





CDCl3 600 MHz 
Figure A-46: 1H NMR spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-O-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-





























CDCl3 151 MHz 





























CDCl3 600 MHz 











CDCl3 300 MHz 
Figure A-49: 1H NMR spectrum of Ethyl 3,6-di-O-benzyl-2-deoxy-4-O-
fluorenylmethoxycarbonyl-2-phthalimido-1-thio-β-D-glucopyranoside (3.13) 
CDCl3 75 MHz 
Figure A-50: 13C NMR spectrum of Ethyl 3,6-di-O-benzyl-2-deoxy-4-O-
fluorenylmethoxycarbonyl-2-phthalimido-1-thio-β-D-glucopyranoside (3.13) 
 





CDCl3 300 MHz 
Figure A-51: 2-D NMR COSY spectrum of Ethyl 3,6-di-O-benzyl-2-deoxy-4-O-
fluorenylmethoxycarbonyl-2-phthalimido-1-thio-β-D-glucopyranoside (3.13) 
  





CDCl3 300 MHz 
Figure A-52: 1H NMR spectrum of Di-O-butyl 3,6-di-O-benzyl-2-deoxy-4-O-
fluorenylmethoxy-carbonyl-2-phthalimido-β-D-glucopyranosyl phosphate (3.14) 
 
CDCl3 75 MHz 
Figure A-53: 13C NMR spectrum of Di-O-butyl 3,6-di-O-benzyl-2-deoxy-4-O-
fluorenylmethoxy-carbonyl-2-phthalimido-β-D-glucopyranosyl phosphate (3.14) 
 





CDCl3 300 MHz 
Figure A-54: 2-D NMR COSY spectrum of Di-O-butyl 3,6-di-O-benzyl-2-deoxy-4-O-











CDCl3 600 MHz 
Figure A-55: 1H NMR spectrum of Benzyl O-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-
β-D-glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-
galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (3.16) 
CDCl3 151 MHz 
Figure A-56: 13C NMR spectrum of Benzyl O-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-
β-D-glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-
galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (3.16) 






CDCl3 600 MHz 













CDCl3 600 MHz 




CDCl3 151 MHz 
Figure A-59: 13C NMR spectrum of Benzyl O-(3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-O-(2-acetamido-3,6-di-O-benzyl-2-deoxy-β-D-
glucopyranosyl)-(1→3)-O-(4-O-benzyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-
benzyl-β-D-glucopyranoside (3.17)  





CDCl3 600 MHz 








D2O 600 MHz 
Figure A-61: 1H NMR spectrum of O-(β-D-Galactopyranosyl)-(1→3)-O-(2-acetamido-
2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose 
(4.1, LNT)  
 
D2O 151 MHz 
 
Figure A-62: 13C NMR spectrum of O-(β-D-Galactopyranosyl)-(1→3)-O-(2-acetamido-
2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-glucopyranose 
(4.1, LNT)  





D2O 600 MHz 
Figure A-63: 2-D NMR COSY spectrum of O-(β-D-Galactopyranosyl)-(1→3)-O-(2-
acetamido-2-deoxy-β-D-glucopyranosyl)-(1→3)-O-(β-D-galactopyranosyl)-(1→4)-D-












CDCl3 300 MHz 





CDCl3 75 MHz 
Figure A-65: 13C NMR spectrum of of Ethyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-
glucopyranoside (4.2) 





CDCl3 300 MHz 










CDCl3 300 MHz 




CDCl3 75 MHz 
Figure A-68: 13C NMR spectrum of Di-O-butyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl 
phosphate (4.10) 






CDCl3 300 MHz 
Figure A-69: 2-D NMR COSY spectrum of Di-O-butyl O-(2-O-benzoyl-3,4,6-tri-O-
benzyl-β-D-galactopyranosyl)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl phosphate (4.10) 
  





CDCl3 600 MHz 
Figure A-70: 1H NMR spectrum of  Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→3)-O-(4,6-di-O-benzyl-2-deoxy-2-phthlimido-β-D-glucopyranosyl)-
(1→3)-O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-
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CDCl3 600 MHz 
Figure A-72: 2-D NMR COSY spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→3)-O-(4,6-di-O-benzyl-2-deoxy-2-phthlimido-β-D-glucopyranosyl)-
(1→3)-O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-
benzyl-β-D-glucopyranoside (4.11)   





CDCl3 300 MHz 




CDCl3 75 MHz 
 
Figure A-74: 13C NMR spectrum of Ethyl 4,6-di-O-benzyl-2-deoxy-3-O-
fluorenylmethoxycarbonyl-2-phthalimido-1-thio-β-D-glucopyranoside (4.12) 
 







CDCl3 300 MHz 
Figure A-75: 2-D NMR COSY spectrum of Ethyl 4,6-di-O-benzyl-2-deoxy-3-O-
fluorenylmethoxycarbonyl-2-phthalimido-1-thio-β-D-glucopyranoside (4.12)  




CDCl3 300 MHz 
Figure A-76: 1H NMR spectrum of Di-O-butyl 4,6-di-O-benzyl-2-deoxy-3-O-
fluorenylmethoxycarbonyl-2-phthalimido-β-D-glucopyranosyl phosphate (4.13) 
 
CDCl3 75 MHz 
 
Figure A-77: 13C NMR spectrum of Di-O-butyl 4,6-di-O-benzyl-2-deoxy-3-O-
fluorenylmethoxycarbonyl-2-phthalimido-β-D-glucopyranosyl phosphate (4.13) 





CDCl3 300 MHz 
Figure A-78: 2-D NMR COSY spectrum of Di-O-butyl 4,6-di-O-benzyl-2-deoxy-3-O-
fluorenylmethoxycarbonyl-2-phthalimido-β-D-glucopyranosyl phosphate (4.13)  





CDCl3 600 MHz 




CDCl3 151 MHz 
Figure A-80: 13C NMR spectrum of Benzyl O-(4,6-di-O-benzyl-2-deoxy-2-phthalimido-
β-D-glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-
galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (4.15)  






 CDCl3 600 MHz 
Figure A-81: 2-D NMR COSY spectrum of Benzyl O-(4,6-di-O-benzyl-2-deoxy-2-
phthalimido-β-D-glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-benzyl-6-O-picoloyl-β-D-
galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (4.15)  
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CDCl3 600 MHz 





CDCl3 151 MHz 




benzyl-β-D-glucopyranoside (5.4)   





CDCl3 600 MHz 
Figure A-90: 2-D NMR COSY spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-
β-D-galactopyranosyl)-(1→3)-O-(4,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4-O-benzyl-β-D-galactopyranosyl)-(1→4)-
2,3,6-tri-O-benzyl-β-D-glucopyranoside (5.4)   
 
  




CDCl3 300 MHz 
Figure A-91: 1H NMR spectrum of Benzyl O-(2-O-benzoyl-4,6-O-benzylidene-β-D-
galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (5.9) 
 
CDCl3 75 MHz 
Figure A-92: 13C NMR spectrum of Benzyl O-(2-O-benzoyl-4,6-O-benzylidene-β-D-
galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (5.9) 
 





CDCl3 300 MHz 
Figure A-93: 2-D NMR COSY spectrum of Benzyl O-(2-O-benzoyl-4,6-O-benzylidene-
β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (5.9) 
  




CDCl3 300 MHz 




CDCl3 75 MHz 
Figure A-95: 13C NMR spectrum of O-(2-O-Benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl 
trichloroacetimidate (5.12)  
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CDCl3 600 MHz 
Figure A-99: 2-D NMR COSY spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-
β-D-galactopyranosyl)-(1→3)-O-(4,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranosyl)-
(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (5.13)  
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CDCl3 300 MHz 




CDCl3 75 MHz 
Figure A-122: 13C NMR spectrum of O-(2-O-Benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl 
trichloroacetimidate (6.9) 





CDCl3 300 MHz 
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CDCl3 600 MHz 
Figure A-124: 1H NMR spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-O-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranosyl)-





















CDCl3 151 MHz 
Figure A-125: 13C NMR spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-O-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranosyl)-




















CDCl3 600 MHz 
 
Figure A-126: 2-D NMR COSY spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-
β-D-galactopyranosyl)-(1→4)-O-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(1→3)-O-(2-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranosyl)-
(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (6.10)   
W. M. Mithila D. Bandara | UMSL 2019 | Page  308 
 
 
CDCl3 600 MHz 
Figure A-127: 1H NMR spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-O-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(1→3)-O-(2-O-benzoyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-
























CDCl3 151 MHz 
Figure A-128: 13C NMR spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-O-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(1→3)-O-(2-O-benzoyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-

























CDCl3 600 MHz 
 
Figure A-129: 2-D NMR COSY spectrum of Benzyl O-(2-O-benzoyl-3,4,6-tri-O-benzyl-
β-D-galactopyranosyl)-(1→4)-O-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(1→3)-O-(2-O-benzoyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-
benzyl-β-D-glucopyranoside (6.11)   
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O-benzoyl-β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (6.12)   
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CDCl3 600 MHz 
 
Figure A-138: 2-D NMR COSY spectrum of Benzyl O-(3,4,6-tri-O-benzyl-β-D-
galactopyranosyl)-(1→4)-O-(2-acetamido-3,6-di-O-benzyl-2-deoxy-β-D-
glucopyranosyl)-(1→3)-O-(β-D-galactopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-β-D-
glucopyranoside (6.14) 
